Details of Disease

General Information of Disease (ID: DISBXRFJ)

• Disease Name: Clear cell renal carcinoma
• Synonyms: hypernephroma; clear-cell metastatic renal cell carcinoma; kidney clear cell adenocarcinoma; clear cell adenocarcinoma of the kidney; Grawitz tumour; clear cell carcinoma of the kidney; RCC, clear cell adenocarcinoma; Grawitz tumor; conventional (clear cell) renal cell adenocarcinoma; clear cell carcinoma of kidney; clear cell renal cell carcinoma; conventional renal cell carcinoma; clear cell adenocarcinoma of kidney; renal cell carcinoma, clear cell adenocarcinoma; renal clear cell adenocarcinoma; clear cell renal cell cancer; clear cell adenocarcinoma, kidney; kidney clear cell carcinoma; clear cell kidney carcinoma; renal clear cell carcinoma; conventional (clear cell) renal cell carcinoma
• Definition: A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network. The tumor may metastasize to unusual sites and late metastasis is common.
• Disease Hierarchy:
  DISGFURW: Nonpapillary renal cell carcinoma
  DISYUGHZ: Clear cell adenocarcinoma
  DISWH728: Renal cell adenocarcinoma
  DISBXRFJ: Clear cell renal carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0005005
  MESH ID: D002292
  UMLS CUI: C0279702
  OMIM ID: 144700
  MedGen ID: 76018
  HPO ID: HP:0006770
  Orphanet ID: 319276
  SNOMED CT ID: 1187306007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nicotinamide	DMUPE07	Approved	Small molecular drug	[1]
Sorafenib	DMS8IFC	Approved	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 527 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCG2	TTIMJ02	Limited	Biomarker	[3]
ACAT1	TTK3C21	Limited	Biomarker	[4]
ACR	TTAHE2N	Limited	Biomarker	[5]
ADAM10	TTVXEGU	Limited	Biomarker	[6]
ADAM9	TTTYQNS	Limited	Biomarker	[7]
ALOX12B	TTQ4QQH	Limited	Biomarker	[8]
ANGPTL4	TTWALY5	Limited	Biomarker	[9]
APEH	TTYWEDQ	Limited	Biomarker	[10]
APLNR	TTJ8E43	Limited	Biomarker	[11]
AQP9	TTQEI32	Limited	Altered Expression	[12]
AURKA	TTPS3C0	Limited	Altered Expression	[13]
B2M	TTY7FKA	Limited	Biomarker	[14]
CA12	TTSYM0R	Limited	Altered Expression	[15]
CCL22	TTBTWI1	Limited	Altered Expression	[16]
CCR4	TT7HQD0	Limited	Altered Expression	[17]
CDH2	TT1WS0T	Limited	Altered Expression	[18]
CDH5	TTXLCFO	Limited	Biomarker	[19]
CDH6	TT9QHUK	Limited	Altered Expression	[20]
CDK1	TTH6V3D	Limited	Biomarker	[21]
CEACAM6	TTIGH2W	Limited	Altered Expression	[22]
CEBPB	TTUI35N	Limited	Altered Expression	[23]
CENPE	TTZD5QR	Limited	Biomarker	[24]
COL18A1	TT63DI9	Limited	Biomarker	[25]
COL6A3	TT5WCAH	Limited	Altered Expression	[26]
CXCL12	TT4UGTF	Limited	Biomarker	[27]
DCLK1	TTOHTCY	Limited	Biomarker	[28]
DKK1	TTE3RAC	Limited	Biomarker	[29]
DKK2	TTST5KX	Limited	Altered Expression	[30]
DKK3	TTY2ZV6	Limited	Altered Expression	[31]
EDNRB	TT3ZTGU	Limited	Altered Expression	[32]
ENPP3	TTD4TKP	Limited	Biomarker	[33]
EPOR	TTAUX24	Limited	Biomarker	[34]
ESRRA	TTPNQAC	Limited	Biomarker	[35]
ESRRG	TT9ZRHB	Limited	Biomarker	[36]
FABP1	TTIV96N	Limited	Biomarker	[37]
FHIT	TTMS54D	Limited	Posttranslational Modification	[38]
FKBP10	TT4P8O2	Limited	Biomarker	[39]
GHR	TTHJWYD	Limited	Altered Expression	[40]
GIP	TT40HS5	Limited	Biomarker	[41]
GNG7	TTCMBKF	Limited	Altered Expression	[42]
HIPK2	TTOB49C	Limited	Altered Expression	[43]
HPGDS	TTCYE56	Limited	Biomarker	[44]
IDUA	TT0IUKX	Limited	Altered Expression	[45]
IFNB1	TT4TZ8J	Limited	Biomarker	[46]
IKBKB	TTJ3E9X	Limited	Biomarker	[47]
IMP3	TTEJA2R	Limited	Altered Expression	[48]
ITGA5	TTHIZP9	Limited	Altered Expression	[49]
ITGAE	TTH0Z37	Limited	Biomarker	[50]
KAT6A	TT6O1J0	Limited	Biomarker	[51]
KCNJ1	TTJ13ST	Limited	Altered Expression	[52]
KDM5A	TTIG67W	Limited	Biomarker	[53]
KIF20B	TTQECT2	Limited	Altered Expression	[54]
KISS1	TTU2O6T	Limited	Altered Expression	[55]
LAIR1	TTSI7A8	Limited	Biomarker	[56]
LEPR	TT0HD6V	Limited	Biomarker	[57]
LIFR	TTID542	Limited	Biomarker	[58]
MAP4K1	TTSHWUP	Limited	Genetic Variation	[59]
MCAM	TTHRE05	Limited	Biomarker	[60]
MKNK1	TTEZAUX	Limited	Biomarker	[61]
MMP3	TTUZ2L5	Limited	Biomarker	[62]
MST1R	TTBQ3OC	Limited	Biomarker	[63]
NEDD9	TT1UREA	Limited	Biomarker	[64]
NOD1	TTYSRXM	Limited	Biomarker	[65]
PAK4	TT7Y3BZ	Limited	Biomarker	[66]
PDCD1LG2	TTW14O3	Limited	Biomarker	[67]
PLOD1	TTEKJP3	Limited	Biomarker	[68]
PRTN3	TT5MLC4	Limited	Posttranslational Modification	[69]
PSMD10	TT2H4LN	Limited	Biomarker	[70]
RBCK1	TTIKUVC	Limited	Altered Expression	[71]
RCVRN	TTDQTEY	Limited	Altered Expression	[72]
RUNX3	TTKCVO7	Limited	Posttranslational Modification	[73]
S100A9	TT0TMQG	Limited	Altered Expression	[74]
S1PR1	TT9JZCK	Limited	Biomarker	[75]
SFRP4	TTX8I1Y	Limited	Genetic Variation	[76]
SIRT5	TTH0IOD	Limited	Altered Expression	[77]
SLC5A2	TTF8JAT	Limited	Biomarker	[78]
SLC9A1	TTGSEFH	Limited	Biomarker	[79]
SOCS3	TTI0ME6	Limited	Altered Expression	[80]
SORD	TTLSRBZ	Limited	Genetic Variation	[81]
SOX5	TTXHSZK	Limited	Biomarker	[82]
SRPK1	TTU3WV6	Limited	Biomarker	[83]
TGFBR1	TTP4520	Limited	Biomarker	[84]
THRB	TTGER3L	Limited	Biomarker	[85]
TRPC6	TTRBT3W	Limited	Biomarker	[86]
TSG101	TTHU7JA	Limited	Altered Expression	[87]
TTK	TTP7EGM	Limited	Altered Expression	[88]
XIAP	TTK3WBU	Limited	Altered Expression	[89]
YAP1	TT8UN2D	Limited	Biomarker	[90]
FLT4	TTDCBX5	Disputed	Posttranslational Modification	[91]
HSPB1	TT9AZWY	Disputed	Biomarker	[92]
PAK1	TTFN95D	Disputed	Altered Expression	[93]
SOD2	TT9O4C5	Disputed	Altered Expression	[94]
ACLY	TT0Z6Y2	moderate	Altered Expression	[95]
ACVRL1	TTGYPTC	moderate	Biomarker	[96]
ALOX5	TTSJ6Q4	moderate	Biomarker	[8]
ARG2	TTV1AG6	moderate	Altered Expression	[97]
ARRB2	TT8SO2I	moderate	Biomarker	[98]
ASIC2	TTVMWLP	moderate	Biomarker	[99]
ATF4	TTQCKWT	moderate	Biomarker	[100]
BCL2A1	TTGT9C7	moderate	Altered Expression	[95]
BMP1	TT0L58T	moderate	Altered Expression	[101]
CBL	TT7QT13	moderate	Altered Expression	[102]
CCL17	TTMPHAE	moderate	Altered Expression	[103]
CCNE1	TTCEJ4F	moderate	Altered Expression	[104]
CD27	TTDO1MV	moderate	Biomarker	[105]
CLIC1	TT8KZG6	moderate	Altered Expression	[106]
CSNK1E	TTA8PLI	moderate	Biomarker	[107]
CXCR5	TTIW59R	moderate	Biomarker	[108]
DDR1	TTI1FPZ	moderate	Altered Expression	[109]
DYSF	TTA7MXQ	moderate	Altered Expression	[110]
EPHA5	TTV9KOD	moderate	Altered Expression	[111]
ESRRB	TTKF0XS	moderate	Biomarker	[112]
ETS2	TT9AH0M	moderate	Altered Expression	[113]
F2RL3	TTD0652	moderate	Biomarker	[114]
GPNMB	TT7315J	moderate	Biomarker	[115]
GRB2	TTEYRJ9	moderate	Altered Expression	[116]
GRM4	TTICZ1O	moderate	Genetic Variation	[117]
HOXA11	TTEX4ZA	moderate	Altered Expression	[118]
ITGB8	TTIF29E	moderate	Altered Expression	[119]
KDM1B	TT8VP2T	moderate	Biomarker	[53]
KIF11	TTBGTCW	moderate	Altered Expression	[120]
LAG3	TTNVXAW	moderate	Biomarker	[121]
LAMP2	TTULDG7	moderate	Altered Expression	[122]
LATS2	TTML7FG	moderate	Posttranslational Modification	[123]
LIPA	TTS8T1M	moderate	Altered Expression	[124]
MAPK12	TTYT93M	moderate	Altered Expression	[125]
MBNL2	TTH9OLG	moderate	Biomarker	[126]
MTA1	TTO4HUS	moderate	Altered Expression	[127]
NCR1	TTQNRJM	moderate	Altered Expression	[128]
NPTX2	TTNJ5A6	moderate	Altered Expression	[129]
PBRM1	TTH8ZRL	moderate	Biomarker	[130]
PDPK1	TTYMGWX	moderate	Biomarker	[131]
PLD1	TT3T17P	moderate	Biomarker	[132]
PLD2	TTRLMKF	moderate	Biomarker	[132]
PRMT5	TTR1D7X	moderate	Posttranslational Modification	[133]
PSIP1	TTH9LDP	moderate	Altered Expression	[134]
RCE1	TT2AP5B	moderate	Altered Expression	[135]
RIPK1	TTVJHX8	moderate	Biomarker	[136]
RRM2	TT1S4LJ	moderate	Biomarker	[137]
RTN4	TT7GXMU	moderate	Genetic Variation	[138]
SERPINH1	TTPSWQG	moderate	Biomarker	[139]
SIRT2	TTLKF5M	moderate	Altered Expression	[140]
SLC27A4	TT20AYF	moderate	Altered Expression	[141]
SLC6A1	TTPRKM0	moderate	Altered Expression	[142]
SMPD4	TTZSJIV	moderate	Biomarker	[143]
ST8SIA4	TTDP8YM	moderate	Altered Expression	[144]
STK39	TTYQTIU	moderate	Altered Expression	[145]
STXBP4	TTKS60G	moderate	Biomarker	[90]
TEP1	TTQGAVX	moderate	Altered Expression	[146]
TXNRD1	TTR7UJ3	moderate	Biomarker	[147]
ULK1	TT4D7MJ	moderate	Altered Expression	[148]
ABCB1	TT3OT40	Strong	Biomarker	[149]
ABCC1	TTOI92F	Strong	Biomarker	[150]
ABCC2	TTFLHJV	Strong	Genetic Variation	[151]
ABL2	TT1A6HL	Strong	Altered Expression	[152]
ACHE	TT1RS9F	Strong	Biomarker	[153]
ACKR3	TTRQJTC	Strong	Biomarker	[154]
ADAM8	TTQWYMD	Strong	Altered Expression	[155]
ADAMTS1	TTS2TEI	Strong	Altered Expression	[155]
ADORA1	TTK25J1	Strong	Biomarker	[156]
AKR1C3	TT5ZWB6	Strong	Altered Expression	[157]
AKT3	TTO6SGY	Strong	Biomarker	[158]
ALAD	TTJHKYD	Strong	Biomarker	[159]
ALOX12	TT12ABZ	Strong	Altered Expression	[160]
ALOX15	TTN9T81	Strong	Altered Expression	[160]
ALPI	TTHYMUV	Strong	Altered Expression	[161]
AMACR	TTLN1AP	Strong	Biomarker	[162]
AMOT	TTI48OS	Strong	Biomarker	[163]
ANGPT1	TTWNQ1T	Strong	Biomarker	[164]
ANGPTL3	TT59GO7	Strong	Biomarker	[165]
APLN	TT87D3J	Strong	Biomarker	[11]
APOH	TT2OUI9	Strong	Biomarker	[166]
APOL1	TTDB8PW	Strong	Biomarker	[167]
AR	TTKPW01	Strong	Altered Expression	[168]
ASRGL1	TT4WT91	Strong	Biomarker	[169]
ATAD2	TT9A0HI	Strong	Altered Expression	[170]
ATG7	TTLVB9Z	Strong	Genetic Variation	[171]
ATIC	TT9NVXQ	Strong	Biomarker	[172]
ATM	TTKBM7V	Strong	Genetic Variation	[173]
ATP1A1	TTWK8D0	Strong	Biomarker	[174]
AURKB	TT9RTBL	Strong	Altered Expression	[175]
AXL	TTZPY6J	Strong	Altered Expression	[176]
BBC3	TT7JUKC	Strong	Altered Expression	[177]
BCHE	TT3MSAO	Strong	Biomarker	[153]
BCL2L2	TTQ79W8	Strong	Altered Expression	[178]
BIRC7	TTHZ8TA	Strong	Biomarker	[179]
BMP6	TT07RIB	Strong	Biomarker	[180]
BMX	TTN2I9E	Strong	Altered Expression	[181]
BSG	TT5UJWD	Strong	Biomarker	[182]
BST2	TT90BJT	Strong	Altered Expression	[183]
BTLA	TTER58P	Strong	Genetic Variation	[184]
C1QBP	TTWTD7F	Strong	Biomarker	[185]
C5AR1	TTHXFA1	Strong	Altered Expression	[186]
CA4	TTZHA0O	Strong	Altered Expression	[187]
CAPN1	TT1WBIJ	Strong	Altered Expression	[188]
CAPN2	TTG5QB7	Strong	Altered Expression	[189]
CASP10	TTX5HEK	Strong	Biomarker	[190]
CASP2	TT12VNG	Strong	Biomarker	[191]
CCL21	TTLZK1U	Strong	Altered Expression	[192]
CCNB1	TT9P6OW	Strong	Biomarker	[193]
CCR3	TTD3XFU	Strong	Biomarker	[194]
CD209	TTBXIM9	Strong	Biomarker	[195]
CD24	TTCTYNP	Strong	Altered Expression	[196]
CD276	TT6CQUM	Strong	Altered Expression	[197]
CD38	TTPURFN	Strong	Genetic Variation	[198]
CD70	TTNCIE0	Strong	Biomarker	[199]
CD74	TTCMYP9	Strong	Biomarker	[200]
CD80	TT89Z17	Strong	Biomarker	[201]
CDC20	TTBKFDV	Strong	Altered Expression	[202]
CDC25B	TTR0SWN	Strong	Altered Expression	[203]
CDH3	TTARMD9	Strong	Biomarker	[204]
CDK2	TT7HF4W	Strong	Biomarker	[205]
CDK5R1	TTBYM6V	Strong	Genetic Variation	[206]
CDK7	TTQYF7G	Strong	Biomarker	[207]
CEACAM1	TTA9CK4	Strong	Altered Expression	[208]
CFLAR	TTJZQYH	Strong	Altered Expression	[209]
CLN3	TTORF9W	Strong	Altered Expression	[183]
CLU	TTRL76H	Strong	Biomarker	[210]
CMA1	TT8VUE0	Strong	Biomarker	[15]
COPS5	TTSTNJR	Strong	Biomarker	[211]
CRHBP	TT3PKZE	Strong	Biomarker	[212]
CRHR2	TTIY658	Strong	Biomarker	[213]
CRP	TTWRN6M	Strong	Altered Expression	[214]
CRYAB	TT7RUHB	Strong	Biomarker	[215]
CRYZ	TTP6UO8	Strong	Biomarker	[216]
CSNK2A1	TTER6YH	Strong	Biomarker	[217]
CTAG1A	TTE5ITK	Strong	Biomarker	[218]
CTDSP1	TTHZAF0	Strong	Altered Expression	[219]
CTLA4	TTI2S1D	Strong	Genetic Variation	[220]
CTSB	TTF2LRI	Strong	Biomarker	[215]
CTSD	TTPT2QI	Strong	Biomarker	[215]
CTSK	TTDZN01	Strong	Biomarker	[221]
CUL7	TTI8R0P	Strong	Biomarker	[222]
CXCL11	TTWG0RE	Strong	Biomarker	[223]
CXCL13	TT0NIZ1	Strong	Biomarker	[224]
CXCL9	TTWE5PB	Strong	Biomarker	[223]
CXCR1	TTMWT8Z	Strong	Altered Expression	[225]
CXCR2	TT30C9G	Strong	Altered Expression	[226]
CYP1B1	TTI84H7	Strong	Biomarker	[227]
CYP24A1	TT82UI1	Strong	Biomarker	[228]
CYP3A5	TTHS0OK	Strong	Biomarker	[229]
DAAM2	TTN0Z6H	Strong	Genetic Variation	[76]
DAG1	TT4X7PG	Strong	Biomarker	[230]
DDC	TTN451K	Strong	Altered Expression	[231]
DDIT4	TTVEOY6	Strong	Altered Expression	[232]
DFFA	TTYVQ9C	Strong	Altered Expression	[233]
DIABLO	TTN74LE	Strong	Altered Expression	[234]
DIO1	TTU3X26	Strong	Altered Expression	[235]
DLK1	TTF4AVB	Strong	Posttranslational Modification	[236]
DLL4	TTV23LH	Strong	Biomarker	[237]
DNAJB1	TTPXAWS	Strong	Biomarker	[238]
DOT1L	TTSZ8T1	Strong	Altered Expression	[239]
DRD1	TTZFYLI	Strong	Altered Expression	[240]
DUSP9	TT1GV6C	Strong	Altered Expression	[241]
E2F1	TTASI04	Strong	Biomarker	[242]
E2F2	TT5FYX0	Strong	Biomarker	[243]
E2F3	TTWIJYH	Strong	Altered Expression	[244]
EBP	TT4VQZX	Strong	Biomarker	[245]
ECE1	TTQ9RYT	Strong	Altered Expression	[246]
EGFL7	TT7WD0H	Strong	Biomarker	[247]
EIF2AK3	TT79U1M	Strong	Altered Expression	[248]
EIF4E	TTZGCP6	Strong	Posttranslational Modification	[249]
EIF4EBP1	TTKGEBL	Strong	Altered Expression	[250]
ENPEP	TT9PBIL	Strong	Altered Expression	[251]
ENPP2	TTSCIM2	Strong	Altered Expression	[252]
EPCAM	TTZ8WH4	Strong	Altered Expression	[253]
EPHA1	TTLFZVU	Strong	Altered Expression	[254]
EPHA2	TTRJB2G	Strong	Altered Expression	[255]
EPHA3	TTHS2LR	Strong	Altered Expression	[256]
EPHB4	TTI4ZX2	Strong	Altered Expression	[257]
ERAP2	TTVGS1C	Strong	Altered Expression	[258]
EZH1	TTNJA0C	Strong	Biomarker	[259]
F11R	TT3C8EG	Strong	Altered Expression	[260]
F12	TTRJSMV	Strong	Biomarker	[261]
F2RL2	TTVSEBF	Strong	Altered Expression	[262]
FAAH2	TTWTES7	Strong	Biomarker	[263]
FABP5	TTNT2S6	Strong	Altered Expression	[37]
FBXO11	TT6G10V	Strong	Altered Expression	[264]
FCER1G	TTDGEC0	Strong	Altered Expression	[265]
FGL2	TTYBS89	Strong	Altered Expression	[266]
FLT1	TT1VAUK	Strong	Biomarker	[267]
FOLH1	TT9G4N0	Strong	Genetic Variation	[268]
FOXM1	TTD3KOX	Strong	Altered Expression	[269]
FOXO1	TTLRVIA	Strong	Biomarker	[270]
FSCN1	TTTRS9B	Strong	Biomarker	[271]
FTH1	TT975ZT	Strong	Altered Expression	[272]
FUT3	TTUPAD7	Strong	Altered Expression	[273]
FUT4	TTNV1KZ	Strong	Biomarker	[274]
FZD7	TTUQMO5	Strong	Biomarker	[275]
G3BP1	TTG0R8Z	Strong	Altered Expression	[276]
GABRQ	TTXDUR9	Strong	Biomarker	[277]
GAD1	TTKGEP3	Strong	Biomarker	[278]
GAS6	TT69QD2	Strong	Biomarker	[279]
GHSR	TTWDC17	Strong	Biomarker	[280]
GNAI1	TTL1HWR	Strong	Biomarker	[281]
GNAO1	TTAXD8Z	Strong	Biomarker	[281]
GNE	TT4DP5S	Strong	Biomarker	[282]
GPR182	TTT23CG	Strong	Biomarker	[283]
GPRC6A	TTI1PRE	Strong	Biomarker	[284]
GRHL2	TTUGH4C	Strong	Biomarker	[285]
GRIA4	TTPJR0G	Strong	Altered Expression	[286]
GRK5	TTTCXO0	Strong	Biomarker	[287]
GRM1	TTVBPDM	Strong	Biomarker	[288]
GSK3A	TTQWAU1	Strong	Biomarker	[289]
GSTO1	TTWO3SH	Strong	Genetic Variation	[290]
HCK	TT42OGM	Strong	Altered Expression	[152]
HDAC1	TT6R7JZ	Strong	Biomarker	[242]
HGFAC	TTD96RW	Strong	Altered Expression	[291]
HK2	TTK02H8	Strong	Biomarker	[292]
HLA-G	TTLKFB3	Strong	Biomarker	[293]
HNF1A	TT01M3K	Strong	Biomarker	[294]
HNF4A	TT2F3CD	Strong	Posttranslational Modification	[295]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[296]
HOXA5	TTXSVQP	Strong	Posttranslational Modification	[297]
HOXB13	TTZ6I58	Strong	Altered Expression	[298]
HSPA5	TTW26OG	Strong	Biomarker	[299]
HSPA9	TTMTPG3	Strong	Biomarker	[215]
IAPP	TTHN8EM	Strong	Altered Expression	[161]
IFNAR2	TTMQB37	Strong	Altered Expression	[300]
IGFBP5	TTDWEA8	Strong	Biomarker	[301]
IGFBP6	TTLAYV8	Strong	Altered Expression	[301]
IGFBP7	TTUQ01B	Strong	Genetic Variation	[302]
IL11	TTGUYTR	Strong	Biomarker	[303]
IL2	TTF89GD	Strong	Biomarker	[304]
IL4R	TTDWHC3	Strong	Biomarker	[305]
ILK	TT7ALZG	Strong	Biomarker	[306]
IMPA2	TTXWL6D	Strong	Altered Expression	[307]
IRF8	TTHUBNK	Strong	Altered Expression	[308]
ITGB1	TTBVIQC	Strong	Biomarker	[309]
ITK	TT3C80U	Strong	Biomarker	[310]
ITPR2	TTK9OV3	Strong	Genetic Variation	[311]
JAG2	TTOJY1B	Strong	Altered Expression	[312]
KAT2B	TTVK7SB	Strong	Genetic Variation	[313]
KCNMA1	TTE87WJ	Strong	Biomarker	[314]
KDM3A	TTKXS4A	Strong	Biomarker	[315]
KDM4C	TTV8CRH	Strong	Genetic Variation	[316]
KDM5C	TT94UCF	Strong	Genetic Variation	[317]
KDM6B	TTDIJUQ	Strong	Biomarker	[318]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[319]
KHK	TTPAFR9	Strong	Altered Expression	[320]
KISS1R	TT3KBZY	Strong	Altered Expression	[321]
KLK1	TT5T3P6	Strong	Biomarker	[322]
KLK2	TTJLNAW	Strong	Biomarker	[323]
KLK3	TTS78AZ	Strong	Altered Expression	[324]
KLK7	TTE6GTB	Strong	Altered Expression	[325]
KLRC1	TTC4IMS	Strong	Biomarker	[326]
KMT5A	TTGC95K	Strong	Altered Expression	[327]
L1CAM	TTC9D3K	Strong	Altered Expression	[185]
LAPTM4B	TTEJQT0	Strong	Biomarker	[328]
LASP1	TTZJA87	Strong	Biomarker	[329]
LBP	TTVQJLY	Strong	Altered Expression	[330]
LDHA	TTW76JE	Strong	Altered Expression	[331]
LGALS1	TTO3NYT	Strong	Altered Expression	[332]
LILRB1	TTC0QRJ	Strong	Biomarker	[29]
LOXL2	TTFSUHX	Strong	Altered Expression	[333]
LPAR3	TTE2YJR	Strong	Biomarker	[284]
LRRK2	TTK0FEA	Strong	Biomarker	[222]
M6PR	TT95ICL	Strong	Biomarker	[314]
MAGEA2	TTOZT28	Strong	Genetic Variation	[334]
MAGEA4	TT9EQUY	Strong	Altered Expression	[335]
MAGEA6	TTJIWMO	Strong	Altered Expression	[336]
MAOB	TTGP7BY	Strong	Biomarker	[337]
MAP3K3	TTJZNIG	Strong	Biomarker	[338]
MAP3K5	TTOQCD8	Strong	Biomarker	[339]
MAP3K7	TTJQT60	Strong	Biomarker	[340]
MAP3K8	TTGECUM	Strong	Biomarker	[341]
MAP3K9	TTUNSIX	Strong	Altered Expression	[342]
MAPK7	TTU6FSC	Strong	Genetic Variation	[343]
MAPK8	TT0K6EO	Strong	Biomarker	[344]
MAPK9	TT3IVG2	Strong	Altered Expression	[345]
MARK2	TTAJ45Y	Strong	Genetic Variation	[346]
MCL1	TTL53M6	Strong	Altered Expression	[309]
MDM2	TT9TE0O	Strong	Biomarker	[347]
MKI67	TTB4UNG	Strong	Altered Expression	[348]
MLANA	TT362RB	Strong	Genetic Variation	[349]
MLH1	TTISG27	Strong	Biomarker	[350]
MME	TT5TKPM	Strong	Biomarker	[351]
MMP11	TTZW4MV	Strong	Biomarker	[352]
MRGPRX1	TTIX6PK	Strong	Biomarker	[284]
MTDH	TTH6SA5	Strong	Altered Expression	[353]
MTNR1A	TT0WAIE	Strong	Altered Expression	[354]
MUC17	TTVO0JU	Strong	Altered Expression	[355]
MVD	TTE5J6X	Strong	Biomarker	[356]
MYCN	TT9JBY5	Strong	Biomarker	[357]
NDUFA13	TTRU1NG	Strong	Altered Expression	[358]
NEDD8	TTNDC4K	Strong	Altered Expression	[359]
NEK1	TTO5QT2	Strong	Altered Expression	[360]
NELL1	TT7H4BF	Strong	Biomarker	[361]
NF2	TTZIK7P	Strong	Biomarker	[263]
NFKB2	TTKLNRV	Strong	Altered Expression	[134]
NLRC5	TTWZC78	Strong	Biomarker	[362]
NOD2	TTYPUHA	Strong	Biomarker	[65]
NR1H2	TTXA6PH	Strong	Genetic Variation	[363]
NR4A1	TTMXE2Q	Strong	Biomarker	[364]
NRP1	TTIPJCB	Strong	Biomarker	[365]
NRP2	TTRXUVC	Strong	Biomarker	[366]
NTN1	TT0AH4L	Strong	Biomarker	[367]
OGG1	TTRU01G	Strong	Genetic Variation	[368]
OXER1	TT7WBSV	Strong	Biomarker	[284]
P2RY1	TTA93TL	Strong	Biomarker	[369]
PCNA	TTLG1PD	Strong	Altered Expression	[370]
PCSK7	TTD30LY	Strong	Biomarker	[371]
PDCD1	TTNBFWK	Strong	Altered Expression	[372]
PDGFC	TTOABM9	Strong	Biomarker	[373]
PDGFD	TTSN0GA	Strong	Altered Expression	[374]
PDGFRB	TTI7421	Strong	Biomarker	[375]
PDK1	TTCZOF2	Strong	Altered Expression	[131]
PDK3	TTDEQIP	Strong	Altered Expression	[232]
PDZK1	TTDTBLM	Strong	Altered Expression	[376]
PECAM1	TT4EZB2	Strong	Altered Expression	[377]
PGF	TT48I1Y	Strong	Biomarker	[179]
PGRMC1	TTY3LAZ	Strong	Biomarker	[174]
PHGDH	TT8DRCK	Strong	Biomarker	[378]
PIK3CB	TT9H4P3	Strong	Genetic Variation	[379]
PIM1	TTTN5QW	Strong	Altered Expression	[380]
PINX1	TT4FJ3A	Strong	Biomarker	[381]
PKM	TT4LOT8	Strong	Biomarker	[382]
PKMYT1	TTB4PAZ	Strong	Altered Expression	[383]
PLA2R1	TTHKW7D	Strong	Biomarker	[384]
PLOD2	TT8MEUD	Strong	Biomarker	[385]
PML	TTLH9NY	Strong	Biomarker	[386]
POMC	TT21AKM	Strong	Altered Expression	[387]
PPIA	TTL2ADK	Strong	Biomarker	[388]
PPM1D	TTENJAB	Strong	Biomarker	[389]
PPP3CA	TTA4LDE	Strong	Biomarker	[390]
PRKCA	TTFJ8Q1	Strong	Biomarker	[391]
PRKCE	TT57MT2	Strong	Altered Expression	[392]
PRKCZ	TTBSN0L	Strong	Altered Expression	[393]
PSMB6	TT8EPLT	Strong	Genetic Variation	[394]
PSMB8	TTEAD9J	Strong	Altered Expression	[395]
PSMB9	TTOUSTQ	Strong	Genetic Variation	[395]
PTBP1	TTWMX0U	Strong	Biomarker	[396]
PTGER4	TT79WV3	Strong	Biomarker	[397]
PTK2	TTON5IT	Strong	Biomarker	[398]
PTPRZ1	TT4SEA8	Strong	Altered Expression	[399]
QPCT	TTJ7YTV	Strong	Posttranslational Modification	[400]
RAB22A	TTAJ746	Strong	Biomarker	[401]
RACK1	TTJ10AL	Strong	Biomarker	[402]
RALBP1	TTVSRUA	Strong	Biomarker	[403]
RASA1	TTPNZ1F	Strong	Altered Expression	[404]
RHO	TTH0KSX	Strong	Biomarker	[405]
RHOB	TT6LPFO	Strong	Biomarker	[406]
RICTOR	TT143WL	Strong	Altered Expression	[407]
RNF34	TTEWDK1	Strong	Biomarker	[408]
ROR2	TTUDPCI	Strong	Biomarker	[409]
RPS6KA6	TT3KYWB	Strong	Biomarker	[410]
RSF1	TTMP86V	Strong	Altered Expression	[411]
RXRA	TT6PEUO	Strong	Genetic Variation	[412]
RXRG	TTH029C	Strong	Altered Expression	[413]
RYR1	TTU5CIX	Strong	Biomarker	[222]
S100A12	TTQ4ESF	Strong	Altered Expression	[414]
S100A6	TT716MY	Strong	Biomarker	[415]
SATB1	TTLFRIC	Strong	Biomarker	[416]
SELE	TT1PL7M	Strong	Altered Expression	[417]
SENP1	TTW9HY5	Strong	Altered Expression	[418]
SLC12A3	TTP362L	Strong	Biomarker	[419]
SLC15A1	TT5LF3C	Strong	Biomarker	[420]
SLC16A1	TTN1J82	Strong	Biomarker	[15]
SLC16A3	TTG6VD5	Strong	Biomarker	[421]
SLC1A5	TTF7WRM	Strong	Altered Expression	[422]
SLC22A2	TT0XOJN	Strong	Biomarker	[423]
SLC2A1	TT79TKF	Strong	Altered Expression	[424]
SLC2A4	TTP6MT5	Strong	Biomarker	[425]
SLC34A2	TTQPZTM	Strong	Biomarker	[426]
SLC3A2	TT5CZSM	Strong	Altered Expression	[427]
SLC7A5	TTPH2JB	Strong	Biomarker	[428]
SMN1	TT8QL6X	Strong	Genetic Variation	[429]
SMYD2	TT7YJFO	Strong	Altered Expression	[430]
SPHK1	TTOHFIY	Strong	Altered Expression	[431]
SQSTM1	TTOT2RY	Strong	Altered Expression	[319]
SREBF1	TTER0UB	Strong	Biomarker	[432]
ST14	TTPRO7W	Strong	Altered Expression	[433]
STC1	TTDLUER	Strong	Altered Expression	[434]
SULF2	TTLQTHB	Strong	Altered Expression	[435]
TAGLN2	TTP6BIJ	Strong	Biomarker	[215]
TEC	TT1ZV49	Strong	Biomarker	[436]
TEK	TT9VGXW	Strong	Biomarker	[164]
TERF1	TT1Y6J2	Strong	Altered Expression	[437]
TERF2	TT5XSLT	Strong	Altered Expression	[437]
TFAP2A	TTDY4BS	Strong	Biomarker	[85]
TGFA	TTTLQFR	Strong	Altered Expression	[438]
TGM2	TT2F4OL	Strong	Biomarker	[439]
TIAM1	TTNU6I5	Strong	Genetic Variation	[440]
TIE1	TTT4236	Strong	Biomarker	[441]
TLR1	TTW14D0	Strong	Biomarker	[442]
TMSB4X	TTMVAIU	Strong	Altered Expression	[443]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[444]
TNFRSF10B	TTW20TU	Strong	Biomarker	[445]
TNFRSF12A	TTKPS7V	Strong	Altered Expression	[446]
TNFSF10	TTA5MS9	Strong	Altered Expression	[80]
TNFSF12	TTBTDM1	Strong	Altered Expression	[446]
TNFSF15	TTEST6I	Strong	Altered Expression	[447]
TOP2A	TTCGY2K	Strong	Biomarker	[448]
TPT1	TT3PTB6	Strong	Altered Expression	[449]
TPX2	TT0PHL4	Strong	Biomarker	[450]
TREM2	TTQRMSJ	Strong	Altered Expression	[451]
TRIM59	TT613U4	Strong	Biomarker	[452]
TRIP10	TTKHTGE	Strong	Biomarker	[453]
TRPC4	TTX0H5W	Strong	Biomarker	[454]
TRPM3	TTO3TD8	Strong	Biomarker	[455]
TSPAN7	TTMT6VE	Strong	Altered Expression	[456]
TWIST1	TTX1MY7	Strong	Altered Expression	[457]
TXNIP	TTTLDZK	Strong	Biomarker	[458]
TYMP	TTO0IB8	Strong	Altered Expression	[459]
UBE2T	TT0A1R8	Strong	Altered Expression	[460]
UCHL1	TTX9IFP	Strong	Altered Expression	[461]
UCP1	TTI12YJ	Strong	Altered Expression	[462]
USP1	TTG9MT5	Strong	Posttranslational Modification	[461]
VEGFB	TTPJQHE	Strong	Altered Expression	[463]
VEGFC	TT0QUFV	Strong	Biomarker	[464]
VEGFD	TTOM5H4	Strong	Biomarker	[465]
VTCN1	TTCK85E	Strong	Biomarker	[466]
XPNPEP2	TTI9MBZ	Strong	Biomarker	[467]
ZEB2	TTT2WK4	Strong	Biomarker	[468]
BIRC5	TTTPU1G	Definitive	Altered Expression	[469]
CCK	TT90CMU	Definitive	Biomarker	[400]
CUBN	TT9YLCR	Definitive	Altered Expression	[470]
DCLK3	TTMYK4Z	Definitive	Altered Expression	[284]
GJB1	TTSJIRP	Definitive	Biomarker	[471]
HSPD1	TT9HL5R	Definitive	Altered Expression	[472]
IFNA2	TTSIUJ9	Definitive	Biomarker	[473]
KEAP1	TT3Z6Y9	Definitive	Altered Expression	[474]
PEBP1	TT1BGU8	Definitive	Biomarker	[475]
PRAME	TTPH7T0	Definitive	Altered Expression	[476]
PTEN	TTXJ3W7	Definitive	Altered Expression	[477]
PTGS2	TTVKILB	Definitive	Altered Expression	[478]
SCARB1	TTRE324	Definitive	Genetic Variation	[479]

This Disease Is Related to 17 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC4A4	DTWDEIL	Limited	Biomarker	[480]
SLCO6A1	DTIFXNS	Limited	Genetic Variation	[339]
SLC16A12	DTZOKFJ	moderate	Biomarker	[481]
SLC22A17	DTXI9E6	moderate	Altered Expression	[482]
ABCD1	DTKM9DZ	Strong	Altered Expression	[483]
ATP2B1	DTJWQ1L	Strong	Altered Expression	[484]
SLC25A3	DTCRIWV	Strong	Genetic Variation	[485]
SLC2A5	DTOR02F	Strong	Biomarker	[486]
SLC31A1	DTP8L4F	Strong	Biomarker	[487]
SLC39A10	DTK02RZ	Strong	Biomarker	[488]
SLC39A11	DTEOAND	Strong	Genetic Variation	[489]
SLC43A1	DTBMSWG	Strong	Altered Expression	[427]
SLC43A2	DTK02I1	Strong	Altered Expression	[427]
SLC50A1	DTI9CQU	Strong	Biomarker	[278]
SLC5A3	DT8ACN1	Strong	Biomarker	[263]
SLC7A6	DTTBSQG	Strong	Altered Expression	[427]
SLC7A7	DTE4HJ8	Strong	Altered Expression	[427]

This Disease Is Related to 24 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1A1	DED2FW3	Limited	Genetic Variation	[490]
CYP1A1	DE6OQ3W	Limited	Biomarker	[491]
GLS	DE3E0VT	Limited	Biomarker	[492]
NNMT	DECVGJ3	Limited	Altered Expression	[493]
PSAT1	DEBS17P	Limited	Biomarker	[212]
ALDH1A1	DE2JP1Y	Disputed	Biomarker	[494]
LDHC	DEQG7F9	moderate	Biomarker	[495]
UBASH3B	DE10BJ5	moderate	Biomarker	[496]
ACSS2	DEE76VW	Strong	Biomarker	[497]
AGMAT	DEG5L6E	Strong	Biomarker	[498]
APRT	DE2MV1R	Strong	Biomarker	[336]
CYP2R1	DEBIHM3	Strong	Biomarker	[228]
CYP4B1	DEMF740	Strong	Posttranslational Modification	[499]
FUT11	DERG61P	Strong	Biomarker	[500]
GPT	DER5HFI	Strong	Biomarker	[501]
GSTO2	DEHMPZR	Strong	Genetic Variation	[290]
HIF1AN	DEY1CBW	Strong	Altered Expression	[502]
MT1A	DE5ME8A	Strong	Altered Expression	[503]
NAT1	DE7OAB3	Strong	Genetic Variation	[504]
NAT10	DEZV4AP	Strong	Biomarker	[169]
NDUFS7	DEIW03B	Strong	Biomarker	[505]
PARK7	DEPOVCH	Strong	Biomarker	[506]
XPNPEP1	DE8E6X9	Strong	Biomarker	[467]
GSTT1	DE3PKUG	Definitive	Genetic Variation	[507]

This Disease Is Related to 841 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACADM	OTA4P0FC	Limited	Biomarker	[24]
ACD	OTC54EPO	Limited	Biomarker	[508]
ADAMTS9	OTV3Q0DS	Limited	Biomarker	[270]
ADIPOR2	OT2HDTL8	Limited	Biomarker	[509]
AGFG1	OTI8ZKC4	Limited	Biomarker	[136]
ALDH6A1	OT8LCZCT	Limited	Biomarker	[85]
APAF1	OTJWIVY0	Limited	Biomarker	[510]
APLP2	OTTFE53M	Limited	Altered Expression	[511]
ARL4C	OTQ3QNNU	Limited	Biomarker	[512]
ARNT	OTMSIEZY	Limited	Biomarker	[513]
ASF1B	OTKXX12I	Limited	Altered Expression	[514]
ASPM	OTKXQMNA	Limited	Altered Expression	[515]
ASPSCR1	OTXTOD10	Limited	Biomarker	[516]
AZIN2	OT8OB7CG	Limited	Biomarker	[517]
B4GALNT1	OTCY80HS	Limited	Biomarker	[518]
CA8	OT9Y8GA8	Limited	Biomarker	[519]
CASZ1	OTWJ2OR8	Limited	Altered Expression	[520]
CAVIN1	OTFO915U	Limited	Biomarker	[521]
CBLL2	OTB4AD3V	Limited	Altered Expression	[522]
CHCHD2	OTL5PA3Y	Limited	Biomarker	[523]
CHI3L2	OT26R3HQ	Limited	Biomarker	[524]
CHSY1	OTB1XSSF	Limited	Biomarker	[269]
CLDN7	OTNE0XHQ	Limited	Altered Expression	[525]
CLDN8	OT7IIWXG	Limited	Biomarker	[526]
CMTM5	OTMS7NDP	Limited	Biomarker	[527]
CMTM6	OT70T27A	Limited	Biomarker	[528]
COMMD10	OT1ANQLQ	Limited	Biomarker	[529]
CORO1A	OTVAZOHC	Limited	Altered Expression	[530]
CRYBA4	OTQJ5XGE	Limited	Altered Expression	[45]
CUL5	OTMTZD47	Limited	Biomarker	[531]
CXCL16	OTD49T9R	Limited	Biomarker	[532]
DCAF1	OT3ZDVOE	Limited	Biomarker	[136]
DCTN4	OTM7C943	Limited	Altered Expression	[319]
DCTN6	OTI8PIN9	Limited	Altered Expression	[533]
EBAG9	OTTQLQCP	Limited	Biomarker	[534]
ECHS1	OTS0593S	Limited	Biomarker	[535]
ELAVL2	OT6EJ8MQ	Limited	Genetic Variation	[85]
EN2	OT7EZCM2	Limited	Genetic Variation	[536]
FABP7	OTRE2H4G	Limited	Biomarker	[537]
GADL1	OTJM4A0R	Limited	Biomarker	[517]
GNPTAB	OT2Z03OB	Limited	Biomarker	[538]
GSTK1	OTDNGWAF	Limited	Genetic Variation	[339]
GTF2H1	OTCRXC6B	Limited	Altered Expression	[319]
HAS1	OTJIAG1W	Limited	Biomarker	[539]
HELLS	OTVVV668	Limited	Altered Expression	[170]
HILPDA	OTEID3ZM	Limited	Biomarker	[540]
HJURP	OTWMV16B	Limited	Altered Expression	[515]
HOXA3	OTIX5XFB	Limited	Biomarker	[398]
HOXD3	OTBUZ35T	Limited	Posttranslational Modification	[541]
IFI27	OTI2XGIT	Limited	Altered Expression	[533]
ILF3	OTKMZ5K5	Limited	Biomarker	[542]
KDSR	OTCIES3H	Limited	Biomarker	[543]
KIF20A	OTXOQHE0	Limited	Biomarker	[515]
KLF6	OTQY9S7F	Limited	Altered Expression	[544]
KPNA2	OTU7FOE6	Limited	Altered Expression	[545]
LGALS8	OT71LJ8T	Limited	Altered Expression	[546]
LMNB1	OT100T3P	Limited	Altered Expression	[547]
MAP1LC3B	OTUYHB84	Limited	Biomarker	[548]
MBD2	OTUQPP0R	Limited	Biomarker	[549]
MCM3	OTOOHQPM	Limited	Posttranslational Modification	[550]
MFSD14A	OT7G17V5	Limited	Biomarker	[551]
MGAT5	OTU4DD4G	Limited	Altered Expression	[552]
MGAT5B	OT5HP73K	Limited	Biomarker	[552]
MICA	OTPEIEAR	Limited	Biomarker	[553]
MPC1	OT6DYFUO	Limited	Biomarker	[554]
MT1G	OTAV1OCR	Limited	Altered Expression	[555]
MT1M	OTVT8PLU	Limited	Posttranslational Modification	[555]
MYOF	OTRFC3IJ	Limited	Altered Expression	[556]
NDC80	OTS7D306	Limited	Biomarker	[24]
NDNF	OTCDL9PG	Limited	Biomarker	[557]
NDRG2	OT5L6KD7	Limited	Biomarker	[250]
NDST1	OT9E10W2	Limited	Altered Expression	[45]
NFE2L3	OT1MGXT0	Limited	Posttranslational Modification	[541]
NOP53	OTA2YKO6	Limited	Altered Expression	[558]
NUP62	OTMN63DH	Limited	Altered Expression	[319]
OGT	OT1Z1ZXE	Limited	Altered Expression	[559]
OXR1	OTPIDMT3	Limited	Genetic Variation	[63]
PAPPA	OTTTG9PG	Limited	Biomarker	[560]
PAX8	OTRPD9MI	Limited	Biomarker	[561]
PDCD4	OTZ6NXUX	Limited	Altered Expression	[562]
PDIA3	OTHPQ0Q3	Limited	Altered Expression	[542]
PIK3R1	OT5BZ1J9	Limited	Biomarker	[563]
PIWIL1	OT7CRGZ3	Limited	Biomarker	[564]
PIWIL4	OTDA9MY0	Limited	Biomarker	[564]
PNRC2	OTE7W7Y5	Limited	Biomarker	[565]
POLR2A	OTHJQ1DZ	Limited	Altered Expression	[566]
PPP1R13B	OTC88VQO	Limited	Biomarker	[563]
PRF1	OTFVXD7H	Limited	Altered Expression	[528]
PRKAA1	OT7TNF0L	Limited	Biomarker	[382]
PRKAB1	OT1OG4QZ	Limited	Biomarker	[382]
PRRX1	OTTZK5G8	Limited	Altered Expression	[567]
PSMD9	OT6Y5CC3	Limited	Altered Expression	[533]
RAB25	OTW0W6NP	Limited	Biomarker	[212]
RAB27A	OT9SQRWY	Limited	Biomarker	[568]
RAB27B	OTPF9D0K	Limited	Altered Expression	[568]
RBX1	OTYA1UIO	Limited	Biomarker	[569]
RIN1	OTPBROUD	Limited	Biomarker	[570]
RIT1	OTVNOGOH	Limited	Biomarker	[571]
RNF2	OTFPLOIN	Limited	Genetic Variation	[572]
RNF20	OT9NK6ZT	Limited	Biomarker	[573]
RPAIN	OTBMXAYK	Limited	Biomarker	[136]
SAP30L	OTI15CY4	Limited	Altered Expression	[45]
SCAMP1	OTFS4IKJ	Limited	Biomarker	[574]
SDHAF2	OT0UG9H5	Limited	Genetic Variation	[77]
SDS	OT5WTJ2M	Limited	Genetic Variation	[81]
SESN2	OT889IXY	Limited	Biomarker	[575]
SFRP1	OT0U9G41	Limited	Biomarker	[576]
SH3BGRL3	OTKMW34I	Limited	Biomarker	[577]
SHC1	OT1J5IRN	Limited	Altered Expression	[521]
SLC12A9	OTR7VRAK	Limited	Biomarker	[578]
SMARCA2	OTSGJ8SV	Limited	Posttranslational Modification	[579]
SMARCB1	OT2LP7LJ	Limited	Altered Expression	[580]
SNAI1	OTDPYAMC	Limited	Biomarker	[581]
SNAI2	OT7Y8EJ2	Limited	Biomarker	[581]
SOX18	OTPUMHWA	Limited	Biomarker	[582]
SPAAR	OTWXG2R8	Limited	Altered Expression	[583]
SPAG4	OTVXS2SM	Limited	Altered Expression	[584]
SPINK13	OTEU2OSU	Limited	Altered Expression	[585]
SPINT2	OTQV7BKQ	Limited	Biomarker	[586]
SRA1	OTYOGMTG	Limited	Altered Expression	[333]
SRL	OT7IEBWZ	Limited	Genetic Variation	[587]
STX6	OTC5F5M6	Limited	Altered Expression	[588]
TGFBI	OTR443C5	Limited	Altered Expression	[589]
TIMP3	OTDGQAD1	Limited	Biomarker	[590]
TNIP1	OTRAOTEW	Limited	Biomarker	[591]
TRIB3	OTG5OS7X	Limited	Altered Expression	[592]
ANXA4	OTUCRYXL	Disputed	Biomarker	[593]
COMMD5	OT6R7DXN	Disputed	Biomarker	[594]
KRT8	OTTM4X11	Disputed	Biomarker	[253]
RNF139	OT0PR1X5	Disputed	Genetic Variation	[595]
SAG	OTDNS3ZQ	Disputed	Altered Expression	[596]
ABCB10	OT1C44F9	moderate	Biomarker	[597]
ACSL1	OTB06ESI	moderate	Altered Expression	[141]
ACSS1	OT6C1WQD	moderate	Biomarker	[497]
AGO2	OT4JY32Q	moderate	Biomarker	[136]
ALDOA	OTWRFTIB	moderate	Altered Expression	[598]
ALDOB	OT7FR69A	moderate	Biomarker	[599]
ALKAL1	OTZGAZ79	moderate	Posttranslational Modification	[600]
ANXA6	OT9KIQ0Y	moderate	Biomarker	[496]
ARHGEF7	OT9BPJCL	moderate	Biomarker	[563]
ARRDC1	OTMCTFHC	moderate	Altered Expression	[601]
ARRDC3	OTAKW7R9	moderate	Biomarker	[601]
ATP5F1A	OT3FZDLX	moderate	Biomarker	[602]
AVL9	OTZLRZ55	moderate	Biomarker	[603]
AZU1	OTHXU264	moderate	Biomarker	[604]
B3GALT6	OTF4HBAT	moderate	Biomarker	[605]
BMPR1B	OTGFN0OD	moderate	Biomarker	[606]
CANT1	OT1TPWQR	moderate	Biomarker	[607]
CAV2	OT1FGRQX	moderate	Biomarker	[608]
CCN4	OT69BER9	moderate	Altered Expression	[609]
CCNC	OTMVK4K4	moderate	Biomarker	[610]
CIRBP	OTXWTPBL	moderate	Altered Expression	[611]
CLEC3B	OTFD29NF	moderate	Biomarker	[612]
CNPY2	OTGY8ESX	moderate	Altered Expression	[613]
COL5A1	OT24078H	moderate	Altered Expression	[614]
COPS7B	OTZEPV2T	moderate	Biomarker	[615]
DHRS4	OTTPOIOP	moderate	Biomarker	[616]
DIRAS1	OT07F6PE	moderate	Altered Expression	[617]
DNASE1L3	OTEUIMC2	moderate	Altered Expression	[143]
DPF3	OTEWLMNB	moderate	Genetic Variation	[618]
EEF1A1	OT00THXS	moderate	Biomarker	[619]
FBP1	OTQBANEP	moderate	Altered Expression	[424]
FGB	OT6RKLI9	moderate	Altered Expression	[620]
FGD5	OT5VIRP2	moderate	Biomarker	[621]
FOXK2	OTFXDZ3R	moderate	Biomarker	[622]
FRK	OTEKV1SC	moderate	Altered Expression	[623]
FRMPD2	OT8OM5MA	moderate	Biomarker	[143]
GAB2	OTBFN705	moderate	Altered Expression	[116]
GABPB1	OTEXDEJN	moderate	Biomarker	[624]
GOT2	OT6XBWN0	moderate	Biomarker	[37]
GPR149	OTN36PTI	moderate	Biomarker	[625]
GTF2H4	OTPD1DIU	moderate	Altered Expression	[134]
HAPLN1	OTXWR9TJ	moderate	Biomarker	[626]
HIKESHI	OTPKV3UZ	moderate	Biomarker	[143]
HSD17B6	OTSB55D2	moderate	Biomarker	[147]
HSPA14	OTZCA5LK	moderate	Altered Expression	[472]
IGFN1	OTJIPVSM	moderate	Biomarker	[627]
ING4	OT0VVG4V	moderate	Altered Expression	[628]
INTS1	OT7TY1M1	moderate	Biomarker	[629]
ITGA7	OTTBTAYW	moderate	Biomarker	[630]
ITGA9	OTHN1IKA	moderate	Biomarker	[631]
KIFC1	OTNQDS00	moderate	Biomarker	[632]
LAMA4	OTHI7TA0	moderate	Biomarker	[633]
LDHD	OTTKLJWP	moderate	Biomarker	[634]
LETM1	OT8N4MRU	moderate	Biomarker	[635]
MAN1C1	OT44TM7D	moderate	Altered Expression	[636]
MATN4	OT0CD0VH	moderate	Biomarker	[637]
MCM2	OTGGORIQ	moderate	Altered Expression	[638]
MCM4	OT19PNNG	moderate	Altered Expression	[638]
MCM5	OTAHLB62	moderate	Altered Expression	[639]
MMUT	OTBBBV70	moderate	Biomarker	[638]
MTA2	OTCCYIQJ	moderate	Biomarker	[640]
MTHFD1	OTMKHVWC	moderate	Altered Expression	[641]
MYL12B	OTXMLQOT	moderate	Biomarker	[631]
NANOG	OTUEY1FM	moderate	Biomarker	[642]
NCOA1	OTLIUJQD	moderate	Biomarker	[147]
NCR3	OT20M764	moderate	Altered Expression	[128]
NR2F2	OTJFS67N	moderate	Altered Expression	[112]
NRK	OTGR01FF	moderate	Biomarker	[643]
NRXN3	OTJ0I7HJ	moderate	Altered Expression	[119]
NSD2	OTQ6SW4R	moderate	Biomarker	[644]
OPTN	OT2UXWH9	moderate	Biomarker	[645]
OTX1	OTRGSGH9	moderate	Biomarker	[637]
PAFAH1B1	OT9T2TCJ	moderate	Altered Expression	[646]
PANX2	OTAQ2S8R	moderate	Altered Expression	[647]
PCBP2	OTXCN9CG	moderate	Genetic Variation	[126]
PCDHGC3	OTDXTUMI	moderate	Biomarker	[648]
PCLO	OTXJZZ98	moderate	Biomarker	[649]
PDZD2	OTPPVRGY	moderate	Genetic Variation	[311]
PHF2	OTJCIQR2	moderate	Altered Expression	[650]
PIK3R2	OTZSUQK5	moderate	Biomarker	[563]
PISD	OTP9COQT	moderate	Biomarker	[147]
PITX2	OTWMXAOY	moderate	Biomarker	[149]
PLAC8	OT3SYRUJ	moderate	Altered Expression	[651]
PLAGL1	OTZAO900	moderate	Biomarker	[652]
PLIN3	OT9ZA7MR	moderate	Altered Expression	[653]
PPAN	OT0UFQBZ	moderate	Genetic Variation	[654]
PPP1R12C	OT9Q86JO	moderate	Biomarker	[563]
PRDX1	OTZ3BEC4	moderate	Biomarker	[655]
PTTG1	OTIMYS4W	moderate	Biomarker	[656]
PYCR1	OTQHB52T	moderate	Altered Expression	[657]
RAB23	OTBAKFBR	moderate	Altered Expression	[658]
RAC2	OTAOHFNH	moderate	Altered Expression	[659]
RASAL2	OTGMMX6W	moderate	Biomarker	[660]
RASL11B	OTHEVZS6	moderate	Biomarker	[661]
RCAN1	OT1MVXC7	moderate	Biomarker	[662]
RGN	OTD04KB1	moderate	Biomarker	[663]
RTCA	OTSJRVTD	moderate	Biomarker	[664]
RWDD3	OTE76DY5	moderate	Altered Expression	[665]
SARS2	OTU4T99W	moderate	Biomarker	[666]
SELENOW	OTVSKPAN	moderate	Biomarker	[667]
SGK3	OTQ6QO99	moderate	Biomarker	[668]
SH3GL2	OTOE443G	moderate	Biomarker	[669]
SKA1	OTDYJ12A	moderate	Biomarker	[670]
SMURF1	OT5UIZR8	moderate	Altered Expression	[671]
SOX12	OT93P8C9	moderate	Biomarker	[672]
SPOP	OTP0107S	moderate	Altered Expression	[673]
SPTLC1	OTN0Z98K	moderate	Altered Expression	[543]
STIP1	OT7TXLOX	moderate	Biomarker	[674]
STK3	OTLNSCQD	moderate	Altered Expression	[675]
SYP	OTFJKMO4	moderate	Biomarker	[676]
TCEA1	OTBFO594	moderate	Biomarker	[677]
TMEM52B	OTOC70IF	moderate	Altered Expression	[678]
TRIM2	OT0V1YVC	moderate	Biomarker	[679]
TRPV5	OTWF4L0U	moderate	Altered Expression	[680]
TSHZ1	OTYQ9ECW	moderate	Genetic Variation	[138]
AADAC	OT8VACT2	Strong	Biomarker	[681]
ABCA13	OTTHTUQN	Strong	Altered Expression	[682]
ACCS	OTHIHI9D	Strong	Genetic Variation	[683]
ACOT7	OT7C68YV	Strong	Biomarker	[684]
ACTBL2	OTD6B81U	Strong	Biomarker	[684]
ACTG2	OTRDWUO0	Strong	Biomarker	[684]
ACY1	OT9WU7X3	Strong	Biomarker	[215]
ADAM28	OT3GBVHL	Strong	Altered Expression	[685]
ADAMTS18	OTRMFI04	Strong	Altered Expression	[686]
ADAMTS2	OTTK22NO	Strong	Biomarker	[155]
AHNAK	OT6KH1WG	Strong	Biomarker	[222]
AHNAK2	OTD2X4BX	Strong	Altered Expression	[687]
AIM2	OT86QUI8	Strong	Altered Expression	[688]
AKAP13	OTOZAR14	Strong	Biomarker	[222]
AKT1S1	OT4JHN4Y	Strong	Biomarker	[689]
ALPP	OTZU4G9W	Strong	Biomarker	[169]
AMBP	OTLU8GU8	Strong	Altered Expression	[690]
AMFR	OTQRX7LC	Strong	Biomarker	[691]
ANKHD1	OTVYQ7ZL	Strong	Biomarker	[692]
ANP32B	OT3SQMLU	Strong	Altered Expression	[446]
AP5M1	OTDLWEBL	Strong	Biomarker	[314]
APH1A	OT97F1TU	Strong	Genetic Variation	[302]
APOBEC3B	OTHLNI51	Strong	Altered Expression	[693]
ARC	OTN2QQPG	Strong	Biomarker	[694]
ARHGAP24	OTCQCEZS	Strong	Biomarker	[695]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[696]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[697]
ASB15	OTI0ZVLJ	Strong	Biomarker	[222]
ASS1	OT4ZMG0Q	Strong	Biomarker	[136]
ATF2	OTNIZPEA	Strong	Altered Expression	[698]
ATG9B	OTJMJZW8	Strong	Biomarker	[699]
ATP1B1	OTTO6ZP4	Strong	Biomarker	[700]
ATP5MC1	OTOLSYOI	Strong	Altered Expression	[701]
ATP5MC2	OTA5F480	Strong	Genetic Variation	[702]
ATP6V0A4	OT149Z7Q	Strong	Biomarker	[500]
ATP6V1G3	OTVQHEH6	Strong	Biomarker	[500]
ATPAF1	OTG1V44F	Strong	Altered Expression	[701]
ATRNL1	OTY5JUX2	Strong	Biomarker	[169]
AXIN1	OTRGZGZ5	Strong	Genetic Variation	[703]
AXIN2	OTRMGQNU	Strong	Altered Expression	[704]
B3GAT1	OTXFP98E	Strong	Biomarker	[705]
BAZ1A	OTWHOVZS	Strong	Genetic Variation	[316]
BBS2	OTPF9JIB	Strong	Genetic Variation	[706]
BHLHE40	OTITX14U	Strong	Biomarker	[707]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[708]
BIK	OTTH1T3D	Strong	Altered Expression	[709]
BNC1	OTGJ5WUF	Strong	Biomarker	[710]
BNIP3	OT4SO7J4	Strong	Altered Expression	[711]
BRAP	OTB7BAFQ	Strong	Genetic Variation	[712]
BSND	OTYWZWPD	Strong	Altered Expression	[713]
BTG2	OTZF6K1H	Strong	Altered Expression	[714]
BTG3	OT9ANHVT	Strong	Altered Expression	[715]
C4orf46	OTXL7SLI	Strong	Posttranslational Modification	[716]
CABIN1	OT4G5CIK	Strong	Genetic Variation	[717]
CACYBP	OTJMZD2T	Strong	Biomarker	[718]
CADM2	OT45PVKC	Strong	Altered Expression	[719]
CADM4	OT0TFMFE	Strong	Biomarker	[720]
CAPG	OTJ86KI6	Strong	Biomarker	[215]
CAPNS1	OT95EBBD	Strong	Biomarker	[721]
CAPRIN1	OTEJAMS3	Strong	Biomarker	[722]
CARD10	OT2RPM4I	Strong	Altered Expression	[723]
CARD11	OTRCTLYC	Strong	Biomarker	[222]
CAVIN2	OTFHHDRU	Strong	Altered Expression	[724]
CBFA2T2	OTNOIB23	Strong	Biomarker	[563]
CCAR1	OTUXLQZZ	Strong	Biomarker	[408]
CCDC8	OTO295IH	Strong	Genetic Variation	[702]
CCL18	OT7JYSK9	Strong	Altered Expression	[725]
CCL27	OTUZYC61	Strong	Biomarker	[169]
CCL7	OTDIS99H	Strong	Altered Expression	[726]
CCN3	OTOW5YL4	Strong	Altered Expression	[727]
CD151	OTF3UZS7	Strong	Biomarker	[728]
CD1D	OT3ROU4J	Strong	Altered Expression	[729]
CD68	OTOYEY3J	Strong	Biomarker	[730]
CD82	OTH8MC64	Strong	Biomarker	[731]
CDC14B	OTAESVOZ	Strong	Altered Expression	[732]
CDC73	OT6JASZ1	Strong	Altered Expression	[733]
CDCP1	OTD7RRWK	Strong	Altered Expression	[734]
CDH15	OTJ1TO02	Strong	Biomarker	[204]
CDH8	OTS3SRZ6	Strong	Biomarker	[735]
CDH9	OTV9N5XK	Strong	Altered Expression	[736]
CDHR5	OTTBWQMN	Strong	Biomarker	[737]
CDK2AP2	OTR99SJ8	Strong	Genetic Variation	[206]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[738]
CEMIP	OTK80FYN	Strong	Altered Expression	[739]
CENPH	OTPOO9LK	Strong	Biomarker	[740]
CENPX	OTG1RAKJ	Strong	Altered Expression	[741]
CEP55	OTGSG2PA	Strong	Biomarker	[742]
CETN1	OTGQ8JOZ	Strong	Altered Expression	[743]
CHD5	OTS5EVHH	Strong	Genetic Variation	[744]
CHMP1A	OTVQ5UWX	Strong	Biomarker	[745]
CHMP1B	OTP715L8	Strong	Biomarker	[746]
CHPT1	OT4FJ0K3	Strong	Biomarker	[747]
CIAPIN1	OTWS90F9	Strong	Biomarker	[748]
CIB1	OT4BVCRU	Strong	Altered Expression	[749]
CIITA	OTRJNZFO	Strong	Biomarker	[750]
CISH	OT8T5NYL	Strong	Altered Expression	[80]
CLDN1	OT27KV99	Strong	Biomarker	[751]
CLEC1B	OTO38TRG	Strong	Biomarker	[752]
CLTRN	OTXGFJ3F	Strong	Altered Expression	[753]
CMAS	OTFQJG3C	Strong	Altered Expression	[754]
CMTM4	OTA3Z072	Strong	Biomarker	[528]
CNN2	OTH3CSXA	Strong	Biomarker	[215]
COL14A1	OTLNJ13O	Strong	Biomarker	[710]
COL15A1	OTTFKK18	Strong	Genetic Variation	[710]
COL23A1	OTYE0N3I	Strong	Biomarker	[755]
COL3A1	OTT1EMLM	Strong	Altered Expression	[726]
COL4A3	OT6SB8X5	Strong	Biomarker	[756]
COP1	OT6J2K12	Strong	Biomarker	[757]
COPS3	OTZWPJ24	Strong	Altered Expression	[758]
CORO6	OT9TFSVB	Strong	Genetic Variation	[702]
COX5A	OTP0961M	Strong	Biomarker	[177]
COX5B	OTDP94F3	Strong	Biomarker	[505]
COX6B1	OTNKXYQI	Strong	Biomarker	[505]
CPQ	OTTNZNLD	Strong	Biomarker	[263]
CRABP1	OTISDG5X	Strong	Biomarker	[759]
CRABP2	OTY01V9G	Strong	Altered Expression	[760]
CRADD	OT02TZ4S	Strong	Biomarker	[191]
CRB3	OTQKPTMU	Strong	Posttranslational Modification	[761]
CRISP2	OT8HLTV5	Strong	Altered Expression	[454]
CRPPA	OTC85K8Q	Strong	Altered Expression	[230]
CRYGD	OTW29JC4	Strong	Biomarker	[762]
CSMD3	OTAT75SW	Strong	Biomarker	[314]
CTAG1B	OTIQGW6U	Strong	Biomarker	[218]
CTDSPL	OTZJ0CZK	Strong	Altered Expression	[219]
CTHRC1	OTV88X2G	Strong	Biomarker	[763]
CTNNA1	OTFC725Z	Strong	Biomarker	[204]
CUL1	OTXPE1UZ	Strong	Biomarker	[764]
CXCL14	OTM189TA	Strong	Biomarker	[415]
CXCL5	OTZOUPCA	Strong	Biomarker	[765]
CYLD	OT37FKH0	Strong	Altered Expression	[766]
DAB2IP	OTF456VC	Strong	Altered Expression	[767]
DACH1	OTMKNAGG	Strong	Altered Expression	[768]
DAPK1	OTNCNUCO	Strong	Altered Expression	[769]
DDX31	OTNWY581	Strong	Altered Expression	[770]
DEF6	OTIRBYVK	Strong	Altered Expression	[771]
DHDDS	OTVLYBUS	Strong	Biomarker	[747]
DKC1	OTX7DJR6	Strong	Altered Expression	[772]
DKK4	OTWCCVF6	Strong	Altered Expression	[773]
DLC1	OTP8LMCR	Strong	Biomarker	[774]
DLEC1	OTMKKBUW	Strong	Biomarker	[775]
DMAC2L	OT2OQ1UD	Strong	Biomarker	[701]
DNAJB8	OT2CDBH6	Strong	Biomarker	[238]
DNHD1	OT4U3HUW	Strong	Biomarker	[314]
DOK4	OTUEWLG8	Strong	Altered Expression	[776]
DSG2	OTJPB2TO	Strong	Biomarker	[777]
DVL2	OTMNYNCM	Strong	Genetic Variation	[778]
DYNLL1	OTR69LHT	Strong	Biomarker	[774]
ECT2	OTQDUCT6	Strong	Biomarker	[779]
EEF2	OTZ7SZ39	Strong	Biomarker	[215]
EFNA1	OTU2NUA2	Strong	Biomarker	[254]
EHD2	OTTX391J	Strong	Altered Expression	[780]
EIF3B	OTF67VPH	Strong	Biomarker	[781]
EIF3C	OTR8RF9X	Strong	Altered Expression	[782]
EIF3D	OTDOMP80	Strong	Biomarker	[783]
EIF4B	OTE8TXA8	Strong	Biomarker	[784]
ELF5	OTLRU8YF	Strong	Altered Expression	[785]
ELL2	OTZJRTFM	Strong	Biomarker	[786]
ELOA	OTOQTF5K	Strong	Genetic Variation	[787]
ELOB	OTZ3X84T	Strong	Biomarker	[788]
ELOC	OT0XHHWP	Strong	Genetic Variation	[789]
ENO1	OTB1KWJS	Strong	Altered Expression	[157]
ENO2	OTRODL0T	Strong	Altered Expression	[790]
EOMES	OTB9VQFA	Strong	Altered Expression	[791]
EP400	OTVQ75NX	Strong	Biomarker	[792]
EPB41L3	OTS6CHG2	Strong	Altered Expression	[720]
ERCC4	OTFIOPG1	Strong	Altered Expression	[793]
ERCC6L	OTE9V7D9	Strong	Biomarker	[794]
ESM1	OT331Y8V	Strong	Biomarker	[795]
ESRP2	OTVTKJ4I	Strong	Genetic Variation	[126]
ETV1	OT6PMJIK	Strong	Altered Expression	[757]
FAM107A	OTBG61YZ	Strong	Posttranslational Modification	[796]
FAM111B	OT9IQ9NV	Strong	Biomarker	[222]
FAM20C	OTW5YZ7X	Strong	Biomarker	[797]
FBLN1	OT5MHHOP	Strong	Altered Expression	[798]
FBN2	OT3KYJQL	Strong	Biomarker	[799]
FBXO22	OTEJ5MO0	Strong	Biomarker	[800]
FBXW4	OTEGSZOX	Strong	Biomarker	[681]
FCGR3B	OTSLSPZG	Strong	Altered Expression	[801]
FERMT2	OTZNPWWX	Strong	Altered Expression	[802]
FHL5	OT6C00Z1	Strong	Biomarker	[684]
FLOT1	OT0JPPJZ	Strong	Altered Expression	[803]
FMN2	OTUY7BSV	Strong	Biomarker	[222]
FNIP1	OTB1CC41	Strong	Biomarker	[804]
FNIP2	OT7EX8JJ	Strong	Altered Expression	[805]
FOXH1	OTEXJ9SL	Strong	Altered Expression	[806]
FOXI1	OT2UFOE2	Strong	Altered Expression	[807]
FOXO3	OTHXQG4P	Strong	Biomarker	[808]
FOXO4	OT90X9LN	Strong	Altered Expression	[809]
FPGT	OTVZJL3U	Strong	Biomarker	[314]
FRZB	OTTO3DPY	Strong	Biomarker	[810]
FSD1	OT8P6PT3	Strong	Altered Expression	[811]
FSD1L	OTBQ48RF	Strong	Altered Expression	[811]
FSTL1	OT6KEZUD	Strong	Biomarker	[812]
FUBP1	OT77SC9N	Strong	Altered Expression	[813]
FZD1	OTZATHVS	Strong	Genetic Variation	[814]
FZD5	OTXFFY56	Strong	Biomarker	[815]
FZD8	OTZ9IRFL	Strong	Altered Expression	[816]
GADD45G	OT8V1J4M	Strong	Biomarker	[750]
GAL3ST1	OTSFFZRD	Strong	Biomarker	[817]
GAS1	OTKJXG52	Strong	Biomarker	[818]
GATA1	OTX1R7O1	Strong	Altered Expression	[819]
GATA5	OTO81B63	Strong	Posttranslational Modification	[820]
GC	OTWS63BY	Strong	Biomarker	[821]
GDE1	OTU6FSBF	Strong	Altered Expression	[822]
GDF9	OTNTVKVU	Strong	Altered Expression	[823]
GEMIN4	OTX7402E	Strong	Genetic Variation	[824]
GFOD1	OTOHDWX1	Strong	Biomarker	[825]
GLIS3	OTBC960E	Strong	Altered Expression	[826]
GNA13	OTVDL515	Strong	Biomarker	[827]
GNG4	OTOXNDI9	Strong	Altered Expression	[828]
GOLPH3	OTDLGYM3	Strong	Altered Expression	[829]
GPR151	OT7EACU6	Strong	Biomarker	[284]
GPSM2	OT6RPMRM	Strong	Biomarker	[281]
GRB7	OTF8Y9XY	Strong	Biomarker	[314]
GRHL1	OTZ4MNEW	Strong	Altered Expression	[285]
GRP	OT8JDFNI	Strong	Altered Expression	[830]
GSTM2	OTG4WT05	Strong	Biomarker	[831]
GSTM3	OTLA2WJT	Strong	Genetic Variation	[44]
H4C1	OTB71W46	Strong	Biomarker	[832]
HAO2	OTDWSQ0L	Strong	Biomarker	[833]
HARS1	OTHOEOTS	Strong	Biomarker	[215]
HAVCR2	OTOL603T	Strong	Altered Expression	[834]
HEPACAM	OT1MJ51D	Strong	Altered Expression	[835]
HES4	OTCGMQDT	Strong	Altered Expression	[836]
HEY1	OTJQL0I3	Strong	Altered Expression	[837]
HHLA2	OTYBTVQS	Strong	Biomarker	[838]
HIC1	OTI9TWY4	Strong	Posttranslational Modification	[839]
HIF3A	OTPWAAMC	Strong	Biomarker	[840]
HIVEP3	OTM3QT3L	Strong	Biomarker	[841]
HLA-E	OTX1CTFB	Strong	Biomarker	[842]
HMGN5	OTUUAHVQ	Strong	Altered Expression	[843]
HMMR	OT4M0JTZ	Strong	Altered Expression	[844]
HNRNPK	OTNPRM8U	Strong	Biomarker	[845]
HNRNPUL1	OTJP4U7K	Strong	Altered Expression	[846]
HOXA6	OTHJP8M2	Strong	Altered Expression	[847]
HOXC11	OT8NMHM6	Strong	Biomarker	[848]
HSPA1A	OTKGIE76	Strong	Biomarker	[849]
HSPA2	OTSDET7B	Strong	Biomarker	[849]
HSPB7	OTLATAOV	Strong	Biomarker	[850]
HSPH1	OTVRR73T	Strong	Biomarker	[851]
HTRA3	OTXJ0H4X	Strong	Altered Expression	[852]
IFNA1	OTPMKY0L	Strong	Biomarker	[853]
IGF2BP1	OT9G360P	Strong	Altered Expression	[854]
IGFBP4	OT2HZRBD	Strong	Altered Expression	[855]
IL20RB	OTHFXK95	Strong	Altered Expression	[175]
IL6R	OTCQL07Z	Strong	Biomarker	[856]
INPP4B	OTLROA7G	Strong	Biomarker	[857]
INSRR	OT3F75WA	Strong	Biomarker	[858]
IRF9	OTK4MYQJ	Strong	Biomarker	[859]
ITGA2B	OT4Y17PY	Strong	Genetic Variation	[860]
JADE1	OTBPJIRI	Strong	Biomarker	[861]
KANK1	OT2E7A6W	Strong	Biomarker	[862]
KANK2	OT3SZIWM	Strong	Altered Expression	[863]
KAT8	OT5LPQTR	Strong	Altered Expression	[864]
KDM5D	OTEKG0KD	Strong	Posttranslational Modification	[865]
KDM6A	OTZM3MJJ	Strong	Biomarker	[866]
KIF18B	OTOBUDOE	Strong	Altered Expression	[175]
KIF1B	OTI1XQTO	Strong	Biomarker	[867]
KIF22	OTY6X6BL	Strong	Biomarker	[868]
KIF3A	OTMUBSSK	Strong	Biomarker	[869]
KLF10	OT4F4UGS	Strong	Altered Expression	[870]
KLF8	OTUC5CDB	Strong	Altered Expression	[871]
KLHL1	OTAX6SAD	Strong	Altered Expression	[872]
KLHL35	OT1DL3FY	Strong	Genetic Variation	[702]
KLK10	OTD573EL	Strong	Biomarker	[322]
KLK11	OT5PKX7Y	Strong	Altered Expression	[873]
KLLN	OTV3FPH0	Strong	Biomarker	[510]
KMT2B	OTMMAZQX	Strong	Biomarker	[874]
KRT32	OTZCGZYT	Strong	Biomarker	[314]
KRT72	OTAXW63A	Strong	Biomarker	[875]
L2HGDH	OTW6C712	Strong	Altered Expression	[876]
LAMTOR2	OTHEDISB	Strong	Genetic Variation	[206]
LARGE2	OT5BZS3J	Strong	Altered Expression	[230]
LARP6	OTUQ9QS9	Strong	Altered Expression	[838]
LAT	OTZC1XZ1	Strong	Posttranslational Modification	[541]
LAT2	OTWJDKIH	Strong	Altered Expression	[427]
LATS1	OTOOCG4R	Strong	Biomarker	[877]
LAYN	OT9A9Q1X	Strong	Altered Expression	[878]
LCN1	OT8BWXTV	Strong	Altered Expression	[879]
LDHB	OT9B1CT3	Strong	Biomarker	[215]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[880]
LGALS9	OT7MF91K	Strong	Altered Expression	[881]
LGR6	OTPZ1PWR	Strong	Biomarker	[284]
LHX1	OT6WI2XS	Strong	Biomarker	[882]
LIMD1	OTN1CG6R	Strong	Altered Expression	[883]
LMAN2L	OTJ9FAWS	Strong	Biomarker	[314]
LMLN	OTQF0JPY	Strong	Biomarker	[884]
LPCAT1	OTCV7AGV	Strong	Altered Expression	[885]
LRIG1	OTY5HZN5	Strong	Biomarker	[886]
LRP1B	OT4YZG2N	Strong	Biomarker	[222]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[887]
LRRC3B	OT9VDGPR	Strong	Posttranslational Modification	[888]
LRRFIP1	OTN7XAUD	Strong	Altered Expression	[359]
LSAMP	OTYXVQX2	Strong	Biomarker	[889]
LY6G6D	OTG75QOC	Strong	Biomarker	[340]
LYPD5	OTGP7UKA	Strong	Biomarker	[890]
MAD2L1	OTXNGZCG	Strong	Altered Expression	[891]
MAGEA9	OTWGX2SD	Strong	Biomarker	[892]
MAGEB2	OTAGUVU5	Strong	Altered Expression	[893]
MAGED1	OT6EOLFC	Strong	Altered Expression	[893]
MAGI1	OTMV4ASV	Strong	Biomarker	[894]
MAGT1	OTQSAV5C	Strong	Altered Expression	[161]
MAK16	OTD546E5	Strong	Biomarker	[895]
MAL2	OTVPEI80	Strong	Altered Expression	[896]
MAML1	OTQA4DDN	Strong	Biomarker	[313]
MAP1LC3A	OTPMGIU4	Strong	Biomarker	[897]
MARCHF8	OTH7PNN2	Strong	Biomarker	[898]
MARCKSL1	OT13J2FM	Strong	Biomarker	[899]
MAX	OTKZ0YKM	Strong	Biomarker	[900]
MB	OTYWYL2D	Strong	Altered Expression	[901]
MCAT	OTH07FIW	Strong	Biomarker	[15]
MCC	OTQVI1EM	Strong	Biomarker	[902]
MCF2L	OTEURA8N	Strong	Genetic Variation	[903]
MCRS1	OT8K2X8P	Strong	Biomarker	[904]
MCTS1	OT7SAOJP	Strong	Biomarker	[15]
MED12	OTQZ4D2X	Strong	Biomarker	[905]
MED15	OT0D0JVD	Strong	Genetic Variation	[906]
MED30	OTM3INJN	Strong	Biomarker	[907]
MED8	OTSIZ1I7	Strong	Altered Expression	[905]
METTL3	OTSXP1M3	Strong	Altered Expression	[908]
MFAP1	OTZN4FT3	Strong	Biomarker	[336]
MGP	OTZWU3FU	Strong	Altered Expression	[909]
MIB1	OT5C404P	Strong	Altered Expression	[348]
MINDY4	OTBZ2SZB	Strong	Altered Expression	[187]
MIP	OTEBLU3E	Strong	Biomarker	[882]
MITF	OT6XJCZH	Strong	Biomarker	[910]
MLLT10	OTURMDV7	Strong	Biomarker	[314]
MLXIP	OT30UNI7	Strong	Biomarker	[898]
MOK	OTQK7M9V	Strong	Biomarker	[911]
MPDZ	OT9WY1QM	Strong	Altered Expression	[912]
MRGPRX3	OTRKCCDS	Strong	Biomarker	[284]
MRGPRX4	OTOBHZVA	Strong	Biomarker	[284]
MRPL41	OTG5URO4	Strong	Biomarker	[913]
MSGN1	OTZGNRKZ	Strong	Biomarker	[314]
MST1	OTOC4UNG	Strong	Biomarker	[884]
MT1E	OTXJKU4Y	Strong	Posttranslational Modification	[555]
MT1H	OT0MVBM6	Strong	Biomarker	[503]
MTA3	OTIA6C79	Strong	Biomarker	[890]
MTG1	OTC9U1LI	Strong	Biomarker	[914]
MTHFD2	OT1LQSGX	Strong	Posttranslational Modification	[915]
MUC13	OTWKS9MF	Strong	Altered Expression	[916]
MUC3A	OTI4XUDY	Strong	Altered Expression	[355]
MXI1	OTUQ9E0D	Strong	Altered Expression	[891]
MYH9	OT94Z706	Strong	Biomarker	[917]
MYL2	OT78PC0C	Strong	Biomarker	[828]
MYL9	OT6B22JB	Strong	Biomarker	[828]
MYLIP	OTL0PFGV	Strong	Biomarker	[898]
NAV3	OT97M1TR	Strong	Biomarker	[222]
NCF2	OTAUW7L2	Strong	Biomarker	[750]
NCOA6	OTOMIGTV	Strong	Biomarker	[918]
ND3	OT1OC3K3	Strong	Biomarker	[919]
NDRG1	OTVO66BO	Strong	Biomarker	[215]
NDUFA4L2	OTK0PG7R	Strong	Biomarker	[920]
NDUFB6	OTIXNT91	Strong	Altered Expression	[921]
NEFH	OTMSCW5I	Strong	Posttranslational Modification	[922]
NELL2	OTS4MJZ7	Strong	Biomarker	[361]
NEU1	OTH9BY8Y	Strong	Altered Expression	[923]
NEURL1	OT2C4P70	Strong	Altered Expression	[923]
NFATC1	OT4TMERS	Strong	Biomarker	[86]
NFIA	OTDHQ9CG	Strong	Altered Expression	[924]
NFIC	OTLMCUIB	Strong	Altered Expression	[924]
NLRP12	OTGR132Z	Strong	Biomarker	[314]
NLRP2	OTJA81JU	Strong	Biomarker	[925]
NME2	OTCYGLHV	Strong	Altered Expression	[926]
NOL3	OT1K0L0D	Strong	Altered Expression	[927]
NONO	OTN36Q6U	Strong	Genetic Variation	[928]
NPC2	OTE9UEJC	Strong	Altered Expression	[929]
NPRL2	OTOB10MO	Strong	Biomarker	[930]
NR2C2	OTDZWVOJ	Strong	Biomarker	[931]
NSG1	OTRIMA50	Strong	Altered Expression	[932]
NT5C1A	OTS7UF36	Strong	Genetic Variation	[717]
NUB1	OTWA6RTX	Strong	Biomarker	[933]
NUCB2	OTHO6JWN	Strong	Biomarker	[934]
NUDCD1	OT8DS3CX	Strong	Altered Expression	[646]
NUDT17	OTE8FOEW	Strong	Biomarker	[935]
NUDT5	OTHYCBA6	Strong	Biomarker	[935]
NUSAP1	OT85HIJ5	Strong	Biomarker	[936]
NXF1	OTEFHXG6	Strong	Biomarker	[395]
OBP2A	OTBIJ5TI	Strong	Biomarker	[868]
OCLN	OTSUTVWL	Strong	Biomarker	[818]
OIP5	OTI5C2DE	Strong	Biomarker	[937]
ORC2	OTLIYP8M	Strong	Altered Expression	[383]
OSR1	OTB19LEQ	Strong	Biomarker	[938]
PACC1	OTKBS8CC	Strong	Biomarker	[939]
PACRG	OT1NYNNW	Strong	Altered Expression	[940]
PAG1	OTFOJUIQ	Strong	Altered Expression	[941]
PARD3	OTH5BPLO	Strong	Altered Expression	[262]
PCDH17	OTRK0M05	Strong	Biomarker	[942]
PCDH8	OTDDOQM2	Strong	Biomarker	[943]
PCLAF	OTMVIOUU	Strong	Biomarker	[944]
PDC	OT1UUVYY	Strong	Genetic Variation	[945]
PDHB	OT2NHE5E	Strong	Biomarker	[263]
PDLIM3	OTVXQC81	Strong	Biomarker	[169]
PDXDC1	OTKH7U5Q	Strong	Biomarker	[263]
PHC1	OT1JMX8U	Strong	Altered Expression	[946]
PIAS2	OTJLSC3V	Strong	Altered Expression	[947]
PIDD1	OTWFM930	Strong	Biomarker	[191]
PIP	OTH719AH	Strong	Biomarker	[948]
PITX1	OTA0UN4C	Strong	Biomarker	[49]
PLA2G15	OT6VJTPA	Strong	Genetic Variation	[683]
PLCL1	OTJL2C79	Strong	Biomarker	[949]
PLIN2	OTRXJ9UN	Strong	Biomarker	[950]
PLK5	OTW5YPKM	Strong	Biomarker	[951]
PMAIP1	OTXEE550	Strong	Biomarker	[952]
PMS2	OTNLWTMI	Strong	Biomarker	[953]
PNCK	OT35ZL74	Strong	Biomarker	[954]
PNKD	OT6G9UXN	Strong	Biomarker	[263]
PNO1	OT010GIS	Strong	Biomarker	[895]
POTEM	OT7L2HGH	Strong	Biomarker	[684]
POU2F2	OTPV0J0C	Strong	Biomarker	[423]
POU3F2	OT30NFOC	Strong	Altered Expression	[924]
PPBP	OT1FHGQS	Strong	Biomarker	[955]
PRCC	OTJ0KRYX	Strong	Genetic Variation	[115]
PRDM2	OT8L7CGX	Strong	Altered Expression	[956]
PRDM9	OTWAHLUR	Strong	Biomarker	[957]
PRDX3	OTLB2WEU	Strong	Altered Expression	[958]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[178]
PRRT2	OTCJUBDO	Strong	Biomarker	[959]
PRSS55	OTXXWI5Y	Strong	Altered Expression	[454]
PSME3	OTSTC4YY	Strong	Biomarker	[107]
PTHLH	OTI1JF13	Strong	Biomarker	[960]
PTPRD	OTZPJ3GX	Strong	Genetic Variation	[961]
PTPRG	OT9N2WOF	Strong	Genetic Variation	[485]
PTPRT	OTV5TXNN	Strong	Biomarker	[962]
PTPRU	OTHDO0QG	Strong	Genetic Variation	[485]
PYROXD2	OTJIX22S	Strong	Altered Expression	[963]
QKI	OTTAUGLB	Strong	Biomarker	[964]
RAB37	OTRL8IUO	Strong	Biomarker	[965]
RAB38	OTU0NZU0	Strong	Genetic Variation	[966]
RAG2	OTG9UYTW	Strong	Biomarker	[967]
RALYL	OT232N7Q	Strong	Altered Expression	[968]
RAP1B	OTHEIIMM	Strong	Biomarker	[969]
RAP1GAP	OTC31ONQ	Strong	Altered Expression	[970]
RAP2B	OTD2NDQP	Strong	Biomarker	[971]
RAPGEF5	OT53VS75	Strong	Biomarker	[972]
RARRES1	OTETUPP5	Strong	Altered Expression	[973]
RASSF5	OT6Q41I2	Strong	Biomarker	[889]
RASSF6	OT25GVWY	Strong	Biomarker	[974]
RBM10	OTES2MES	Strong	Biomarker	[975]
RBM14	OTO9GMBD	Strong	Altered Expression	[976]
RBM38	OTPO8EXU	Strong	Biomarker	[977]
RBMS3	OTFSC9MR	Strong	Biomarker	[895]
RBP1	OTRP1MFC	Strong	Biomarker	[759]
RBP2	OTR8QG5V	Strong	Altered Expression	[760]
RCC1	OT25AGMB	Strong	Altered Expression	[978]
RETN	OTW5Z1NH	Strong	Altered Expression	[57]
RGS5	OTUY0Q2I	Strong	Biomarker	[979]
RHEB	OTFLTSEC	Strong	Genetic Variation	[980]
RHEBL1	OTPOMM5J	Strong	Altered Expression	[981]
RIOX1	OTN41QXP	Strong	Posttranslational Modification	[982]
RIOX2	OT2YFPI2	Strong	Altered Expression	[982]
RNASE3	OTVE2XD1	Strong	Biomarker	[983]
RNASEH2A	OT8G3G7K	Strong	Altered Expression	[984]
RNF111	OTO3QT6Q	Strong	Biomarker	[985]
RNF121	OTA0YMLW	Strong	Biomarker	[986]
RNF125	OTBD1Q3X	Strong	Biomarker	[987]
RPL14	OTZZW7TK	Strong	Biomarker	[314]
RPL17	OTTYMPS6	Strong	Altered Expression	[988]
RPP14	OT4OYFSK	Strong	Genetic Variation	[206]
RPS15A	OT0BUA12	Strong	Biomarker	[989]
RPS6	OTT4D1LN	Strong	Biomarker	[990]
RTL10	OTHGB81W	Strong	Genetic Variation	[709]
RUNX1T1	OT30DED5	Strong	Biomarker	[991]
S100A1	OT1F2G4J	Strong	Biomarker	[992]
S100A10	OTI71243	Strong	Biomarker	[279]
S100A11	OTI57KDN	Strong	Altered Expression	[993]
S100A5	OTCGGL6K	Strong	Altered Expression	[994]
SAGE1	OT4H6FFA	Strong	Altered Expression	[995]
SARDH	OTQ49Q27	Strong	Genetic Variation	[587]
SART1	OTHMOGO1	Strong	Biomarker	[261]
SATB2	OT2W80XC	Strong	Altered Expression	[996]
SAV1	OTSAEV92	Strong	Altered Expression	[997]
SCO2	OTJQQDRS	Strong	Altered Expression	[459]
SCPEP1	OT43LYEZ	Strong	Altered Expression	[219]
SCUBE3	OT2EADLC	Strong	Genetic Variation	[702]
SCYL1	OTQ0IN7P	Strong	Biomarker	[998]
SDC3	OT1P0LJM	Strong	Biomarker	[999]
SDF4	OTQ7WFYW	Strong	Altered Expression	[743]
SDHA	OTOJ8QFF	Strong	Genetic Variation	[81]
SEC14L2	OTJST64D	Strong	Biomarker	[395]
SELENOM	OTJ7PORS	Strong	Biomarker	[1000]
SEMG1	OT6Z4BPQ	Strong	Altered Expression	[1001]
SERPINA3	OT9BP2S0	Strong	Biomarker	[684]
SERPINA5	OTTZXPGD	Strong	Genetic Variation	[1002]
SET	OTGYYQJO	Strong	Altered Expression	[1003]
SETD3	OTO5RAU2	Strong	Biomarker	[982]
SETDB2	OTBVVP9Q	Strong	Altered Expression	[982]
SF3B3	OTAC9LZT	Strong	Biomarker	[1004]
SF3B6	OTPRKS6S	Strong	Genetic Variation	[206]
SFMBT1	OTKMZIBW	Strong	Biomarker	[316]
SFPQ	OTLCIAPJ	Strong	Biomarker	[302]
SFRP2	OT8GZ0CA	Strong	Biomarker	[681]
SFRP5	OTLCVVSH	Strong	Biomarker	[1005]
SH3BP2	OT90JNBS	Strong	Altered Expression	[417]
SHANK1	OTK8PV0S	Strong	Biomarker	[222]
SIGLEC8	OTQ5TRRV	Strong	Altered Expression	[1006]
SIX2	OTYOVGSC	Strong	Altered Expression	[1007]
SLC16A4	OT1YXBKC	Strong	Biomarker	[421]
SLC35G2	OTFBVS0P	Strong	Biomarker	[965]
SLFN5	OTT1AESL	Strong	Biomarker	[1008]
SLPI	OTUNFUU8	Strong	Biomarker	[169]
SMAD2	OTC6VB4K	Strong	Biomarker	[1009]
SMARCA1	OT0Y6PTU	Strong	Altered Expression	[1010]
SMG1	OTTS3SXE	Strong	Altered Expression	[252]
SMIM5	OTIN1T0L	Strong	Biomarker	[500]
SMN2	OT54RLO1	Strong	Genetic Variation	[429]
SMUG1	OT2YIOCQ	Strong	Biomarker	[1011]
SMURF2	OT3TRVL7	Strong	Biomarker	[1012]
SOSTDC1	OTAKDNSM	Strong	Biomarker	[1013]
SOX4	OTSS40SS	Strong	Biomarker	[1014]
SOX7	OTOZOFAG	Strong	Biomarker	[1015]
SPAG9	OT45AHMB	Strong	Biomarker	[1016]
SPARCL1	OT74DWMV	Strong	Altered Expression	[1017]
SPATA2	OTOA45GL	Strong	Altered Expression	[988]
SPINK1	OTSUVAL2	Strong	Biomarker	[1018]
SPINT1	OT1CLR5L	Strong	Biomarker	[291]
SPRY2	OTH0CRCZ	Strong	Biomarker	[1019]
SPTBN4	OTAJAVP9	Strong	Biomarker	[222]
SPZ1	OTQH8HJ5	Strong	Altered Expression	[454]
SRRM2	OTSIMMC9	Strong	Biomarker	[895]
SRSF1	OTF61HOV	Strong	Altered Expression	[1020]
SRXN1	OTYDBO4L	Strong	Biomarker	[1021]
SSH2	OT8NCK82	Strong	Altered Expression	[1022]
ST3GAL2	OT8WM21E	Strong	Altered Expression	[1023]
ST3GAL4	OTNENJZQ	Strong	Altered Expression	[1024]
STAG1	OT564IX4	Strong	Altered Expression	[1025]
SUB1	OTK71JYU	Strong	Genetic Variation	[206]
SUMO1	OTJFD4P5	Strong	Altered Expression	[1026]
SUPT20H	OTTMC0LH	Strong	Altered Expression	[1027]
SUSD2	OTSJTAZP	Strong	Biomarker	[1028]
SYCE1L	OTXU44F3	Strong	Altered Expression	[872]
SYCP1	OTWFV4KA	Strong	Altered Expression	[219]
SYCP3	OTKOF54H	Strong	Altered Expression	[219]
SYNE2	OTBUXGQ0	Strong	Biomarker	[222]
SYT6	OTE3F36L	Strong	Altered Expression	[768]
TAP2	OTWSYFI7	Strong	Posttranslational Modification	[1029]
TAPBP	OTL81AVZ	Strong	Biomarker	[395]
TBC1D8	OT2011SS	Strong	Biomarker	[1030]
TBC1D9	OTSSCTB5	Strong	Biomarker	[1031]
TBP	OT6C0S52	Strong	Biomarker	[1032]
TBPL1	OT4I143E	Strong	Altered Expression	[437]
TCEAL1	OTAPG2L5	Strong	Altered Expression	[932]
TCF21	OT393IMA	Strong	Posttranslational Modification	[1033]
TCF4	OTB9ASTK	Strong	Biomarker	[1009]
TCHP	OTVDMHSY	Strong	Altered Expression	[817]
TESC	OTI8C76M	Strong	Altered Expression	[79]
TET2	OTKKT03T	Strong	Biomarker	[314]
TET3	OT76U3YF	Strong	Altered Expression	[170]
TFCP2L1	OT7QIJ0X	Strong	Biomarker	[1034]
TFEB	OTJUJJQY	Strong	Biomarker	[1035]
TGFBR3	OTQOOUC4	Strong	Biomarker	[1036]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[533]
TIGAR	OTR7NMRJ	Strong	Altered Expression	[1037]
TIMD4	OTGGC20G	Strong	Biomarker	[1038]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[697]
TMED7	OTONO8E6	Strong	Altered Expression	[533]
TMED9	OTYGAQS0	Strong	Genetic Variation	[206]
TMEFF2	OT1WZ2QO	Strong	Posttranslational Modification	[1039]
TMEM176B	OTEGF2BV	Strong	Altered Expression	[771]
TMEM213	OTRXSK61	Strong	Biomarker	[500]
TMEM45A	OT54KJG6	Strong	Altered Expression	[1040]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[884]
TMSB10	OTLVZ13T	Strong	Biomarker	[1041]
TNFAIP6	OT1SLUZH	Strong	Biomarker	[1042]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[1043]
TNS3	OTPG2D8Z	Strong	Altered Expression	[1044]
TOX3	OTC9NR4W	Strong	Biomarker	[581]
TP53I3	OTSCM68G	Strong	Biomarker	[913]
TP53INP1	OT2363Z9	Strong	Altered Expression	[863]
TP73	OT0LUO47	Strong	Altered Expression	[1045]
TPD52	OTPKSK43	Strong	Biomarker	[1046]
TPM1	OTD73X6R	Strong	Altered Expression	[1047]
TPM3	OT5RU5G6	Strong	Genetic Variation	[1048]
TPPP	OTCFMSUF	Strong	Genetic Variation	[206]
TRAF1	OTTLM5RU	Strong	Biomarker	[1049]
TRAM1	OT3I0H8E	Strong	Altered Expression	[1050]
TRIM33	OT0KS4J7	Strong	Altered Expression	[1051]
TRIM8	OTS6JFR0	Strong	Biomarker	[1052]
TRIM9	OTKYG33W	Strong	Altered Expression	[837]
TSACC	OT3QW6PH	Strong	Altered Expression	[863]
TSC1	OTFF4YZ7	Strong	Genetic Variation	[477]
ARID1A	OTRWDV3P	Definitive	Altered Expression	[1053]
ELK1	OTH9MXD6	Definitive	Altered Expression	[1054]
HAVCR1	OT184CRZ	Definitive	Biomarker	[1055]
KRT7	OTLT3JFN	Definitive	Biomarker	[1056]
MUC4	OTLT11V1	Definitive	Altered Expression	[1057]
MUL1	OT2JC9YR	Definitive	Altered Expression	[1058]
NDUFS1	OTTIZDFR	Definitive	Altered Expression	[1059]
PGK1	OT6V1ICH	Definitive	Altered Expression	[1060]
PRKN	OTJBN41W	Definitive	Altered Expression	[522]
RELA	OTUJP9CN	Definitive	Biomarker	[134]
SLC49A4	OTXL3KAM	Definitive	Biomarker	[1061]
TMED3	OTNOPHHC	Definitive	Biomarker	[1062]
TMEM127	OTYHUXC1	Definitive	Genetic Variation	[900]
TSC2	OT47LWI9	Definitive	Genetic Variation	[477]

References

• [1] ABAT and ALDH6A1, regulated by transcription factor HNF4A, suppress tumorigenic capability in clear cell renal cell carcinoma. J Transl Med. 2020 Feb 24;18(1):101.
• [2] Sorafenib FDA Label
• [3] Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.Int J Cancer. 2018 Dec 15;143(12):3181-3193. doi: 10.1002/ijc.31741. Epub 2018 Sep 25.
• [4] ACAT1 and Metabolism-Related Pathways Are Essential for the Progression of Clear Cell Renal Cell Carcinoma (ccRCC), as Determined by Co-expression Network Analysis.Front Oncol. 2019 Oct 9;9:957. doi: 10.3389/fonc.2019.00957. eCollection 2019.
• [5] Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes.Cancer Med. 2019 Nov;8(15):6780-6788. doi: 10.1002/cam4.2552. Epub 2019 Sep 11.
• [6] The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.Carcinogenesis. 2011 Nov;32(11):1713-23. doi: 10.1093/carcin/bgr195. Epub 2011 Aug 30.
• [7] Changes in expressions of ADAM9, 10, and 17 as well as -secretase activity in renal cell carcinoma.Urol Oncol. 2017 Jan;35(1):36.e15-36.e22. doi: 10.1016/j.urolonc.2016.08.010. Epub 2016 Sep 28.
• [8] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [9] Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma.Urol Oncol. 2017 May;35(5):279-285. doi: 10.1016/j.urolonc.2016.12.017. Epub 2017 Jan 19.
• [10] The gene from the short arm of chromosome 3, at D3F15S2, frequently deleted in renal cell carcinoma, encodes acylpeptide hydrolase.Oncogene. 1991 Jul;6(7):1293-5.
• [11] Apelin and apelin receptor expression in renal cell carcinoma.Br J Cancer. 2019 Mar;120(6):633-639. doi: 10.1038/s41416-019-0396-7. Epub 2019 Feb 20.
• [12] Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.J Transl Med. 2019 Nov 8;17(1):363. doi: 10.1186/s12967-019-2113-y.
• [13] Bexarotene - a novel modulator of AURKA and the primary cilium in VHL-deficient cells.J Cell Sci. 2018 Dec 14;131(24):jcs219923. doi: 10.1242/jcs.219923.
• [14] Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis.Clin Cancer Res. 2006 Dec 15;12(24):7294-305. doi: 10.1158/1078-0432.CCR-06-2060.
• [15] The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.PLoS One. 2018 Feb 26;13(2):e0193477. doi: 10.1371/journal.pone.0193477. eCollection 2018.
• [16] Circ_0039569 promotes renal cell carcinoma growth and metastasis by regulating miR-34a-5p/CCL22.Am J Transl Res. 2019 Aug 15;11(8):4935-4945. eCollection 2019.
• [17] A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.J Clin Invest. 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. Epub 2017 Jan 30.
• [18] Down-Regulation of Circular RNA_000926 Attenuates Renal Cell Carcinoma Progression through miRNA-411-Dependent CDH2 Inhibition.Am J Pathol. 2019 Dec;189(12):2469-2486. doi: 10.1016/j.ajpath.2019.06.016. Epub 2019 Aug 30.
• [19] sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro.Urol Oncol. 2019 Jun;37(6):355.e1-355.e9. doi: 10.1016/j.urolonc.2019.03.001. Epub 2019 Apr 18.
• [20] Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells.Anticancer Res. 2005 Jan-Feb;25(1A):377-81.
• [21] MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).Biomed Pharmacother. 2019 Mar;111:517-526. doi: 10.1016/j.biopha.2018.12.102. Epub 2018 Dec 28.
• [22] Carcinoembryonic antigen related cell adhesion molecule 6 promotes the proliferation and migration of renal cancer cells through the ERK/AKT signaling pathway.Transl Androl Urol. 2019 Oct;8(5):457-466. doi: 10.21037/tau.2019.09.02.
• [23] TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer.Oncotarget. 2017 Dec 26;9(11):9672-9684. doi: 10.18632/oncotarget.23822. eCollection 2018 Feb 9.
• [24] Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma.PeerJ. 2019 Nov 26;7:e8096. doi: 10.7717/peerj.8096. eCollection 2019.
• [25] Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane.Anticancer Res. 2015 Dec;35(12):6521-8.
• [26] Identification of potential core genes in metastatic renal cell carcinoma using bioinformatics analysis.Am J Transl Res. 2019 Nov 15;11(11):6812-6825. eCollection 2019.
• [27] Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.J Exp Clin Cancer Res. 2017 Mar 9;36(1):41. doi: 10.1186/s13046-017-0507-3.
• [28] Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.Int J Cancer. 2018 Sep 1;143(5):1162-1175. doi: 10.1002/ijc.31400. Epub 2018 Apr 16.
• [29] Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.Cell Cycle. 2019 Nov;18(21):2939-2953. doi: 10.1080/15384101.2019.1664223. Epub 2019 Sep 16.
• [30] Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways.Clin Cancer Res. 2009 Sep 15;15(18):5678-87. doi: 10.1158/1078-0432.CCR-09-0558.
• [31] MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3.Oncol Lett. 2018 Apr;15(4):6003-6008. doi: 10.3892/ol.2018.7998. Epub 2018 Feb 8.
• [32] Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?.Urol Oncol. 2016 May;34(5):215-20. doi: 10.1016/j.urolonc.2015.12.013. Epub 2016 Feb 2.
• [33] AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.Clin Cancer Res. 2016 Apr 15;22(8):1989-99. doi: 10.1158/1078-0432.CCR-15-1542. Epub 2015 Nov 20.
• [34] Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.Tumour Biol. 2016 Oct;37(10):13581-13593. doi: 10.1007/s13277-016-5279-4. Epub 2016 Jul 28.
• [35] Molecular profiling of transcription factors pinpoints MYC-estrogen related receptor -regulatory factor X5 panel for characterizing the immune microenvironment and predicting the efficacy of immune checkpoint inhibitors in renal cell carcinoma.Oncol Lett. 2019 Aug;18(2):1895-1903. doi: 10.3892/ol.2019.10523. Epub 2019 Jun 24.
• [36] Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.Mol Cancer Res. 2019 Jan;17(1):84-96. doi: 10.1158/1541-7786.MCR-17-0636. Epub 2018 Aug 21.
• [37] Study of FABP's interactome and detecting new molecular targets in clear cell renal cell carcinoma.J Cell Physiol. 2020 Apr;235(4):3776-3789. doi: 10.1002/jcp.29272. Epub 2019 Oct 10.
• [38] Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas.Cancer Lett. 2008 Jul 8;265(2):250-7. doi: 10.1016/j.canlet.2008.02.036. Epub 2008 Apr 18.
• [39] FK506 Binding Protein 10 Is Overexpressed and Promotes Renal Cell Carcinoma.Urol Int. 2017;98(2):169-176. doi: 10.1159/000448338. Epub 2016 Sep 8.
• [40] MicroRNA-363 inhibits angiogenesis, proliferation, invasion, and migration of renal cell carcinoma via inactivation of the Janus tyrosine kinases 2-signal transducers and activators of transcription 3 axis by suppressing growth hormone receptor gene.J Cell Physiol. 2019 Mar;234(3):2581-2592. doi: 10.1002/jcp.27020. Epub 2018 Sep 19.
• [41] Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study.Carcinogenesis. 2019 Oct 16;40(10):1191-1197. doi: 10.1093/carcin/bgz074.
• [42] G Protein subunit 7 loss contributes to progression of clear cell renal cell carcinoma.J Cell Physiol. 2019 Nov;234(11):20002-20012. doi: 10.1002/jcp.28597. Epub 2019 Apr 3.
• [43] Homeodomain interacting protein kinase-2 phosphorylates FOXM1 and promotes FOXM1-mediated tumor growth in renal cell carcinoma.J Cell Biochem. 2019 Jun;120(6):10391-10401. doi: 10.1002/jcb.28323. Epub 2019 Jan 4.
• [44] A novel functional polymorphism of GSTM3 reduces clear cell renal cell carcinoma risk through enhancing its expression by interfering miR-556 binding.J Cell Mol Med. 2018 Jun;22(6):3005-3015. doi: 10.1111/jcmm.13528. Epub 2018 Mar 22.
• [45] IDUA, NDST1, SAP30L, CRYBA4, and SI as novel prognostic signatures clear cell renal cell carcinoma.J Cell Physiol. 2019 Sep;234(9):16320-16327. doi: 10.1002/jcp.28297. Epub 2019 Feb 28.
• [46] Significant induction of apoptosis in renal cell carcinoma cells transfected with cationic multilamellar liposomes containing the human interferon- gene through activation of the intracellular type 1 interferon signal pathway.Int J Oncol. 2012 May;40(5):1441-6. doi: 10.3892/ijo.2012.1377. Epub 2012 Feb 16.
• [47] IKBKB expression in clear cell renal cell carcinoma is associated with tumor grade and patient outcomes.Oncol Rep. 2019 Feb;41(2):1189-1197. doi: 10.3892/or.2018.6872. Epub 2018 Nov 19.
• [48] Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.Int J Cancer. 2019 Jul 15;145(2):531-539. doi: 10.1002/ijc.32124. Epub 2019 Jan 31.
• [49] Integrin 5 triggers the metastatic potential in renal cell carcinoma.Oncotarget. 2017 Nov 18;8(64):107530-107542. doi: 10.18632/oncotarget.22501. eCollection 2017 Dec 8.
• [50] CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p.Mol Cancer. 2019 Apr 11;18(1):86. doi: 10.1186/s12943-019-0997-z.
• [51] NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.Mod Pathol. 2019 May;32(5):710-716. doi: 10.1038/s41379-018-0191-7. Epub 2019 Jan 8.
• [52] KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma.Tumour Biol. 2015 Feb;36(2):1251-9. doi: 10.1007/s13277-014-2746-7. Epub 2014 Oct 26.
• [53] Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications.Sci Rep. 2019 Jun 3;9(1):8189. doi: 10.1038/s41598-019-44733-y.
• [54] KIF20B promotes the progression of clear cell renal cell carcinoma by stimulating cell proliferation.J Cell Physiol. 2019 Sep;234(9):16517-16525. doi: 10.1002/jcp.28322. Epub 2019 Feb 25.
• [55] LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.Cell Physiol Biochem. 2018;48(1):371-384. doi: 10.1159/000491767. Epub 2018 Jul 17.
• [56] Leukocyteassociated immunoglobulinlike receptor1 promotes tumorigenesis in RCC.Oncol Rep. 2019 Feb;41(2):1293-1303. doi: 10.3892/or.2018.6875. Epub 2018 Nov 20.
• [57] Prognostic biomarkers in renal cell carcinoma: is there a relationship with obesity?.Transl Androl Urol. 2019 May;8(Suppl 2):S138-S146. doi: 10.21037/tau.2018.11.10.
• [58] Leukemia Inhibitory Factor Receptor Suppresses the Metastasis of Clear Cell Renal Cell Carcinoma Through Negative Regulation of the Yes-Associated Protein.DNA Cell Biol. 2018 Aug;37(8):659-669. doi: 10.1089/dna.2017.4102. Epub 2018 Jun 14.
• [59] Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation.J Biol Chem. 2019 Jun 7;294(23):9029-9036. doi: 10.1074/jbc.AC119.007466. Epub 2019 Apr 24.
• [60] Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma.Oncol Lett. 2018 Apr;15(4):4229-4234. doi: 10.3892/ol.2018.7871. Epub 2018 Jan 26.
• [61] Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.Bioorg Med Chem. 2019 Jun 1;27(11):2268-2279. doi: 10.1016/j.bmc.2019.04.022. Epub 2019 Apr 17.
• [62] Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma.Pathol Oncol Res. 2019 Jan;25(1):289-299. doi: 10.1007/s12253-017-0339-7. Epub 2017 Nov 4.
• [63] Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel.J Transl Med. 2017 Jun 29;15(1):149. doi: 10.1186/s12967-017-1248-y.
• [64] Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion.Oncol Lett. 2017 Dec;14(6):8021-8027. doi: 10.3892/ol.2017.7231. Epub 2017 Oct 20.
• [65] NOD1 and NOD2 of the innate immune system is differently expressed in human clear cell renal cell carcinoma, corresponding healthy renal tissue, its vasculature and primary isolated renal tubular epithelial cells.J Cancer Res Clin Oncol. 2019 Jun;145(6):1405-1416. doi: 10.1007/s00432-019-02901-7. Epub 2019 Mar 22.
• [66] MicroRNA?63 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells by directly targeting PAK4.Mol Med Rep. 2019 Jan;19(1):711-718. doi: 10.3892/mmr.2018.9652. Epub 2018 Nov 13.
• [67] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.BMC Cancer. 2019 Apr 16;19(1):360. doi: 10.1186/s12885-019-5578-4.
• [68] Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma.Aging (Albany NY). 2019 Aug 25;11(16):6503-6521. doi: 10.18632/aging.102206. Epub 2019 Aug 25.
• [69] A large-scale transcriptome analysis identified ELANE and PRTN3 as novel methylation prognostic signatures for clear cell renal cell carcinoma.J Cell Physiol. 2020 Mar;235(3):2582-2589. doi: 10.1002/jcp.29162. Epub 2019 Sep 6.
• [70] Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.EBioMedicine. 2019 Jan;39:255-264. doi: 10.1016/j.ebiom.2018.12.011. Epub 2018 Dec 14.
• [71] RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.Cell Death Dis. 2019 Mar 15;10(4):254. doi: 10.1038/s41419-019-1488-2.
• [72] The cancer-retina antigen recoverin as a potential biomarker for renal tumors.Tumour Biol. 2016 Jul;37(7):9899-907. doi: 10.1007/s13277-016-4885-5. Epub 2016 Jan 26.
• [73] Renal cell carcinoma: predicting RUNX3 methylation level and its consequences on survival with CT features.Eur Radiol. 2019 Oct;29(10):5415-5422. doi: 10.1007/s00330-019-06049-3. Epub 2019 Mar 15.
• [74] Prognostic role of S100A9 expression in patients with clear cell renal cell carcinoma.Medicine (Baltimore). 2019 Oct;98(40):e17188. doi: 10.1097/MD.0000000000017188.
• [75] Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.Mol Cancer Ther. 2019 Apr;18(4):856-867. doi: 10.1158/1535-7163.MCT-18-0548. Epub 2019 Feb 20.
• [76] Wnt antagonist gene polymorphisms and renal cancer.Cancer. 2009 Oct 1;115(19):4488-503. doi: 10.1002/cncr.24491.
• [77] SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis.Free Radic Biol Med. 2019 Apr;134:458-467. doi: 10.1016/j.freeradbiomed.2019.01.030. Epub 2019 Jan 29.
• [78] Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications.Int Braz J Urol. 2019 Jan-Feb;45(1):169-178. doi: 10.1590/S1677-5538.IBJU.2018.0271.
• [79] Suppression of Tescalcin inhibits growth and metastasis in renal cell carcinoma via downregulating NHE1 and NF-kB signaling.Exp Mol Pathol. 2019 Apr;107:110-117. doi: 10.1016/j.yexmp.2018.12.004. Epub 2018 Dec 27.
• [80] Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells.Oncotarget. 2018 Aug 3;9(60):31697-31708. doi: 10.18632/oncotarget.25851. eCollection 2018 Aug 3.
• [81] The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review.Onco Targets Ther. 2019 Sep 26;12:7929-7940. doi: 10.2147/OTT.S207460. eCollection 2019.
• [82] Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway.Cell Cycle. 2019 Feb;18(3):257-263. doi: 10.1080/15384101.2018.1475826. Epub 2019 Jan 29.
• [83] Knockdown of Serine-Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells.Oncol Res. 2017 Mar 13;25(3):389-395. doi: 10.3727/096504016X14743324568129. Epub 2016 Sep 22.
• [84] Interactions between TGF- type I receptor and hypoxia-inducible factor- mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma.Cell Cycle. 2019 Sep;18(17):2141-2156. doi: 10.1080/15384101.2019.1642069. Epub 2019 Jul 24.
• [85] Construction and analysis of circular RNA molecular regulatory networks in clear cell renal cell carcinoma.Mol Med Rep. 2020 Jan;21(1):141-150. doi: 10.3892/mmr.2019.10811. Epub 2019 Nov 11.
• [86] WNK1 promotes renal tumor progression by activating TRPC6-NFAT pathway.FASEB J. 2019 Jul;33(7):8588-8599. doi: 10.1096/fj.201802019RR. Epub 2019 Apr 25.
• [87] siRNA against TSG101 reduces proliferation and induces G0/G1 arrest in renal cell carcinoma - involvement of c-myc, cyclin E1, and CDK2.Cell Mol Biol Lett. 2019 Jan 15;24:7. doi: 10.1186/s11658-018-0124-y. eCollection 2019.
• [88] TTK contributes to tumor growth and metastasis of clear cell renal cell carcinoma by inducing cell proliferation and invasion.Neoplasma. 2019 Nov;66(6):946-953. doi: 10.4149/neo_2019_190207N109. Epub 2019 Oct 8.
• [89] Potential biological process of X-linked inhibitor of apoptosis protein in renal cell carcinoma based upon differential protein expression analysis.Oncol Lett. 2018 Jan;15(1):821-832. doi: 10.3892/ol.2017.7383. Epub 2017 Nov 9.
• [90] Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.EMBO J. 2020 Jan 2;39(1):e102406. doi: 10.15252/embj.2019102406. Epub 2019 Nov 29.
• [91] NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.Cancer Res. 2017 Sep 15;77(18):4835-4845. doi: 10.1158/0008-5472.CAN-17-0143. Epub 2017 Jul 28.
• [92] Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma.Oncotarget. 2014 Jan 30;5(2):506-18. doi: 10.18632/oncotarget.1529.
• [93] p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-B/IL-6 activation in renal cell carcinoma.Cell Death Dis. 2015 Feb 12;6(2):e1637. doi: 10.1038/cddis.2015.2.
• [94] Superoxide dismutase 2 expression can predict prognosis of renal cell carcinoma patients.Cancer Biomark. 2018;22(4):755-761. doi: 10.3233/CBM-181308.
• [95] Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro.Oncol Lett. 2018 May;15(5):6967-6974. doi: 10.3892/ol.2018.8211. Epub 2018 Mar 8.
• [96] A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.
• [97] Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.Cell Metab. 2018 Jun 5;27(6):1263-1280.e6. doi: 10.1016/j.cmet.2018.04.009. Epub 2018 May 10.
• [98] Arrestin2 Mediates Renal Cell Carcinoma Tumor Growth.Sci Rep. 2018 Mar 20;8(1):4879. doi: 10.1038/s41598-018-23212-w.
• [99] Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer.Cancer Gene Ther. 2020 Jun;27(6):473-485. doi: 10.1038/s41417-019-0125-7. Epub 2019 Jul 16.
• [100] Sorafenib induces renal cell carcinoma apoptosis via upregulating activating transcription factor 4.Pharmazie. 2018 Mar 5;73(3):156-160. doi: 10.1691/ph.2018.7855.
• [101] Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma.Cancer Gene Ther. 2020 May;27(5):330-340. doi: 10.1038/s41417-019-0107-9. Epub 2019 Jun 3.
• [102] Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL.J Cell Biochem. 2018 Dec;119(12):9974-9985. doi: 10.1002/jcb.27326. Epub 2018 Sep 1.
• [103] Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.BMC Cancer. 2017 Feb 8;17(1):117. doi: 10.1186/s12885-017-3106-y.
• [104] LINC01510 suppresses cell proliferation and invasion by inhibiting Wnt/-catenin signaling in renal cell carcinoma.Biochem Biophys Res Commun. 2018 Oct 20;505(1):7-12. doi: 10.1016/j.bbrc.2018.08.167. Epub 2018 Sep 14.
• [105] pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.Clin Cancer Res. 2015 Feb 15;21(4):889-98. doi: 10.1158/1078-0432.CCR-14-1425.
• [106] Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma.Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):299-307. doi: 10.21873/cgp.20135.
• [107] REG deficiency suppresses tumor progression via stabilizing CK1 in renal cell carcinoma.Cell Death Dis. 2018 May 24;9(6):627. doi: 10.1038/s41419-018-0646-2.
• [108] CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma.Front Oncol. 2019 Jan 22;8:682. doi: 10.3389/fonc.2018.00682. eCollection 2018.
• [109] Altered Expression of DDR1 in Clear Cell Renal Cell Carcinoma Correlates With miR-199a/b-5p and Patients' Outcome.Cancer Genomics Proteomics. 2019 May-Jun;16(3):179-193. doi: 10.21873/cgp.20124.
• [110] DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.Urol Oncol. 2019 Oct;37(10):735-741. doi: 10.1016/j.urolonc.2019.07.007. Epub 2019 Jul 31.
• [111] Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in ccRCC.Int J Exp Pathol. 2017 Feb;98(1):34-39. doi: 10.1111/iep.12219. Epub 2017 Apr 19.
• [112] Orphan nuclear receptor COUP-TFII is an oncogenic gene in renal cell carcinoma.Clin Transl Oncol. 2020 May;22(5):772-781. doi: 10.1007/s12094-019-02190-z. Epub 2019 Jul 31.
• [113] High expression level of MMP9 is associated with poor prognosis in patients with clear cell renal carcinoma.PeerJ. 2018 Jul 4;6:e5050. doi: 10.7717/peerj.5050. eCollection 2018.
• [114] High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma.J Cancer. 2018 Sep 8;9(18):3400-3406. doi: 10.7150/jca.23923. eCollection 2018.
• [115] TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.Mol Cancer Res. 2019 Aug;17(8):1613-1626. doi: 10.1158/1541-7786.MCR-18-1235. Epub 2019 May 1.
• [116] microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2).Oncotarget. 2017 Apr 18;8(16):26334-26343. doi: 10.18632/oncotarget.15463.
• [117] Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival.Cancer Med. 2018 Dec;7(12):6104-6111. doi: 10.1002/cam4.1901. Epub 2018 Nov 28.
• [118] Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.Oncotarget. 2017 Mar 28;8(13):21861-21870. doi: 10.18632/oncotarget.15668.
• [119] The Role of YB1 in Renal Cell Carcinoma Cell Adhesion.Int J Med Sci. 2018 Aug 6;15(12):1304-1311. doi: 10.7150/ijms.25580. eCollection 2018.
• [120] High kinesin family member 11 expression predicts poor prognosis in patients with clear cell renal cell carcinoma.J Clin Pathol. 2019 May;72(5):354-362. doi: 10.1136/jclinpath-2018-205390. Epub 2019 Feb 28.
• [121] Immune infiltration in renal cell carcinoma.Cancer Sci. 2019 May;110(5):1564-1572. doi: 10.1111/cas.13996. Epub 2019 Apr 7.
• [122] Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells.Oncol Lett. 2018 Jan;15(1):893-900. doi: 10.3892/ol.2017.7423. Epub 2017 Nov 15.
• [123] Long non-coding RNA HOTTIP is upregulated in renal cell carcinoma and regulates cell growth and apoptosis by epigenetically silencing of LATS2.Biomed Pharmacother. 2018 Sep;105:1133-1140. doi: 10.1016/j.biopha.2018.06.081. Epub 2018 Jun 21.
• [124] Lysosomal acid lipase promotes cholesterol ester metabolism and drives clear cell renal cell carcinoma progression.Cell Prolif. 2018 Aug;51(4):e12452. doi: 10.1111/cpr.12452. Epub 2018 Mar 23.
• [125] p38gamma overexpression promotes renal cell carcinoma cell growth, proliferation and migration.Biochem Biophys Res Commun. 2019 Aug 20;516(2):466-473. doi: 10.1016/j.bbrc.2019.06.056. Epub 2019 Jun 20.
• [126] A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes.Cell Rep. 2018 May 8;23(6):1639-1650. doi: 10.1016/j.celrep.2018.04.031.
• [127] Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents.Onco Targets Ther. 2017 Feb 2;10:579-590. doi: 10.2147/OTT.S115791. eCollection 2017.
• [128] Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.J Exp Clin Cancer Res. 2018 Dec 4;37(1):297. doi: 10.1186/s13046-018-0952-7.
• [129] MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma.J Cell Biochem. 2020 Feb;121(2):1504-1513. doi: 10.1002/jcb.29385. Epub 2019 Sep 9.
• [130] Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.Int J Clin Oncol. 2020 Feb;25(2):338-346. doi: 10.1007/s10147-019-01564-1. Epub 2019 Nov 13.
• [131] Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway.Cell Signal. 2019 Apr;56:1-14. doi: 10.1016/j.cellsig.2018.11.016. Epub 2018 Nov 20.
• [132] Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin.Cancer Sci. 2018 Jun;109(6):1865-1875. doi: 10.1111/cas.13609. Epub 2018 May 25.
• [133] The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):337-342. doi: 10.1016/j.bbrc.2018.11.036. Epub 2018 Nov 14.
• [134] Nuclear factor-kappa B subunits and their prognostic cancer-specific survival value in renal cell carcinoma patients.Pathology. 2018 Aug;50(5):511-518. doi: 10.1016/j.pathol.2018.03.003. Epub 2018 Jun 21.
• [135] Rce1 expression in renal cell carcinoma and its regulatory effect on 786-O cell apoptosis through endoplasmic reticulum stress.Acta Biochim Biophys Sin (Shanghai). 2017 Mar 1;49(3):254-261. doi: 10.1093/abbs/gmx002.
• [136] Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth.Cell Death Dis. 2019 Apr 18;10(5):339. doi: 10.1038/s41419-019-1330-x.
• [137] Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.Onco Targets Ther. 2019 Apr 30;12:3267-3275. doi: 10.2147/OTT.S196347. eCollection 2019.
• [138] Association of genetic variations in RTN4 3'-UTR with risk for clear cell renal cell carcinoma.Fam Cancer. 2018 Jan;17(1):129-134. doi: 10.1007/s10689-017-0005-y.
• [139] SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker.J Cell Mol Med. 2018 Feb;22(2):1224-1235. doi: 10.1111/jcmm.13495. Epub 2017 Dec 14.
• [140] Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.Cell Physiol Biochem. 2018;49(6):2348-2357. doi: 10.1159/000493835. Epub 2018 Sep 27.
• [141] High Membranous Expression of Fatty Acid Transport Protein 4 Is Associated with Tumorigenesis and Tumor Progression in Clear Cell Renal Cell Carcinoma.Dis Markers. 2019 Apr 4;2019:5702026. doi: 10.1155/2019/5702026. eCollection 2019.
• [142] MiR-200c-3p inhibits cell migration and invasion of clear cell renal cell carcinoma via regulating SLC6A1.Cancer Biol Ther. 2018 Apr 3;19(4):282-291. doi: 10.1080/15384047.2017.1394551. Epub 2018 Feb 2.
• [143] Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer.Sci Rep. 2017 Mar 28;7:44997. doi: 10.1038/srep44997.
• [144] Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha-2, 8-sialyltransferase 4 by sponging microRNA-124.Cell Prolif. 2018 Dec;51(6):e12507. doi: 10.1111/cpr.12507. Epub 2018 Aug 13.
• [145] STK39 blockage by RNA interference inhibits the proliferation and induces the apoptosis of renal cell carcinoma.Onco Targets Ther. 2018 Mar 16;11:1511-1519. doi: 10.2147/OTT.S153806. eCollection 2018.
• [146] Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.Crit Rev Oncol Hematol. 2018 Nov;131:1-6. doi: 10.1016/j.critrevonc.2018.07.008. Epub 2018 Aug 1.
• [147] Forkhead-box series expression network is associated with outcome of clear-cell renal cell carcinoma.Oncol Lett. 2018 Jun;15(6):8669-8680. doi: 10.3892/ol.2018.8405. Epub 2018 Apr 2.
• [148] Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell Renal Carcinoma and the Antitumor Effects of SBI-0206965.EBioMedicine. 2018 Aug;34:85-93. doi: 10.1016/j.ebiom.2018.07.034. Epub 2018 Aug 2.
• [149] Oncogenic PITX2 facilitates tumor cell drug resistance by inverse regulation of hOCT3/SLC22A3 and ABC drug transporters in colon and kidney cancers.Cancer Lett. 2019 May 1;449:237-251. doi: 10.1016/j.canlet.2019.01.044. Epub 2019 Feb 10.
• [150] Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.Cell Biosci. 2018 Feb 7;8:9. doi: 10.1186/s13578-018-0209-3. eCollection 2018.
• [151] Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013 Mar;24(3):310-4.
• [152] Tyrosine kinase expression profile in clear cell renal cell carcinoma.World J Urol. 2012 Aug;30(4):559-65. doi: 10.1007/s00345-011-0767-z. Epub 2011 Oct 4.
• [153] The expression of cholinesterases in human renal tumours varies according to their histological types.Chem Biol Interact. 2008 Sep 25;175(1-3):340-2. doi: 10.1016/j.cbi.2008.04.003. Epub 2008 Apr 12.
• [154] Evaluation of the role of downregulation of SNF5/INI1 core subunit of SWI/SNF complex in clear cell renal cell carcinoma development.Am J Cancer Res. 2017 Nov 1;7(11):2275-2289. eCollection 2017.
• [155] Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome.Oncol Rep. 2004 Feb;11(2):529-36.
• [156] The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma.Cell Physiol Biochem. 2017;43(2):733-742. doi: 10.1159/000481557. Epub 2017 Sep 27.
• [157] Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma.Anticancer Res. 2017 Aug;37(8):4379-4388. doi: 10.21873/anticanres.11832.
• [158] Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals.Mol Cancer. 2019 Nov 1;18(1):151. doi: 10.1186/s12943-019-1072-5.
• [159] Comprehensive analysis of 5-aminolevulinic acid dehydrogenase (ALAD) variants and renal cell carcinoma risk among individuals exposed to lead.PLoS One. 2011;6(7):e20432. doi: 10.1371/journal.pone.0020432. Epub 2011 Jul 20.
• [160] 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.Oncol Rep. 2005 Jul;14(1):73-9.
• [161] Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate.Jpn J Cancer Res. 1997 Feb;88(2):120-8. doi: 10.1111/j.1349-7006.1997.tb00356.x.
• [162] Do clear cell papillary renal cell carcinomas have malignant potential? Diolombi ML, Cheng L, Argani P, Epstein JI.Am J Surg Pathol. December 2015;39(12):1621-1634.Urol Oncol. 2017 Jun;35(6):451-452. doi: 10.1016/j.urolonc.2017.03.020. Epub 2017 Apr 14.
• [163] Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma.Int J Oncol. 2013 Jun;42(6):2078-86. doi: 10.3892/ijo.2013.1889. Epub 2013 Apr 10.
• [164] Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.Mol Cancer Ther. 2020 Jan;19(1):147-156. doi: 10.1158/1535-7163.MCT-18-1202. Epub 2019 Oct 3.
• [165] ANGPTL3 inhibits renal cell carcinoma metastasis by inhibiting VASP phosphorylation.Biochem Biophys Res Commun. 2019 Aug 27;516(3):880-887. doi: 10.1016/j.bbrc.2019.06.120. Epub 2019 Jun 30.
• [166] Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients.Biomarkers. 2018 Mar;23(2):123-130. doi: 10.1080/1354750X.2016.1269132. Epub 2016 Dec 22.
• [167] Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.FEBS Lett. 2012 Apr 5;586(7):947-55. doi: 10.1016/j.febslet.2012.03.002. Epub 2012 Mar 8.
• [168] The androgen receptor expression and association with patient's survival in different cancers.Genomics. 2020 Mar;112(2):1926-1940. doi: 10.1016/j.ygeno.2019.11.005. Epub 2019 Nov 20.
• [169] Reduced L/B/K alkaline phosphatase gene expression in renal cell carcinoma: plausible role in tumorigenesis.Biochimie. 2014 Sep;104:27-35. doi: 10.1016/j.biochi.2014.05.011. Epub 2014 Jun 5.
• [170] TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma.Urology. 2017 Apr;102:265.e1-265.e7. doi: 10.1016/j.urology.2016.12.050. Epub 2017 Jan 6.
• [171] Association of ATG7 Polymorphisms and Clear Cell Renal Cell Carcinoma Risk.Curr Mol Med. 2019;19(1):40-47. doi: 10.2174/1566524019666190227202003.
• [172] AMPK as a therapeutic target in renal cell carcinoma.Cancer Biol Ther. 2010 Dec 1;10(11):1168-77. doi: 10.4161/cbt.10.11.13629. Epub 2010 Dec 1.
• [173] Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.Carcinogenesis. 2018 May 28;39(6):752-757. doi: 10.1093/carcin/bgy021.
• [174] Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.Oncol Rep. 2018 Sep;40(3):1467-1476. doi: 10.3892/or.2018.6541. Epub 2018 Jul 2.
• [175] Bioinformatics Analysis Suggests the Combined Expression of AURKB and KIF18B Being an Important Event in the Development of Clear Cell Renal Cell Carcinoma.Pathol Oncol Res. 2020 Jul;26(3):1583-1594. doi: 10.1007/s12253-019-00740-y. Epub 2019 Sep 5.
• [176] Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.Oncogene. 2020 Jan;39(3):530-545. doi: 10.1038/s41388-019-0962-8. Epub 2019 Sep 9.
• [177] Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.Genet Mol Res. 2017 Jul 6;16(3). doi: 10.4238/gmr16039278.
• [178] LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma.Mol Cancer. 2017 Oct 25;16(1):166. doi: 10.1186/s12943-017-0735-3.
• [179] Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.Oncol Lett. 2018 Oct;16(4):4953-4960. doi: 10.3892/ol.2018.9239. Epub 2018 Jul 31.
• [180] BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages.Cancer Res. 2013 Jun 15;73(12):3604-14. doi: 10.1158/0008-5472.CAN-12-4563. Epub 2013 Apr 30.
• [181] The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.J Exp Clin Cancer Res. 2014 Mar 7;33(1):25. doi: 10.1186/1756-9966-33-25.
• [182] Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis.Oncotarget. 2017 Apr 10;8(31):51331-51344. doi: 10.18632/oncotarget.17376. eCollection 2017 Aug 1.
• [183] The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell Carcinoma.Anticancer Res. 2017 Jun;37(6):2853-2860. doi: 10.21873/anticanres.11637.
• [184] Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population.Urol Oncol. 2016 Sep;34(9):419.e13-9. doi: 10.1016/j.urolonc.2016.04.010. Epub 2016 May 24.
• [185] C1QBP suppresses cell adhesion and metastasis of renal carcinoma cells.Sci Rep. 2017 Apr 20;7(1):999. doi: 10.1038/s41598-017-01084-w.
• [186] C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.Oncol Rep. 2015 Apr;33(4):1844-50. doi: 10.3892/or.2015.3800. Epub 2015 Feb 13.
• [187] Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy.Int J Cancer. 1998 Feb 20;79(1):1-7. doi: 10.1002/(sici)1097-0215(19980220)79:1<1::aid-ijc1>3.0.co;2-5.
• [188] Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type.Int J Cancer. 1999 Feb 19;84(1):6-9. doi: 10.1002/(sici)1097-0215(19990219)84:1<6::aid-ijc2>3.0.co;2-t.
• [189] Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma.Oncotarget. 2017 Oct 26;8(58):97811-97821. doi: 10.18632/oncotarget.22083. eCollection 2017 Nov 17.
• [190] Caspase-10, matrix metalloproteinase-9 and total laminin are correlated with the tumor malignancy of clear cell renal cell carcinoma.Oncol Lett. 2018 Aug;16(2):2039-2045. doi: 10.3892/ol.2018.8845. Epub 2018 May 30.
• [191] PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs.Cell Oncol. 2010;32(1-2):29-42. doi: 10.3233/CLO-2009-0492.
• [192] Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.Oncotarget. 2017 Apr 11;8(15):25650-25659. doi: 10.18632/oncotarget.12827.
• [193] Overexpression of CKAP4 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma and Functions via Cyclin B Signaling.J Cancer. 2017 Oct 23;8(19):4018-4026. doi: 10.7150/jca.21226. eCollection 2017.
• [194] Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.Clin Cancer Res. 2005 Apr 1;11(7):2459-65. doi: 10.1158/1078-0432.CCR-04-0405.
• [195] Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.Am J Pathol. 2011 Jul;179(1):436-51. doi: 10.1016/j.ajpath.2011.03.011. Epub 2011 May 18.
• [196] Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma.Pathol Oncol Res. 2017 Apr;23(2):409-416. doi: 10.1007/s12253-016-0128-8. Epub 2016 Oct 13.
• [197] Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma.Cancer Manag Res. 2019 Jul 25;11:7021-7030. doi: 10.2147/CMAR.S209205. eCollection 2019.
• [198] Renal cell carcinoma with t(X;17): singular pediatric neoplasm with specific phenotype/genotype features.Pediatr Dev Pathol. 2003 Jan-Feb;6(1):84-7. doi: 10.1007/s10024-002-1010-0. Epub 2002 Dec 10.
• [199] First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063. doi: 10.1007/s00280-019-03796-4. Epub 2019 Mar 26.
• [200] Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enables identification of molecular mechanisms.Am J Physiol Renal Physiol. 2019 May 1;316(5):F1053-F1067. doi: 10.1152/ajprenal.00424.2018. Epub 2019 Mar 6.
• [201] B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.World J Urol. 2000 Apr;18(2):157-63. doi: 10.1007/s003450050190.
• [202] Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression.Mol Cancer Res. 2018 Nov;16(11):1750-1760. doi: 10.1158/1541-7786.MCR-17-0762. Epub 2018 Jul 23.
• [203] Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.Asian Pac J Cancer Prev. 2012;13(3):931-5. doi: 10.7314/apjcp.2012.13.3.931.
• [204] MicroRNA-720 Regulates E-cadherin-E-catenin Complex and Promotes Renal Cell Carcinoma.Mol Cancer Ther. 2017 Dec;16(12):2840-2848. doi: 10.1158/1535-7163.MCT-17-0400. Epub 2017 Aug 11.
• [205] Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.J Exp Clin Cancer Res. 2018 Feb 27;37(1):40. doi: 10.1186/s13046-018-0706-6.
• [206] Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis.Genes Chromosomes Cancer. 1996 Jan;15(1):64-72. doi: 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2.
• [207] The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.Cancer Lett. 2020 Feb 28;471:27-37. doi: 10.1016/j.canlet.2019.12.005. Epub 2019 Dec 6.
• [208] The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.J Pathol. 2004 Nov;204(3):258-67. doi: 10.1002/path.1657.
• [209] c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma.Cell Death Dis. 2019 May 16;10(6):384. doi: 10.1038/s41419-019-1609-y.
• [210] Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.Cancer Biomark. 2018;21(4):915-923. doi: 10.3233/CBM-171018.
• [211] CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation.Biochem Biophys Res Commun. 2017 Jun 17;488(1):101-108. doi: 10.1016/j.bbrc.2017.05.016. Epub 2017 May 4.
• [212] Integrative analysis reveals CRHBP inhibits renal cell carcinoma progression by regulating inflammation and apoptosis.Cancer Gene Ther. 2020 Aug;27(7-8):607-618. doi: 10.1038/s41417-019-0138-2. Epub 2019 Oct 1.
• [213] Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.World J Urol. 2009 Dec;27(6):825-30. doi: 10.1007/s00345-009-0417-x.
• [214] The Vitamin D status is associated with serum C-reactive protein and adhesion molecules in patients with renal cell carcinoma.Sci Rep. 2019 Nov 13;9(1):16719. doi: 10.1038/s41598-019-53395-9.
• [215] Differential protein profiling in renal-cell carcinoma.Mol Carcinog. 2004 May;40(1):47-61. doi: 10.1002/mc.20015.
• [216] Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines.Carcinogenesis. 1994 Feb;15(2):219-25. doi: 10.1093/carcin/15.2.219.
• [217] Molecular characterization of clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1 as promising novel prognostic markers.APMIS. 2016 May;124(5):372-83. doi: 10.1111/apm.12519. Epub 2016 Feb 15.
• [218] Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.Int J Clin Exp Pathol. 2014 Jun 15;7(7):4112-9. eCollection 2014.
• [219] SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.Cancer Res. 2014 Dec 1;74(23):6935-46. doi: 10.1158/0008-5472.CAN-14-1330. Epub 2014 Oct 7.
• [220] The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.Oncologist. 2019 Mar;24(3):338-348. doi: 10.1634/theoncologist.2018-0267. Epub 2018 Aug 29.
• [221] PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.PLoS One. 2017 Sep 26;12(9):e0185337. doi: 10.1371/journal.pone.0185337. eCollection 2017.
• [222] Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.Nat Genet. 2011 Dec 4;44(1):17-9. doi: 10.1038/ng.1014.
• [223] CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma.J Urol. 2009 Feb;181(2):843-8. doi: 10.1016/j.juro.2008.10.063. Epub 2008 Dec 17.
• [224] Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.Biomed Pharmacother. 2019 Oct;118:109264. doi: 10.1016/j.biopha.2019.109264. Epub 2019 Aug 4.
• [225] IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.J Pathol. 2019 Jul;248(3):377-389. doi: 10.1002/path.5267. Epub 2019 Apr 11.
• [226] Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.J Cell Mol Med. 2018 Dec;22(12):5909-5918. doi: 10.1111/jcmm.13860. Epub 2018 Sep 24.
• [227] Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget. 2015 Apr 10;6(10):7774-87.
• [228] Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma.Eur J Clin Invest. 2013 Dec;43(12):1282-90. doi: 10.1111/eci.12176. Epub 2013 Oct 12.
• [229] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17.
• [230] Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma.Mol Cancer. 2015 Jul 30;14:141. doi: 10.1186/s12943-015-0416-z.
• [231] L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma.Clin Biochem. 2015 Jun;48(9):590-5. doi: 10.1016/j.clinbiochem.2015.02.007. Epub 2015 Feb 23.
• [232] VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.J Med Biochem. 2018 Jan 1;37(1):31-38. doi: 10.1515/jomb-2017-0030. eCollection 2018 Jan.
• [233] Renal carcinoma cells undergo apoptosis without oligonucleosomal DNA fragmentation.Biochem Biophys Res Commun. 2004 Jun 4;318(3):710-3. doi: 10.1016/j.bbrc.2004.04.086.
• [234] Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance.J Clin Oncol. 2005 Jan 20;23(3):448-54. doi: 10.1200/JCO.2005.02.191. Epub 2004 Nov 30.
• [235] MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer.PLoS One. 2011;6(9):e24541. doi: 10.1371/journal.pone.0024541. Epub 2011 Sep 2.
• [236] Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.Hum Mol Genet. 2006 Mar 15;15(6):821-30. doi: 10.1093/hmg/ddl001. Epub 2006 Jan 26.
• [237] Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2143-52. eCollection 2014.
• [238] HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.Cancer Res. 2012 Jun 1;72(11):2844-54. doi: 10.1158/0008-5472.CAN-11-3062. Epub 2012 May 2.
• [239] Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.Oncotarget. 2016 Dec 20;7(51):84775-84784. doi: 10.18632/oncotarget.12476.
• [240] Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers.Pathol Oncol Res. 2020 Jul;26(3):1539-1547. doi: 10.1007/s12253-019-00734-w. Epub 2019 Sep 2.
• [241] Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.BMC Cancer. 2011 Sep 26;11:413. doi: 10.1186/1471-2407-11-413.
• [242] A novel human lncRNA SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma. RNA Biol. 2019 Jul;16(7):940-949.
• [243] miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2.Oncotarget. 2016 Apr 12;7(15):20324-37. doi: 10.18632/oncotarget.7951.
• [244] E2F3 upregulation promotes tumor malignancy through the transcriptional activation of HIF-2 in clear cell renal cell carcinoma.Oncotarget. 2016 Jul 13;8(33):54021-54036. doi: 10.18632/oncotarget.10568. eCollection 2017 Aug 15.
• [245] Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.J Control Release. 2017 Apr 10;251:1-10. doi: 10.1016/j.jconrel.2017.02.010. Epub 2017 Feb 10.
• [246] Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.Cancer. 2004 May 15;100(10):2118-24. doi: 10.1002/cncr.20222.
• [247] Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.Asian Pac J Cancer Prev. 2014;15(7):3045-50. doi: 10.7314/apjcp.2014.15.7.3045.
• [248] Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.PLoS One. 2016 Aug 2;11(8):e0160484. doi: 10.1371/journal.pone.0160484. eCollection 2016.
• [249] Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma.Oncotarget. 2019 Jun 18;10(40):4053-4068. doi: 10.18632/oncotarget.27017. eCollection 2019 Jun 18.
• [250] The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.Invest New Drugs. 2020 Aug;38(4):956-966. doi: 10.1007/s10637-019-00839-8. Epub 2019 Aug 28.
• [251] Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.PLoS One. 2017 Aug 15;12(8):e0181711. doi: 10.1371/journal.pone.0181711. eCollection 2017.
• [252] Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.Med Oncol. 2016 Nov;33(11):131. doi: 10.1007/s12032-016-0836-7. Epub 2016 Oct 18.
• [253] Comparison of isolation platforms for detection of circulating renal cell carcinoma cells.Oncotarget. 2017 Sep 23;8(50):87710-87717. doi: 10.18632/oncotarget.21197. eCollection 2017 Oct 20.
• [254] Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.PLoS One. 2014 Jul 15;9(7):e102262. doi: 10.1371/journal.pone.0102262. eCollection 2014.
• [255] EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.PLoS One. 2015 Jul 15;10(7):e0130975. doi: 10.1371/journal.pone.0130975. eCollection 2015.
• [256] Loss of EphA3 Protein Expression Is Associated With Advanced TNM Stage in Clear-Cell Renal Cell Carcinoma.Clin Genitourin Cancer. 2017 Apr;15(2):e169-e173. doi: 10.1016/j.clgc.2016.07.028. Epub 2016 Aug 8.
• [257] Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.Growth Factors. 2014 Dec;32(6):202-6. doi: 10.3109/08977194.2014.980904. Epub 2014 Nov 13.
• [258] Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes.Int J Clin Exp Pathol. 2013 May 15;6(6):998-1008. Print 2013.
• [259] HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.Sci Transl Med. 2017 Jul 12;9(398):eaal5272. doi: 10.1126/scitranslmed.aal5272.
• [260] Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma.Biochem Biophys Res Commun. 2009 Mar 6;380(2):387-91. doi: 10.1016/j.bbrc.2009.01.100. Epub 2009 Jan 23.
• [261] HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1 and HIF-2 balance in renal cell carcinoma.Oncotarget. 2017 Jul 25;8(30):49713-49724. doi: 10.18632/oncotarget.17923.
• [262] Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.Int J Cancer. 2017 Jan 1;140(1):142-148. doi: 10.1002/ijc.30429. Epub 2016 Sep 23.
• [263] Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.Nat Genet. 2015 Jan;47(1):13-21. doi: 10.1038/ng.3146. Epub 2014 Nov 17.
• [264] Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.BMC Cancer. 2019 Jun 3;19(1):534. doi: 10.1186/s12885-019-5736-8.
• [265] Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.Int J Biol Sci. 2017 Nov 1;13(11):1361-1372. doi: 10.7150/ijbs.21657. eCollection 2017.
• [266] Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma.Sci Rep. 2017 Oct 4;7(1):12676. doi: 10.1038/s41598-017-13149-x.
• [267] Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis.Biomed Res Int. 2019 Feb 13;2019:6480865. doi: 10.1155/2019/6480865. eCollection 2019.
• [268] PET imaging in renal cancer.Curr Opin Oncol. 2019 May;31(3):216-221. doi: 10.1097/CCO.0000000000000518.
• [269] FOXM1-Activated LINC01094 Promotes Clear Cell Renal Cell Carcinoma Development via MicroRNA 224-5p/CHSY1.Mol Cell Biol. 2020 Jan 16;40(3):e00357-19. doi: 10.1128/MCB.00357-19. Print 2020 Jan 16.
• [270] LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis.Aging (Albany NY). 2019 Aug 10;11(15):5705-5725. doi: 10.18632/aging.102154. Epub 2019 Aug 10.
• [271] FSCN1 predicts survival and is regulated by a PI3K-dependent mechanism in renal cell carcinoma.J Cell Physiol. 2018 Jun;233(6):4748-4758. doi: 10.1002/jcp.26264. Epub 2018 Jan 15.
• [272] Value of Ferritin Heavy Chain (FTH1) Expression in Diagnosis and Prognosis of Renal Cell Carcinoma.Med Sci Monit. 2019 May 19;25:3700-3715. doi: 10.12659/MSM.914162.
• [273] High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma.Oncotarget. 2017 May 9;8(37):61036-61047. doi: 10.18632/oncotarget.17717. eCollection 2017 Sep 22.
• [274] Loss of CD15 expression in clear cell renal cell carcinoma is correlated with worse prognosis in Chinese patients.Jpn J Clin Oncol. 2017 Dec 1;47(12):1182-1188. doi: 10.1093/jjco/hyx139.
• [275] MicroRNA?13 inhibits proliferation and invasion of renal cell carcinoma cells through targeting FZD7.Mol Med Rep. 2017 Oct;16(4):4279-4286. doi: 10.3892/mmr.2017.7076. Epub 2017 Jul 24.
• [276] The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-B signaling axis.J Exp Clin Cancer Res. 2019 Sep 3;38(1):386. doi: 10.1186/s13046-019-1347-0.
• [277] GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma.Oncol Lett. 2019 Dec;18(6):5731-5738. doi: 10.3892/ol.2019.10960. Epub 2019 Oct 4.
• [278] Low-grade spindle cell proliferation in clear cell renal cell carcinoma is unlikely to be an initial step in sarcomatoid differentiation.Histopathology. 2018 Apr;72(5):804-813. doi: 10.1111/his.13447. Epub 2018 Jan 31.
• [279] S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.Cancer Res. 2019 Nov 15;79(22):5758-5768. doi: 10.1158/0008-5472.CAN-19-1366. Epub 2019 Oct 4.
• [280] Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.J Pathol. 2015 Sep;237(1):50-61. doi: 10.1002/path.4552. Epub 2015 May 28.
• [281] Identification of key genes and pathways in renal cell carcinoma through expression profiling data.Kidney Blood Press Res. 2015;40(3):288-97. doi: 10.1159/000368504. Epub 2015 May 27.
• [282] VHL-dependent regulation of a -dystroglycan glycoform and glycogene expression in renal cancer.Int J Oncol. 2013 Nov;43(5):1368-76. doi: 10.3892/ijo.2013.2066. Epub 2013 Aug 21.
• [283] Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.Oncotarget. 2016 Sep 27;7(39):63374-63387. doi: 10.18632/oncotarget.11463.
• [284] The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis.Clin Cancer Res. 2013 Oct 15;19(20):5740-8. doi: 10.1158/1078-0432.CCR-13-1712. Epub 2013 Aug 22.
• [285] Potential protective role of Grainyhead-like genes in the development of clear cell renal cell carcinoma.Mol Carcinog. 2017 Nov;56(11):2414-2423. doi: 10.1002/mc.22682. Epub 2017 Jun 15.
• [286] Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.
• [287] GRK5 promotes tumor progression in renal cell carcinoma.Neoplasma. 2019 Feb 6;66(2):261-270. doi: 10.4149/neo_2018_180621N409.
• [288] Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Oncogene. 2013 Sep 12;32(37):4366-76. doi: 10.1038/onc.2012.471. Epub 2012 Oct 22.
• [289] Signal integration and gene induction by a functionally distinct STAT3 phosphoform.Mol Cell Biol. 2014 May;34(10):1800-11. doi: 10.1128/MCB.00034-14. Epub 2014 Mar 10.
• [290] Concomitance of Polymorphisms in Glutathione Transferase Omega Genes Is Associated with Risk of Clear Cell Renal Cell Carcinoma.Tohoku J Exp Med. 2018 Sep;246(1):35-44. doi: 10.1620/tjem.246.35.
• [291] Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.J Urol. 2004 Feb;171(2 Pt 1):890-6. doi: 10.1097/01.ju.0000092861.21122.d2.
• [292] RETRACTED: Physcion 8-O--glucopyranoside inhibits clear-cell renal cell carcinoma bydownregulating hexokinase II and inhibiting glycolysis.Biomed Pharmacother. 2018 Aug;104:28-35. doi: 10.1016/j.biopha.2018.05.013. Epub 2018 May 11.
• [293] CD8(+)PD-1(-)ILT2(+) T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G.Cancer Immunol Res. 2019 Oct;7(10):1619-1632. doi: 10.1158/2326-6066.CIR-18-0764. Epub 2019 Aug 26.
• [294] Loss of function of the tissue specific transcription factor HNF1 alpha in renal cell carcinoma and clinical prognosis.Anticancer Res. 1999 May-Jun;19(3A):2105-10.
• [295] Silencing of tumor-suppressive NR_023387 in renal cell carcinoma via promoter hypermethylation and HNF4A deficiency.J Cell Physiol. 2020 Mar;235(3):2113-2128. doi: 10.1002/jcp.29115. Epub 2019 Aug 20.
• [296] Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors.PLoS One. 2010 Oct 27;5(10):e13690. doi: 10.1371/journal.pone.0013690.
• [297] Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma.Pathol Int. 2010 Oct;60(10):661-6. doi: 10.1111/j.1440-1827.2010.02578.x.
• [298] Tumor-suppressive function and mechanism of HOXB13 in right-sided colon cancer.Signal Transduct Target Ther. 2019 Nov 29;4:51. doi: 10.1038/s41392-019-0086-1. eCollection 2019.
• [299] GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma.PLoS One. 2019 Jan 17;14(1):e0210246. doi: 10.1371/journal.pone.0210246. eCollection 2019.
• [300] Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.Cancer Immunol Immunother. 2011 Jun;60(6):793-808. doi: 10.1007/s00262-011-0989-3. Epub 2011 Feb 25.
• [301] Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.Int J Urol. 2005 Jan;12(1):17-28. doi: 10.1111/j.1442-2042.2004.00993.x.
• [302] SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.Hum Pathol. 2017 May;63:190-200. doi: 10.1016/j.humpath.2017.02.022. Epub 2017 Mar 14.
• [303] KRT8 upregulation promotes tumor metastasis and is predictive of a poor prognosis in clear cell renal cell carcinoma.Oncotarget. 2017 Jul 12;8(44):76189-76203. doi: 10.18632/oncotarget.19198. eCollection 2017 Sep 29.
• [304] Immunotherapy for genitourinary tumors.Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1.
• [305] Polymorphism rs4787951 in IL-4R contributes to the increased risk of renal cell carcinoma in a Chinese population.Gene. 2019 Feb 15;685:242-247. doi: 10.1016/j.gene.2018.11.070. Epub 2018 Nov 23.
• [306] Oleic acid promotes cell invasion through an integrin-linked kinase signaling pathway in renal cell carcinoma.Nutr Cancer. 2020;72(6):968-975. doi: 10.1080/01635581.2019.1669672. Epub 2019 Oct 1.
• [307] Dysregulation of the miR-25-IMPA2 axis promotes metastatic progression in clear cell renal cell carcinoma.EBioMedicine. 2019 Jul;45:220-230. doi: 10.1016/j.ebiom.2019.06.006. Epub 2019 Jun 12.
• [308] Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma.J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0.
• [309] Long noncoding RNA ITGB1 promotes migration and invasion of clear cell renal cell carcinoma by downregulating Mcl-1.Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):1996-2002. doi: 10.26355/eurrev_201903_17238.
• [310] miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties.Oncotarget. 2015 Mar 20;6(8):5567-81. doi: 10.18632/oncotarget.1901.
• [311] Germline genetic variations in PDZD2 and ITPR2 genes are associated with clear cell renal cell carcinoma in Chinese population.Oncotarget. 2017 Apr 11;8(15):24196-24201. doi: 10.18632/oncotarget.6917.
• [312] Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.J Biol Chem. 2017 Jan 20;292(3):837-846. doi: 10.1074/jbc.M116.745208. Epub 2016 Dec 1.
• [313] Genetic alteration in notch pathway is associated with better prognosis in renal cell carcinoma.Biofactors. 2016 Jan-Feb;42(1):41-8. doi: 10.1002/biof.1250. Epub 2015 Dec 10.
• [314] Integrated molecular analysis of clear-cell renal cell carcinoma.Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24.
• [315] KDM3A is not associated with metastasis and prognosis of breast cancer.Oncol Lett. 2018 Jun;15(6):9751-9756. doi: 10.3892/ol.2018.8578. Epub 2018 Apr 25.
• [316] Renal cell neoplasms contain shared tumor type-specific copy number variations.Am J Pathol. 2012 Jun;180(6):2427-39. doi: 10.1016/j.ajpath.2012.01.044. Epub 2012 Apr 3.
• [317] Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.Urol Oncol. 2017 Aug;35(8):532.e7-532.e13. doi: 10.1016/j.urolonc.2017.03.015. Epub 2017 Apr 10.
• [318] Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer.Cancer Biomark. 2017;18(2):125-131. doi: 10.3233/CBM-160003.
• [319] Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.Eur J Med Chem. 2019 Oct 1;179:347-357. doi: 10.1016/j.ejmech.2019.06.060. Epub 2019 Jun 23.
• [320] The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.Proteomics. 2006 Feb;6(3):1077-84. doi: 10.1002/pmic.200401345.
• [321] Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.Eur Urol. 2009 Feb;55(2):441-9. doi: 10.1016/j.eururo.2008.02.048. Epub 2008 Mar 11.
• [322] Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.Biol Chem. 2010 Apr;391(4):411-23. doi: 10.1515/BC.2010.041.
• [323] The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library.Immunopharmacology. 1999 Dec;45(1-3):83-8. doi: 10.1016/s0162-3109(99)00059-4.
• [324] Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.Clin Nucl Med. 2017 Mar;42(3):221-222. doi: 10.1097/RLU.0000000000001522.
• [325] Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications.Biol Chem. 2010 Apr;391(4):403-9. doi: 10.1515/BC.2010.025.
• [326] Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.
• [327] KMT5A promotes metastasis of clear cell renal cell carcinoma through reducing cadherin-1 expression.Oncol Lett. 2019 Jun;17(6):4907-4913. doi: 10.3892/ol.2019.10163. Epub 2019 Mar 19.
• [328] Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B.Oncol Lett. 2018 May;15(5):7923-7933. doi: 10.3892/ol.2018.8317. Epub 2018 Mar 22.
• [329] LIM and SH3 domain protein 1 (LASP-1) overexpression was associated with aggressive phenotype and poor prognosis in clear cell renal cell cancer.PLoS One. 2014 Jun 23;9(6):e100557. doi: 10.1371/journal.pone.0100557. eCollection 2014.
• [330] Expression of inflammatory lipopolysaccharide binding protein (LBP) predicts the progression of conventional renal cell carcinoma - a short report.Cell Oncol (Dordr). 2017 Dec;40(6):651-656. doi: 10.1007/s13402-017-0346-4. Epub 2017 Sep 21.
• [331] Non-Invasive Assessment of Lactate Production and Compartmentalization in Renal Cell Carcinomas Using Hyperpolarized (13)C Pyruvate MRI.Cancers (Basel). 2018 Sep 5;10(9):313. doi: 10.3390/cancers10090313.
• [332] Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma.Pathol Oncol Res. 2020 Jul;26(3):1451-1458. doi: 10.1007/s12253-019-00710-4. Epub 2019 Aug 19.
• [333] Silencing of lysyl oxidaselike 2 inhibits the migration, invasion and epithelialtomesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.Int J Oncol. 2019 May;54(5):1676-1690. doi: 10.3892/ijo.2019.4726. Epub 2019 Feb 27.
• [334] Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma.Eur Urol. 2018 Nov;74(5):661-667. doi: 10.1016/j.eururo.2018.07.029. Epub 2018 Aug 10.
• [335] Expression of MAGE genes in renal cell carcinoma.Int J Mol Med. 1998 Jul;2(1):57-60. doi: 10.3892/ijmm.2.1.57.
• [336] Knockdown of MAGEA6 Activates AMP-Activated Protein Kinase (AMPK) Signaling to Inhibit Human Renal Cell Carcinoma Cells.Cell Physiol Biochem. 2018;45(3):1205-1218. doi: 10.1159/000487452. Epub 2018 Feb 9.
• [337] Monoamine Oxidase B in Renal Cell Carcinoma.Med Sci Monit. 2018 Aug 4;24:5422-5426. doi: 10.12659/MSM.909507.
• [338] The expression and role of MEKK3 in renal clear cell carcinoma.Anat Rec (Hoboken). 2015 Apr;298(4):727-34. doi: 10.1002/ar.23093. Epub 2014 Dec 9.
• [339] GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma.Urol Oncol. 2017 Jun;35(6):409-417. doi: 10.1016/j.urolonc.2017.02.005. Epub 2017 Mar 9.
• [340] Identification of TGF--activated kinase 1 as a possible novel target for renal cell carcinoma intervention.Biochem Biophys Res Commun. 2014 Oct 10;453(1):106-11. doi: 10.1016/j.bbrc.2014.09.070. Epub 2014 Sep 26.
• [341] miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.Biochem Biophys Res Commun. 2016 Nov 4;480(1):87-93. doi: 10.1016/j.bbrc.2016.10.004. Epub 2016 Oct 4.
• [342] MicroRNA-148b enhances proliferation and apoptosis in human renal cancer cells via directly targeting MAP3K9.Mol Med Rep. 2016 Jan;13(1):83-90. doi: 10.3892/mmr.2015.4555. Epub 2015 Nov 11.
• [343] Prognostic Value of the VHL, HIF-1, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.Clin Genitourin Cancer. 2017 Dec;15(6):e923-e933. doi: 10.1016/j.clgc.2017.05.016. Epub 2017 May 25.
• [344] MicroRNA-10b Promotes Apoptosis via JNK Pathway in Clear Cell Renal Cell Carcinoma.Nephron. 2018;139(2):172-180. doi: 10.1159/000486017. Epub 2018 Apr 19.
• [345] RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma.Cell Cycle. 2014;13(9):1440-9. doi: 10.4161/cc.28416. Epub 2014 Mar 10.
• [346] The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma.J Urol. 2013 Oct;190(4):1392-7. doi: 10.1016/j.juro.2013.03.041. Epub 2013 Mar 19.
• [347] MDM2-positive papillary sarcomatoid renal cell carcinoma: a potential diagnostic pitfall.Virchows Arch. 2020 May;476(5):783-786. doi: 10.1007/s00428-019-02703-9. Epub 2019 Nov 16.
• [348] Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals.Cancer Manag Res. 2017 Nov 21;9:679-689. doi: 10.2147/CMAR.S141670. eCollection 2017.
• [349] t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.Am J Surg Pathol. 2014 May;38(5):604-14. doi: 10.1097/PAS.0000000000000203.
• [350] Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma.Int J Cancer. 2020 Feb 15;146(4):1052-1063. doi: 10.1002/ijc.32543. Epub 2019 Jul 16.
• [351] Spinal Versus Intracranial Meningioma: Aberrant Expression of CD10 and Inhibin with Relation to Clinicopathological Features and Prognosis.Pathol Oncol Res. 2020 Apr;26(2):1313-1318. doi: 10.1007/s12253-019-00704-2. Epub 2019 Aug 1.
• [352] microRNA?45 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma.Mol Med Rep. 2014 Jul;10(1):393-8. doi: 10.3892/mmr.2014.2149. Epub 2014 Apr 15.
• [353] MicroRNA-384 Inhibits the Growth and Invasion of Renal Cell Carcinoma Cells by Targeting Astrocyte Elevated Gene 1.Oncol Res. 2018 Apr 10;26(3):457-466. doi: 10.3727/096504017X15035025554553. Epub 2017 Aug 25.
• [354] Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-B DNA-binding activity.J Pineal Res. 2016 Apr;60(3):277-90. doi: 10.1111/jpi.12308. Epub 2016 Feb 3.
• [355] Quantitative RT-PCR assay for MUC3 and VEGF mRNA in renal clear cell carcinoma: relationship with nuclear grade and prognosis.Urology. 2003 Oct;62(4):771-5. doi: 10.1016/s0090-4295(03)00560-0.
• [356] High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.Br J Cancer. 2007 Jun 18;96(12):1888-95. doi: 10.1038/sj.bjc.6603796. Epub 2007 May 15.
• [357] N-Myc downstream-regulated gene 2 restrains glycolysis and glutaminolysis in clear cell renal cell carcinoma.Oncol Lett. 2017 Dec;14(6):6881-6887. doi: 10.3892/ol.2017.7024. Epub 2017 Sep 22.
• [358] A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas.Oncogene. 2006 Nov 16;25(54):7138-47. doi: 10.1038/sj.onc.1209708. Epub 2006 May 29.
• [359] MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.Sci Rep. 2017 Jul 17;7(1):5599. doi: 10.1038/s41598-017-06098-y.
• [360] Increased Nek1 expression in renal cell carcinoma cells is associated with decreased sensitivity to DNA-damaging treatment.Oncotarget. 2014 Jun 30;5(12):4283-94. doi: 10.18632/oncotarget.2005.
• [361] Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma.Cancer Sci. 2015 May;106(5):656-64. doi: 10.1111/cas.12649. Epub 2015 Mar 26.
• [362] NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/-catenin signalling pathway in clear cell renal cell carcinoma.Cancer Lett. 2019 Mar 1;444:9-19. doi: 10.1016/j.canlet.2018.11.024. Epub 2018 Dec 11.
• [363] Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma.Carcinogenesis. 2008 Nov;29(11):2112-9. doi: 10.1093/carcin/bgn189. Epub 2008 Aug 18.
• [364] Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.PLoS One. 2015 Jun 2;10(6):e0128308. doi: 10.1371/journal.pone.0128308. eCollection 2015.
• [365] Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.Oncoimmunology. 2017 Nov 9;7(2):e1387705. doi: 10.1080/2162402X.2017.1387705. eCollection 2018.
• [366] The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.Tumour Biol. 2015 Nov;36(11):8471-8. doi: 10.1007/s13277-015-3589-6. Epub 2015 May 31.
• [367] PKC is involved in the progression of kidney carcinoma through regulating netrin-1/UNC5B signaling pathway.Tumour Biol. 2013 Jun;34(3):1759-66. doi: 10.1007/s13277-013-0714-2. Epub 2013 Mar 23.
• [368] hOGG1 Ser326Cys polymorphism and renal cell carcinoma risk in a Chinese population.DNA Cell Biol. 2011 May;30(5):317-21. doi: 10.1089/dna.2010.1135. Epub 2010 Dec 17.
• [369] LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.Cell Death Differ. 2017 Sep;24(9):1502-1517. doi: 10.1038/cdd.2017.74. Epub 2017 Jun 23.
• [370] microRNA-505 negatively regulates HMGB1 to suppress cell proliferation in renal cell carcinoma.J Cell Physiol. 2019 Sep;234(9):15025-15034. doi: 10.1002/jcp.28142. Epub 2019 Jan 15.
• [371] Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes.Mol Ther. 2004 Jun;9(6):837-45. doi: 10.1016/j.ymthe.2004.02.014.
• [372] Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.Med Sci Monit. 2019 Feb 16;25:1275-1282. doi: 10.12659/MSM.912632.
• [373] Identification and expression analysis of an N-terminally truncated isoform of human PDGF-C.Exp Cell Res. 2008 Aug 15;314(14):2529-43. doi: 10.1016/j.yexcr.2008.06.007. Epub 2008 Jun 13.
• [374] Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.Cancer Res. 2005 Jul 1;65(13):5711-9. doi: 10.1158/0008-5472.CAN-04-4313.
• [375] Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".Int J Mol Sci. 2019 Apr 17;20(8):1901. doi: 10.3390/ijms20081901.
• [376] Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.EBioMedicine. 2017 Feb;15:62-72. doi: 10.1016/j.ebiom.2016.12.003. Epub 2016 Dec 9.
• [377] Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.Cells. 2019 Nov 19;8(11):1469. doi: 10.3390/cells8111469.
• [378] PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2-Targeting Therapy for Renal Cell Carcinoma.Cancer Res. 2017 Nov 15;77(22):6321-6329. doi: 10.1158/0008-5472.CAN-17-1589. Epub 2017 Sep 26.
• [379] SETD2 loss sensitizes cells to PI3K and AKT inhibition.Oncotarget. 2019 Jan 18;10(6):647-659. doi: 10.18632/oncotarget.26567. eCollection 2019 Jan 18.
• [380] PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.Cell Death Dis. 2018 Feb 22;9(3):307. doi: 10.1038/s41419-018-0348-9.
• [381] PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway.Angiogenesis. 2019 Nov;22(4):507-519. doi: 10.1007/s10456-019-09675-z. Epub 2019 Jun 28.
• [382] Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2.Int J Biol Sci. 2019 Jan 1;15(3):617-627. doi: 10.7150/ijbs.29689. eCollection 2019.
• [383] Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma.Int J Cancer. 2008 Sep 1;123(5):1080-8. doi: 10.1002/ijc.23637.
• [384] Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth.Oncotarget. 2014 Feb 28;5(4):1004-13. doi: 10.18632/oncotarget.1681.
• [385] Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.Int J Oncol. 2016 May;48(5):1837-46. doi: 10.3892/ijo.2016.3440. Epub 2016 Mar 15.
• [386] Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers.Gene. 2015 May 15;562(2):145-51. doi: 10.1016/j.gene.2015.02.079. Epub 2015 Mar 11.
• [387] Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.Endocr J. 2019 Oct 28;66(10):937-941. doi: 10.1507/endocrj.EJ19-0076. Epub 2019 Jun 19.
• [388] Identification of cyclophilin A as a potential prognostic factor for clear-cell renal cell carcinoma by comparative proteomic analysis.Cancer Biol Ther. 2011 Mar 1;11(5):535-46. doi: 10.4161/cbt.11.5.14678.
• [389] Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma.Cancer Lett. 2015 Jan 28;356(2 Pt B):953-61. doi: 10.1016/j.canlet.2014.11.008. Epub 2014 Nov 10.
• [390] Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.PLoS One. 2017 May 9;12(5):e0176659. doi: 10.1371/journal.pone.0176659. eCollection 2017.
• [391] Inhibition of PKC reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis.Exp Ther Med. 2017 May;13(5):2473-2479. doi: 10.3892/etm.2017.4258. Epub 2017 Mar 23.
• [392] The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.J Exp Clin Cancer Res. 2011 Sep 28;30(1):88. doi: 10.1186/1756-9966-30-88.
• [393] Down-regulation of PKC in renal cell carcinoma and its clinicopathological implications.J Biomed Sci. 2012 Apr 5;19(1):39. doi: 10.1186/1423-0127-19-39.
• [394] Different pattern of T cell receptor delta gene rearrangement in tumour-infiltrating lymphocytes and peripheral blood in patients with solid tumours.Cancer Immunol Immunother. 1994 Oct;39(4):275-8. doi: 10.1007/BF01525992.
• [395] Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.Clin Cancer Res. 2003 May;9(5):1721-7.
• [396] PTBP1 knockdown in renal cell carcinoma inhibits cell migration, invasion and angiogenesis in vitro and metastasis in vivo via the hypoxia inducible factor-1 pathway.Int J Oncol. 2018 May;52(5):1613-1622. doi: 10.3892/ijo.2018.4296. Epub 2018 Mar 2.
• [397] Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.J Biol Chem. 2011 Sep 30;286(39):33954-62. doi: 10.1074/jbc.M110.187344. Epub 2011 Aug 10.
• [398] miR-10b suppresses cell invasion and metastasis through targeting HOXA3 regulated by FAK/YAP signaling pathway in clear-cell renal cell carcinoma.BMC Nephrol. 2019 Apr 11;20(1):127. doi: 10.1186/s12882-019-1322-1.
• [399] Protein tyrosine phosphatase enhances proliferation by increasing -catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.World J Urol. 2013 Dec;31(6):1547-54. doi: 10.1007/s00345-013-1077-4. Epub 2013 Apr 16.
• [400] DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.Theranostics. 2019 Aug 14;9(21):6175-6190. doi: 10.7150/thno.35572. eCollection 2019.
• [401] MiR-204 inhibits the proliferation and invasion of renal cell carcinoma by inhibiting RAB22A expression.Oncol Rep. 2016 May;35(5):3000-8. doi: 10.3892/or.2016.4624. Epub 2016 Feb 16.
• [402] Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.Oncogene. 2011 Feb 3;30(5):535-47. doi: 10.1038/onc.2010.427. Epub 2010 Sep 27.
• [403] MiR-137 suppresses tumor growth and metastasis in clear cell renal cell carcinoma.Pharmacol Rep. 2018 Oct;70(5):963-971. doi: 10.1016/j.pharep.2018.04.006. Epub 2018 Apr 22.
• [404] RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.Cell Cycle. 2016 Nov 16;15(22):3094-3104. doi: 10.1080/15384101.2016.1235103. Epub 2016 Oct 21.
• [405] HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma.J Cell Sci. 2003 Jun 1;116(Pt 11):2247-60. doi: 10.1242/jcs.00427. Epub 2003 Apr 15.
• [406] Identification of gene markers associated with metastasis in clear cell renal cell carcinoma.Oncol Lett. 2017 Jun;13(6):4755-4761. doi: 10.3892/ol.2017.6084. Epub 2017 Apr 24.
• [407] Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-B pathway contributes to the metastasis of renal cell carcinoma.Tumour Biol. 2016 Apr;37(4):4457-66. doi: 10.1007/s13277-015-4296-z. Epub 2015 Oct 25.
• [408] A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.Oncotarget. 2017 Sep 5;8(62):104928-104945. doi: 10.18632/oncotarget.20650. eCollection 2017 Dec 1.
• [409] Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.PLoS One. 2014 Dec 26;9(12):e116101. doi: 10.1371/journal.pone.0116101. eCollection 2014.
• [410] Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma.Br J Cancer. 2013 Sep 3;109(5):1137-46. doi: 10.1038/bjc.2013.463. Epub 2013 Aug 13.
• [411] Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma. Oncol Lett. 2018 Mar;15(3):3852-3857.
• [412] Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk.PLoS One. 2009 Sep 15;4(9):e7013. doi: 10.1371/journal.pone.0007013.
• [413] Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma.J Urol. 2007 Oct;178(4 Pt 1):1497-503. doi: 10.1016/j.juro.2007.05.119. Epub 2007 Aug 16.
• [414] Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma.Carcinogenesis. 2014 Apr;35(4):822-7. doi: 10.1093/carcin/bgt485. Epub 2013 Dec 28.
• [415] Elevated S100A6 (Calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma.Oncotarget. 2015 Mar 30;6(9):6656-69. doi: 10.18632/oncotarget.3169.
• [416] SATB1 is Down-regulated in Clear Cell Renal Cell Carcinoma and Correlates with miR-21-5p Overexpression and Poor Prognosis.Cancer Genomics Proteomics. 2016 May-Jun;13(3):209-17.
• [417] Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases.Int J Oncol. 2009 May;34(5):1387-93.
• [418] MicroRNA-186 Suppresses Cell Proliferation and Metastasis Through Targeting Sentrin-Specific Protease 1 in Renal Cell Carcinoma.Oncol Res. 2018 Mar 5;26(2):249-259. doi: 10.3727/096504017X14953948675430. Epub 2017 May 21.
• [419] Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.Eur Urol. 2018 Oct;74(4):483-486. doi: 10.1016/j.eururo.2018.06.007. Epub 2018 Jun 23.
• [420] Expression of Genes Involved in Porphyrin Biosynthesis Pathway in the Human Renal Cell Carcinoma.J Fluoresc. 2015 Sep;25(5):1363-9. doi: 10.1007/s10895-015-1626-x. Epub 2015 Aug 6.
• [421] Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.Urol Oncol. 2018 Jun;36(6):311.e15-311.e25. doi: 10.1016/j.urolonc.2018.03.014. Epub 2018 Apr 12.
• [422] High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.Sci Rep. 2015 Nov 24;5:16954. doi: 10.1038/srep16954.
• [423] Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.Acta Pharm Sin B. 2019 Sep;9(5):1008-1020. doi: 10.1016/j.apsb.2019.01.002. Epub 2019 Jan 8.
• [424] Fructose 1,6-Bisphosphatase 1 Expression Reduces (18)F-FDG Uptake in Clear Cell Renal Cell Carcinoma.Contrast Media Mol Imaging. 2019 Jan 6;2019:9463926. doi: 10.1155/2019/9463926. eCollection 2019.
• [425] The prospect of precision therapy for renal cell carcinoma.Cancer Treat Rev. 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003. Epub 2016 Jul 12.
• [426] Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue.Int J Cancer. 2017 Jun 1;140(11):2526-2534. doi: 10.1002/ijc.30674. Epub 2017 Mar 16.
• [427] Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.BMC Cancer. 2013 Oct 30;13:509. doi: 10.1186/1471-2407-13-509.
• [428] Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.Sci Rep. 2019 Nov 20;9(1):16776. doi: 10.1038/s41598-019-53397-7.
• [429] Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.Biomaterials. 2018 Nov;183:280-294. doi: 10.1016/j.biomaterials.2018.08.053. Epub 2018 Aug 30.
• [430] Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.Theranostics. 2019 Oct 22;9(26):8377-8391. doi: 10.7150/thno.37628. eCollection 2019.
• [431] Soyasapogenol B exhibits anti-growth and anti-metastatic activities in clear cell renal cell carcinoma.Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):551-563. doi: 10.1007/s00210-018-01607-w. Epub 2019 Jan 4.
• [432] SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-B signaling.Biochem Biophys Res Commun. 2018 Jan 1;495(1):1383-1388. doi: 10.1016/j.bbrc.2017.11.163. Epub 2017 Nov 26.
• [433] Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Hum Cell. 2015 Jan;28(1):44-50. doi: 10.1007/s13577-014-0101-3. Epub 2014 Sep 4.
• [434] The importance of serum osteopontin and stanniocalcin-1 in renal cell carcinoma.Neoplasma. 2018 Nov 15;65(6):958-964. doi: 10.4149/neo_2018_171123N759. Epub 2018 Jun 18.
• [435] Impact of Sulfatase-2 on cancer progression and prognosis in patients with renal cell carcinoma.Cancer Sci. 2016 Nov;107(11):1632-1641. doi: 10.1111/cas.13074.
• [436] The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma.Pathol Int. 2013 Jan;63(1):37-44. doi: 10.1111/pin.12031.
• [437] Over-expression of telomere binding factors (TRF1 & TRF2) in renal cell carcinoma and their inhibition by using SiRNA induce apoptosis, reduce cell proliferation and migration invitro.PLoS One. 2015 Mar 2;10(3):e0115651. doi: 10.1371/journal.pone.0115651. eCollection 2015.
• [438] Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.Eur Urol. 2008 Oct;54(4):845-53. doi: 10.1016/j.eururo.2008.01.010. Epub 2008 Jan 16.
• [439] Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.Biomol Ther (Seoul). 2019 Jan 1;27(1):34-40. doi: 10.4062/biomolther.2018.140.
• [440] Tiam1 mutations in human renal-cell carcinomas.Int J Cancer. 2000 Nov 1;88(3):369-76. doi: 10.1002/1097-0215(20001101)88:3<369::aid-ijc8>3.0.co;2-k.
• [441] Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique.Biochem Biophys Res Commun. 1999 Apr 21;257(3):855-9. doi: 10.1006/bbrc.1999.0465.
• [442] Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.Int J Cancer. 2000 Mar 15;85(6):865-70. doi: 10.1002/(sici)1097-0215(20000315)85:6<865::aid-ijc21>3.0.co;2-q.
• [443] Differential expression of thymosin genes in human tumors and in the developing human kidney.Int J Cancer. 1991 Jul 9;48(5):672-7. doi: 10.1002/ijc.2910480507.
• [444] Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin.Anticancer Drugs. 2017 Feb;28(2):180-186. doi: 10.1097/CAD.0000000000000450.
• [445] Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.
• [446] Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas.Anal Cell Pathol (Amst). 2011;34(1-2):49-60. doi: 10.3233/ACP-2011-0001.
• [447] Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.Int J Oncol. 2013 May;42(5):1664-73. doi: 10.3892/ijo.2013.1877. Epub 2013 Mar 29.
• [448] LncRNA SNHG3 promotes clear cell renal cell carcinoma proliferation and migration by upregulating TOP2A.Exp Cell Res. 2019 Nov 1;384(1):111595. doi: 10.1016/j.yexcr.2019.111595. Epub 2019 Sep 7.
• [449] Expression of Translationally Controlled Tumor Protein in Human Kidney and in Renal Cell Carcinoma.Biomed Res Int. 2015;2015:730390. doi: 10.1155/2015/730390. Epub 2015 Sep 3.
• [450] TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.Urol Oncol. 2017 May;35(5):286-293. doi: 10.1016/j.urolonc.2016.12.012. Epub 2017 Jan 17.
• [451] Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.Int J Oncol. 2016 Dec;49(6):2498-2506. doi: 10.3892/ijo.2016.3740. Epub 2016 Oct 19.
• [452] TRIM59 is a key regulator of growth and migration inrenal cell carcinoma.Cell Mol Biol (Noisy-le-grand). 2017 May 20;63(5):68-74. doi: 10.14715/cmb/2017.63.5.13.
• [453] Splicing variant of Cdc42 interacting protein-4 disrupts beta-catenin-mediated cell-cell adhesion: expression and function in renal cell carcinoma.Biochem Biophys Res Commun. 2006 Jan 27;339(4):1083-8. doi: 10.1016/j.bbrc.2005.11.117. Epub 2005 Dec 5.
• [454] Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.FEBS J. 2007 Dec;274(24):6365-77. doi: 10.1111/j.1742-4658.2007.06159.x. Epub 2007 Nov 15.
• [455] Targeting Transient Receptor Potential Channels by MicroRNAs Drives Tumor Development and Progression.Adv Exp Med Biol. 2020;1131:605-623. doi: 10.1007/978-3-030-12457-1_24.
• [456] CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.Int J Cancer. 2012 Sep 1;131(5):E693-704. doi: 10.1002/ijc.27419. Epub 2012 Feb 28.
• [457] Immunoexpression of Snail, Twist1 and Slug in clear cell renal cell carcinoma.Rom J Morphol Embryol. 2019;60(2):463-468.
• [458] CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.Cancer Lett. 2020 Jan 28;469:68-77. doi: 10.1016/j.canlet.2019.10.017. Epub 2019 Oct 17.
• [459] Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.Int J Mol Sci. 2018 Oct 29;19(11):3378. doi: 10.3390/ijms19113378.
• [460] UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.Mol Med Rep. 2019 Aug;20(2):1212-1220. doi: 10.3892/mmr.2019.10322. Epub 2019 Jun 3.
• [461] Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.J Transl Med. 2009 Oct 26;7:90. doi: 10.1186/1479-5876-7-90.
• [462] Increased UCP1 expression in the perirenal adipose tissue of patients with renal cell carcinoma.Oncol Rep. 2019 Nov;42(5):1972-1980. doi: 10.3892/or.2019.7306. Epub 2019 Sep 10.
• [463] Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma.Tohoku J Exp Med. 2001 Oct;195(2):101-13. doi: 10.1620/tjem.195.101.
• [464] VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.Theranostics. 2019 Jan 21;9(3):661-675. doi: 10.7150/thno.27794. eCollection 2019.
• [465] Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis.J Immunol. 2008 Nov 1;181(9):6584-94. doi: 10.4049/jimmunol.181.9.6584.
• [466] Correction: Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma.PLoS One. 2018 Aug 23;13(8):e0203174. doi: 10.1371/journal.pone.0203174. eCollection 2018.
• [467] Proteome profiling of clear cell renal cell carcinoma in von Hippel-Lindau patients highlights upregulation of Xaa-Pro aminopeptidase-1, an anti-proliferative and anti-migratory exoprotease.Oncotarget. 2017 Oct 19;8(59):100066-100078. doi: 10.18632/oncotarget.21929. eCollection 2017 Nov 21.
• [468] MiRNA-206 inhibits proliferation of renal clear cell carcinoma by targeting ZEB2.Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7826-7834. doi: 10.26355/eurrev_201909_18992.
• [469] MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.Cell Prolif. 2019 Sep;52(5):e12640. doi: 10.1111/cpr.12640. Epub 2019 Jun 27.
• [470] A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.BMC Cancer. 2017 Jan 4;17(1):9. doi: 10.1186/s12885-016-3030-6.
• [471] Induction of the connexin 32 gene by epigallocatechin-3-gallate potentiates vinblastine-induced cytotoxicity in human renal carcinoma cells.Chemotherapy. 2013;59(3):192-9. doi: 10.1159/000354715. Epub 2013 Dec 3.
• [472] HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells.Redox Biol. 2019 Jun;24:101218. doi: 10.1016/j.redox.2019.101218. Epub 2019 May 14.
• [473] Development of a novel interferon-2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro.Int J Clin Oncol. 2014;19(3):497-504. doi: 10.1007/s10147-013-0568-z. Epub 2013 Jun 6.
• [474] Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.Int J Mol Med. 2019 May;43(5):2044-2054. doi: 10.3892/ijmm.2019.4134. Epub 2019 Mar 14.
• [475] Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.Oncotarget. 2017 Jun 20;8(25):40412-40424. doi: 10.18632/oncotarget.16341.
• [476] Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.Cancer Immunol Res. 2014 Apr;2(4):371-9. doi: 10.1158/2326-6066.CIR-13-0088. Epub 2013 Nov 25.
• [477] PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.Int J Cancer. 2020 Mar 1;146(5):1435-1444. doi: 10.1002/ijc.32579. Epub 2019 Aug 9.
• [478] Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.Oncol Lett. 2019 Aug;18(2):1442-1450. doi: 10.3892/ol.2019.10442. Epub 2019 Jun 6.
• [479] Variants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell Carcinoma.Biomed Res Int. 2015;2015:860405. doi: 10.1155/2015/860405. Epub 2015 Apr 6.
• [480] MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma.Aging (Albany NY). 2019 Jan 22;11(2):615-633. doi: 10.18632/aging.101763.
• [481] Decreased expression of SLC16A12 mRNA predicts poor prognosis of patients with clear cell renal cell carcinoma.Medicine (Baltimore). 2019 Jul;98(30):e16624. doi: 10.1097/MD.0000000000016624.
• [482] The expression analysis of NGAL and NGALR in clear cell renal cell carcinoma.Gene. 2018 Nov 15;676:269-278. doi: 10.1016/j.gene.2018.08.060. Epub 2018 Aug 20.
• [483] Downregulation of ABCD1 in human renal cell carcinoma.Int J Biol Markers. 2009 Jul-Sep;24(3):171-8. doi: 10.1177/172460080902400307.
• [484] ER-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma.Cancer Res. 2018 May 15;78(10):2550-2563. doi: 10.1158/0008-5472.CAN-17-1575. Epub 2018 Feb 28.
• [485] Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation.Genomics. 1996 Mar 1;32(2):225-35. doi: 10.1006/geno.1996.0109.
• [486] An essential role for GLUT5-mediated fructose utilization in exacerbating the malignancy of clear cell renal cell carcinoma.Cell Biol Toxicol. 2019 Oct;35(5):471-483. doi: 10.1007/s10565-019-09478-4. Epub 2019 May 17.
• [487] Prognostic value of copper transporter 1 expression in patients with clear cell renal cell carcinoma.Oncol Lett. 2017 Nov;14(5):5791-5800. doi: 10.3892/ol.2017.6942. Epub 2017 Sep 14.
• [488] Association between ZIP10 gene expression and tumor aggressiveness in renal cell carcinoma.Gene. 2014 Nov 15;552(1):195-8. doi: 10.1016/j.gene.2014.09.010. Epub 2014 Sep 6.
• [489] Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.Tumour Biol. 2015 Sep;36(10):7431-7. doi: 10.1007/s13277-015-3459-2. Epub 2015 Apr 23.
• [490] The alterations in alcohol dehydrogenase and aldehyde dehydrogenase activities in the sera of patients with renal cell carcinoma.Adv Med Sci. 2018 Mar;63(1):1-4. doi: 10.1016/j.advms.2017.05.001. Epub 2017 Jul 28.
• [491] Association between cytochrome P450 1A1 (CYP1A1) gene polymorphisms and the risk of renal cell carcinoma: a meta-analysis.Sci Rep. 2015 Jan 29;5:8108. doi: 10.1038/srep08108.
• [492] Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.J Clin Invest. 2017 May 1;127(5):1631-1645. doi: 10.1172/JCI87800. Epub 2017 Mar 27.
• [493] Nicotinamide N-Methyltransferase and Its Precursor Substrate Methionine Directly and Indirectly Control Malignant Metabolism During Progression of Renal Cell Carcinoma.Anticancer Res. 2019 Oct;39(10):5427-5436. doi: 10.21873/anticanres.13736.
• [494] Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma.Med Oncol. 2013;30(2):574. doi: 10.1007/s12032-013-0574-z. Epub 2013 Apr 13.
• [495] Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma.Tumour Biol. 2017 Mar;39(3):1010428317695968. doi: 10.1177/1010428317695968.
• [496] Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.Oncol Rep. 2017 Jan;37(1):227-234. doi: 10.3892/or.2016.5232. Epub 2016 Nov 8.
• [497] Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma.Urol Oncol. 2018 May;36(5):243.e9-243.e20. doi: 10.1016/j.urolonc.2018.01.013. Epub 2018 Mar 2.
• [498] Human agmatinase is diminished in the clear cell type of renal cell carcinoma.Int J Cancer. 2004 Jan 20;108(3):342-7. doi: 10.1002/ijc.11459.
• [499] Promoter DNA methylation analysis reveals a novel diagnostic CpG-based biomarker and RAB25 hypermethylation in clear cell renel cell carcinoma.Sci Rep. 2017 Oct 27;7(1):14200. doi: 10.1038/s41598-017-14314-y.
• [500] FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data.Tumour Biol. 2014 Mar;35(3):2607-17. doi: 10.1007/s13277-013-1344-4. Epub 2013 Dec 8.
• [501] The Preoperative Predictive Factors for Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma.Diagnostics (Basel). 2019 Jul 15;9(3):76. doi: 10.3390/diagnostics9030076.
• [502] Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux.Mol Cell Biol. 2007 Oct;27(20):7345-53. doi: 10.1128/MCB.02201-06. Epub 2007 Aug 6.
• [503] In vivo gene expression profile analysis of metallothionein in renal cell carcinoma.Cancer Lett. 2000 Nov 28;160(2):133-40. doi: 10.1016/s0304-3835(00)00534-6.
• [504] Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.Pharmacogenetics. 2001 Aug;11(6):521-35. doi: 10.1097/00008571-200108000-00007.
• [505] Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifies COX5B as a prognostic marker in clear cell renal cell carcinoma.Int J Urol. 2019 Sep;26(9):910-916. doi: 10.1111/iju.14040. Epub 2019 Jul 7.
• [506] Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).World J Urol. 2013 Oct;31(5):1191-6. doi: 10.1007/s00345-012-0874-5. Epub 2012 Apr 29.
• [507] A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility.BMC Med Genet. 2018 Jun 8;19(1):98. doi: 10.1186/s12881-018-0620-y.
• [508] Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison (11)C-choline and FDG PET/CT with dynamic contrast-enhanced CT.Jpn J Radiol. 2019 Feb;37(2):165-177. doi: 10.1007/s11604-018-0789-1. Epub 2018 Oct 30.
• [509] The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma.Neoplasia. 2019 Sep;21(9):921-931. doi: 10.1016/j.neo.2019.07.004. Epub 2019 Aug 8.
• [510] Role of DNA methylation in renal cell carcinoma.J Hematol Oncol. 2015 Jul 22;8:88. doi: 10.1186/s13045-015-0180-y.
• [511] Role of APLP2 in the prognosis and clinicopathology of renal cell carcinoma.Oncol Lett. 2019 Jan;17(1):508-513. doi: 10.3892/ol.2018.9577. Epub 2018 Oct 15.
• [512] Analysis of the characteristics of chemotherapy-resistant renal cell carcinomas based on global transcriptional analysis of their tissues and cell lines.PLoS One. 2019 Nov 27;14(11):e0225721. doi: 10.1371/journal.pone.0225721. eCollection 2019.
• [513] Pharmacologic Targeting of Hypoxia-Inducible Factors.Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:379-403. doi: 10.1146/annurev-pharmtox-010818-021637.
• [514] Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma.Biochem Biophys Res Commun. 2019 Mar 26;511(1):165-172. doi: 10.1016/j.bbrc.2019.02.060. Epub 2019 Feb 15.
• [515] Identification of key genes involved in the metastasis of clear cell renal cell carcinoma.Oncol Lett. 2019 May;17(5):4321-4328. doi: 10.3892/ol.2019.10130. Epub 2019 Mar 8.
• [516] Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.Am J Transl Res. 2019 Jan 15;11(1):327-339. eCollection 2019.
• [517] Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Differentiation of Minimal Fat Angiomyolipoma from Clear Cell Renal Cell Carcinoma.Acad Radiol. 2019 May;26(5):632-639. doi: 10.1016/j.acra.2018.06.015. Epub 2018 Aug 5.
• [518] Exploring the mechanism of clear cell renal cell carcinoma metastasis and key genes based on multi-tool joint analysis.Gene. 2019 Dec 15;720:144103. doi: 10.1016/j.gene.2019.144103. Epub 2019 Sep 3.
• [519] CA8 promotes RCC proliferation and migration though its expression level is lower in tumor compared to adjacent normal tissue.Biomed Pharmacother. 2020 Jan;121:109578. doi: 10.1016/j.biopha.2019.109578. Epub 2019 Nov 10.
• [520] The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma.Dis Markers. 2019 Aug 6;2019:1342161. doi: 10.1155/2019/1342161. eCollection 2019.
• [521] PTRF/CAVIN1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC.Carcinogenesis. 2020 May 14;41(3):274-283. doi: 10.1093/carcin/bgz147.
• [522] HIF2-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.Mol Cancer Ther. 2018 Jan;17(1):140-149. doi: 10.1158/1535-7163.MCT-17-0471. Epub 2017 Oct 27.
• [523] Knockdown of CHCHD2 inhibits migration and angiogenesis of human renal cell carcinoma: A potential molecular marker for treatment of RCC.Oncol Lett. 2019 Jan;17(1):765-772. doi: 10.3892/ol.2018.9686. Epub 2018 Nov 12.
• [524] M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma.Anticancer Res. 2019 Dec;39(12):6939-6943. doi: 10.21873/anticanres.13915.
• [525] Combined Immunohistochemistry for the "Three 7" Markers (CK7, CD117, and Claudin-7) Is Useful in the Diagnosis of Chromophobe Renal Cell Carcinoma and for the Exclusion of Mimics: Diagnostic Experience from a Single Institution.Dis Markers. 2019 Oct 13;2019:4708154. doi: 10.1155/2019/4708154. eCollection 2019.
• [526] Immunohistochemical diagnosis of renal neoplasms.Arch Pathol Lab Med. 2011 Jan;135(1):92-109. doi: 10.5858/2010-0478-RAR.1.
• [527] CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis.Oncol Lett. 2017 Aug;14(2):1536-1542. doi: 10.3892/ol.2017.6350. Epub 2017 Jun 8.
• [528] An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade.J Cell Biochem. 2019 Aug;120(8):13330-13341. doi: 10.1002/jcb.28607. Epub 2019 Mar 27.
• [529] Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human.Cancer Gene Ther. 2020 Apr;27(3-4):216-225. doi: 10.1038/s41417-019-0087-9. Epub 2019 Feb 21.
• [530] Cyclin D1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma.J BUON. 2019 Jan-Feb;24(1):301-309.
• [531] Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability.Oncogenesis. 2019 Jan 9;8(1):4. doi: 10.1038/s41389-018-0110-2.
• [532] Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.Eur J Cancer. 2009 Feb;45(3):478-89. doi: 10.1016/j.ejca.2008.10.023. Epub 2008 Dec 11.
• [533] The long noncoding RNA KCNQ1DN suppresses the survival of renal cell carcinoma cells through downregulating c-Myc.J Cancer. 2019 Aug 19;10(19):4662-4670. doi: 10.7150/jca.29280. eCollection 2019.
• [534] Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer.Int J Urol. 2009 Mar;16(3):329-32. doi: 10.1111/j.1442-2042.2008.02233.x. Epub 2009 Jan 20.
• [535] Inactivation of the AMPK-GATA3-ECHS1 Pathway Induces Fatty Acid Synthesis That Promotes Clear Cell Renal Cell Carcinoma Growth.Cancer Res. 2020 Jan 15;80(2):319-333. doi: 10.1158/0008-5472.CAN-19-1023. Epub 2019 Nov 5.
• [536] Engrailed-2 promoter hyper-methylation is associated with its downregulation in clear cell renal cell carcinoma.Oncol Lett. 2017 Dec;14(6):6888-6894. doi: 10.3892/ol.2017.7000. Epub 2017 Sep 19.
• [537] Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.BMC Cancer. 2018 Nov 15;18(1):1114. doi: 10.1186/s12885-018-5060-8.
• [538] Transforming growth factor- promotes aggressiveness and invasion of clear cell renal cell carcinoma.Oncotarget. 2016 Jun 14;7(24):35917-35931. doi: 10.18632/oncotarget.9177.
• [539] MicroRNA-125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells.J Cell Biochem. 2019 Feb;120(2):1894-1902. doi: 10.1002/jcb.27503. Epub 2018 Sep 6.
• [540] Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.Cancer Immunol Immunother. 2017 Jan;66(1):17-24. doi: 10.1007/s00262-016-1915-5. Epub 2016 Oct 18.
• [541] LAT, HOXD3 and NFE2L3 identified as novel DNA methylation-driven genes and prognostic markers in human clear cell renal cell carcinoma by integrative bioinformatics approaches.J Cancer. 2019 Oct 22;10(26):6726-6737. doi: 10.7150/jca.35641. eCollection 2019.
• [542] Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop.J Exp Clin Cancer Res. 2019 Oct 30;38(1):439. doi: 10.1186/s13046-019-1453-z.
• [543] Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients.J Cell Biochem. 2020 Feb;121(2):1552-1562. doi: 10.1002/jcb.29390. Epub 2019 Sep 12.
• [544] A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma.Nat Commun. 2019 Mar 11;10(1):1152. doi: 10.1038/s41467-019-09116-x.
• [545] Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.Clin Genitourin Cancer. 2019 Feb;17(1):e167-e175. doi: 10.1016/j.clgc.2018.10.008. Epub 2018 Oct 23.
• [546] Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma.Urol Oncol. 2015 Mar;33(3):112.e1-8. doi: 10.1016/j.urolonc.2014.11.001. Epub 2014 Nov 5.
• [547] Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma.Oncol Lett. 2019 Sep;18(3):2654-2660. doi: 10.3892/ol.2019.10593. Epub 2019 Jul 9.
• [548] Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma.Cell Death Dis. 2019 Mar 22;10(4):279. doi: 10.1038/s41419-019-1520-6.
• [549] N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1 signalling axis.J Cell Mol Med. 2019 Mar;23(3):2163-2173. doi: 10.1111/jcmm.14128. Epub 2019 Jan 16.
• [550] PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3.Cancer Gene Ther. 2020 Jun;27(6):412-423. doi: 10.1038/s41417-019-0094-x. Epub 2019 Jun 12.
• [551] Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals.Cancer Lett. 2017 May 28;394:1-12. doi: 10.1016/j.canlet.2016.12.036. Epub 2017 Jan 13.
• [552] 1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.World J Urol. 2015 Nov;33(11):1791-9. doi: 10.1007/s00345-014-1451-x. Epub 2015 Jan 29.
• [553] High expression of MICA in human kidney cancer tissue and renal cell carcinoma lines.Asian Pac J Cancer Prev. 2014;15(4):1715-7. doi: 10.7314/apjcp.2014.15.4.1715.
• [554] Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma.Lab Invest. 2019 Feb;99(2):191-199. doi: 10.1038/s41374-018-0138-0. Epub 2018 Oct 5.
• [555] DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma.Oncol Rep. 2019 Jun;41(6):3535-3544. doi: 10.3892/or.2019.7109. Epub 2019 Apr 10.
• [556] Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.Urol Oncol. 2019 Nov;37(11):812.e9-812.e16. doi: 10.1016/j.urolonc.2019.07.002. Epub 2019 Aug 14.
• [557] NDNF inhibits the migration and invasion of human renal cancer cells through epithelial-mesenchymal transition.Oncol Lett. 2019 Mar;17(3):2969-2975. doi: 10.3892/ol.2019.9937. Epub 2019 Jan 15.
• [558] Suppression of GLTSCR2 expression in renal cell carcinomas.Pathol Res Pract. 2016 Feb;212(2):120-4. doi: 10.1016/j.prp.2015.12.005. Epub 2015 Dec 14.
• [559] Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma.Cancer Manag Res. 2019 Mar 19;11:2215-2223. doi: 10.2147/CMAR.S190642. eCollection 2019.
• [560] The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.Anticancer Res. 2019 Jun;39(6):3249-3253. doi: 10.21873/anticanres.13466.
• [561] PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma.Nat Commun. 2019 Aug 20;10(1):3739. doi: 10.1038/s41467-019-11672-1.
• [562] Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model.Oncol Lett. 2017 Sep;14(3):3371-3378. doi: 10.3892/ol.2017.6605. Epub 2017 Jul 18.
• [563] Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.Int Urol Nephrol. 2018 Feb;50(2):247-255. doi: 10.1007/s11255-017-1782-9. Epub 2017 Dec 29.
• [564] Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma.World J Urol. 2019 Aug;37(8):1639-1647. doi: 10.1007/s00345-018-2575-1. Epub 2018 Nov 28.
• [565] MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC.Biomed Pharmacother. 2019 Feb;110:656-666. doi: 10.1016/j.biopha.2018.11.065. Epub 2018 Dec 12.
• [566] Reference genes for gene expression analysis by real-time reverse transcription polymerase chain reaction of renal cell carcinoma.Diagn Mol Pathol. 2011 Dec;20(4):212-7. doi: 10.1097/PDM.0b013e318212e0a9.
• [567] Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance.Medicine (Baltimore). 2019 Sep;98(36):e17028. doi: 10.1097/MD.0000000000017028.
• [568] RAB27A is an independent prognostic factor in clear cell renal cell carcinoma.Biomark Med. 2019 Mar;13(4):239-247. doi: 10.2217/bmm-2018-0336. Epub 2019 Jan 21.
• [569] Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer.Urol Oncol. 2020 Jan;38(1):6.e17-6.e22. doi: 10.1016/j.urolonc.2019.09.019. Epub 2019 Oct 23.
• [570] RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25.Cancer Sci. 2017 Aug;108(8):1620-1627. doi: 10.1111/cas.13297. Epub 2017 Jul 3.
• [571] Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM.Transl Oncol. 2019 Jun;12(6):810-818. doi: 10.1016/j.tranon.2019.03.002. Epub 2019 Apr 4.
• [572] Giant Pediatric Rhabdoid Meningioma Associated with a Germline BAP1 Pathogenic Variation: A Rare Clinical Case.World Neurosurg. 2018 Nov;119:402-415. doi: 10.1016/j.wneu.2018.06.227. Epub 2018 Jul 6.
• [573] RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer.Mol Cell Biol. 2017 Oct 27;37(22):e00265-17. doi: 10.1128/MCB.00265-17. Print 2017 Nov 15.
• [574] LncRNA SCAMP1 regulates ZEB1/JUN and autophagy to promote pediatric renal cell carcinoma under oxidative stress via miR-429.Biomed Pharmacother. 2019 Dec;120:109460. doi: 10.1016/j.biopha.2019.109460. Epub 2019 Sep 21.
• [575] Vimentin Overexpressions Induced by Cell Hypoxia Promote Vasculogenic Mimicry by Renal Cell Carcinoma Cells.Biomed Res Int. 2019 Jul 21;2019:7259691. doi: 10.1155/2019/7259691. eCollection 2019.
• [576] Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.Mol Cancer Ther. 2012 Oct;11(10):2105-15. doi: 10.1158/1535-7163.MCT-11-0873. Epub 2012 Jul 23.
• [577] TIP-B1 promotes kidney clear cell carcinoma growth and metastasis via EGFR/AKT signaling.Aging (Albany NY). 2019 Sep 27;11(18):7914-7937. doi: 10.18632/aging.102298. Epub 2019 Sep 27.
• [578] Targeted p21(WAF1/CIP1) activation by miR-1236 inhibits cell proliferation and correlates with favorable survival in renal cell carcinoma.Urol Oncol. 2016 Feb;34(2):59.e23-34. doi: 10.1016/j.urolonc.2015.08.014. Epub 2015 Sep 28.
• [579] BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation.Histopathology. 2017 Apr;70(5):711-721. doi: 10.1111/his.13120. Epub 2017 Jan 9.
• [580] Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.Anticancer Res. 2018 Jun;38(6):3757-3761. doi: 10.21873/anticanres.12657.
• [581] TOX3 inhibits cancer cell migration and invasion via transcriptional regulation of SNAI1 and SNAI2 in clear cell renal cell carcinoma.Cancer Lett. 2019 May 1;449:76-86. doi: 10.1016/j.canlet.2019.02.020. Epub 2019 Feb 14.
• [582] Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects.Mol Cancer Ther. 2019 Dec;18(12):2433-2445. doi: 10.1158/1535-7163.MCT-19-0043. Epub 2019 Sep 16.
• [583] LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma.J Cell Physiol. 2019 May;234(5):7257-7265. doi: 10.1002/jcp.27483. Epub 2018 Oct 26.
• [584] Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro.Mol Carcinog. 2014 Dec;53(12):970-8. doi: 10.1002/mc.22065. Epub 2013 Jul 2.
• [585] The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.Med Sci Monit. 2019 Dec 11;25:9458-9470. doi: 10.12659/MSM.917754.
• [586] Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation.Cancers (Basel). 2018 Jun 8;10(6):190. doi: 10.3390/cancers10060190.
• [587] Standardized report template for indeterminate renal masses at CT and MRI: a collaborative product of the SAR Disease-Focused Panel on Renal Cell Carcinoma.Abdom Radiol (NY). 2019 Apr;44(4):1423-1429. doi: 10.1007/s00261-018-1851-2.
• [588] Syntaxin 6: A novel predictive and prognostic biomarker in papillary renal cell carcinoma.Sci Rep. 2019 Feb 28;9(1):3146. doi: 10.1038/s41598-019-39305-z.
• [589] VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.J BUON. 2017 Jul-Aug;22(4):1038-1045.
• [590] MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4566-4576.
• [591] TNIP1 Inhibits Proliferation And Promotes Apoptosis In Clear Cell Renal Carcinoma Through Targeting C/Ebp.Onco Targets Ther. 2019 Nov 18;12:9861-9871. doi: 10.2147/OTT.S216138. eCollection 2019.
• [592] TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway.Int J Biol Sci. 2019 Jan 1;15(3):587-597. doi: 10.7150/ijbs.29737. eCollection 2019.
• [593] Genomic and proteomic approaches to renal cell carcinoma.J Nephrol. 2011 Mar-Apr;24(2):155-64. doi: 10.5301/jn.2010.90.
• [594] HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.Oncotarget. 2017 May 19;8(41):69559-69576. doi: 10.18632/oncotarget.18012. eCollection 2017 Sep 19.
• [595] A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma.Genes Chromosomes Cancer. 2007 Sep;46(9):805-12. doi: 10.1002/gcc.20466.
• [596] Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma.Biochimie. 2019 Feb;157:26-37. doi: 10.1016/j.biochi.2018.10.019. Epub 2018 Oct 30.
• [597] Circular RNA ABCB10 promotes tumor progression and correlates with pejorative prognosis in clear cell renal cell carcinoma.Int J Biol Markers. 2019 Jun;34(2):176-183. doi: 10.1177/1724600819842279. Epub 2019 May 20.
• [598] High expression of fructose-bisphosphate aldolaseA induces progression of renal cell carcinoma.Oncol Rep. 2018 Jun;39(6):2996-3006. doi: 10.3892/or.2018.6378. Epub 2018 Apr 18.
• [599] Clinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma.Clin Genitourin Cancer. 2018 Aug;16(4):e795-e805. doi: 10.1016/j.clgc.2018.02.013. Epub 2018 Feb 23.
• [600] Novel method for DNA methylation analysis using high-performance liquid chromatography and its clinical application.Cancer Sci. 2018 May;109(5):1690-1700. doi: 10.1111/cas.13566. Epub 2018 Apr 17.
• [601] ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.Am J Cancer Res. 2018 Jan 1;8(1):132-143. eCollection 2018.
• [602] A novel correlation between ATP5A1 gene expression and progression of human clear cell renal cell carcinoma identified by coexpression analysis.Oncol Rep. 2018 Feb;39(2):525-536. doi: 10.3892/or.2017.6132. Epub 2017 Dec 4.
• [603] Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas.Onco Targets Ther. 2018 Aug 3;11:4537-4545. doi: 10.2147/OTT.S169155. eCollection 2018.
• [604] Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin.Int J Cancer. 2018 Feb 1;142(3):607-617. doi: 10.1002/ijc.31080. Epub 2017 Oct 14.
• [605] Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma.Tumour Biol. 2017 Feb;39(2):1010428317691417. doi: 10.1177/1010428317691417.
• [606] Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma.Oncol Rep. 2018 Jan;39(1):173-181. doi: 10.3892/or.2017.6098. Epub 2017 Nov 15.
• [607] Calcium-activated nucleotidase 1 silencing inhibits proliferation, migration, and invasion in human clear cell renal cell carcinoma.J Cell Physiol. 2019 Dec;234(12):22635-22647. doi: 10.1002/jcp.28829. Epub 2019 May 17.
• [608] CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway.Onco Targets Ther. 2018 Sep 25;11:6209-6216. doi: 10.2147/OTT.S172803. eCollection 2018.
• [609] Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue.Cell Mol Life Sci. 2018 Jun;75(12):2241-2256. doi: 10.1007/s00018-017-2731-6. Epub 2017 Dec 27.
• [610] Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma.J Cancer. 2019 Jun 9;10(15):3389-3396. doi: 10.7150/jca.31676. eCollection 2019.
• [611] Expression of cold-inducible RNA-binding protein (CIRP) in renal cell carcinoma and the effect of CIRP downregulation cell proliferation and chemosensitivity to gemcitabine.Oncol Lett. 2018 May;15(5):7611-7616. doi: 10.3892/ol.2018.8338. Epub 2018 Mar 23.
• [612] CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.Oncol Rep. 2018 Oct;40(4):2023-2035. doi: 10.3892/or.2018.6590. Epub 2018 Jul 23.
• [613] CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.Biochem Biophys Res Commun. 2017 Apr 1;485(2):267-271. doi: 10.1016/j.bbrc.2017.02.095. Epub 2017 Feb 21.
• [614] Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma.Cancer Manag Res. 2019 Feb 7;11:1263-1274. doi: 10.2147/CMAR.S188216. eCollection 2019.
• [615] Novel insights into biomarkers associated with renal cell carcinoma.Oncol Lett. 2018 Jul;16(1):83-90. doi: 10.3892/ol.2018.8665. Epub 2018 May 8.
• [616] The downregulated long noncoding RNA DHRS4-AS1 is protumoral and associated with the prognosis of clear cell renal cell carcinoma.Onco Targets Ther. 2018 Sep 10;11:5631-5646. doi: 10.2147/OTT.S164984. eCollection 2018.
• [617] RNAa and Vector-Mediated Overexpression of DIRAS1 Suppresses Tumor Growth and Migration in Renal Cell Carcinoma.Mol Ther Nucleic Acids. 2018 Sep 7;12:845-853. doi: 10.1016/j.omtn.2018.07.019. Epub 2018 Aug 8.
• [618] Sex specific associations in genome wide association analysis of renal cell carcinoma.Eur J Hum Genet. 2019 Oct;27(10):1589-1598. doi: 10.1038/s41431-019-0455-9. Epub 2019 Jun 23.
• [619] High eukaryotic translation elongation factor 1 alpha 1 expression promotes proliferation and predicts poor prognosis in clear cell renal cell carcinoma.Neoplasma. 2020 Jan;67(1):78-84. doi: 10.4149/neo_2019_190224N158. Epub 2019 Nov 26.
• [620] SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3.Exp Cell Res. 2019 Sep 15;382(2):111466. doi: 10.1016/j.yexcr.2019.06.011. Epub 2019 Jun 12.
• [621] Global isoform-specific transcript alterations and deregulated networks in clear cell renal cell carcinoma.Oncotarget. 2018 May 4;9(34):23670-23680. doi: 10.18632/oncotarget.25330. eCollection 2018 May 4.
• [622] FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma.Int J Cancer. 2018 Jun 15;142(12):2543-2557. doi: 10.1002/ijc.31278. Epub 2018 Feb 14.
• [623] miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis.Onco Targets Ther. 2019 Apr 10;12:2713-2727. doi: 10.2147/OTT.S199238. eCollection 2019.
• [624] Knockdown of GA-binding protein subunit 1 inhibits cell proliferation via p21 induction in renal cell carcinoma.Int J Oncol. 2018 Aug;53(2):886-894. doi: 10.3892/ijo.2018.4411. Epub 2018 May 17.
• [625] ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Arraybased DNA methylation profiling.Oncol Rep. 2019 Jul;42(1):453-460. doi: 10.3892/or.2019.7151. Epub 2019 May 7.
• [626] Identification of potential pathogenic biomarkers in clear cell renal cell carcinoma.Oncol Lett. 2018 Jun;15(6):8491-8499. doi: 10.3892/ol.2018.8398. Epub 2018 Mar 30.
• [627] Novel splicing in IGFN1 intron 15 and role of stable G-quadruplex in the regulation of splicing in renal cell carcinoma.PLoS One. 2018 Oct 18;13(10):e0205660. doi: 10.1371/journal.pone.0205660. eCollection 2018.
• [628] Inhibitor of growth 4 inhibits cell proliferation, migration, and induces apoptosis of renal cell carcinoma cells.J Cell Biochem. 2019 Apr;120(4):6709-6717. doi: 10.1002/jcb.27967. Epub 2018 Nov 2.
• [629] Nephrometry score correlated with tumor proliferative activity inT1 clear cell renal cell carcinoma.Urol Oncol. 2019 May;37(5):301.e19-301.e25. doi: 10.1016/j.urolonc.2019.02.005. Epub 2019 Feb 27.
• [630] Integrin 7 is overexpressed and correlates with higher pathological grade, increased T stage, advanced TNM stage as well as worse survival in clear cell renal cell carcinoma patients: A retrospective study.J Clin Lab Anal. 2020 Jan;34(1):e23034. doi: 10.1002/jcla.23034. Epub 2019 Nov 11.
• [631] Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level.Ren Fail. 2017 Nov;39(1):258-264. doi: 10.1080/0886022X.2016.1256322. Epub 2016 Nov 21.
• [632] Kinesin Motor Protein KIFC1 Is a Target Protein of miR-338-3p and Is Associated With Poor Prognosis and Progression of Renal Cell Carcinoma.Oncol Res. 2018 Dec 27;27(1):125-137. doi: 10.3727/096504018X15213115046567. Epub 2018 Mar 21.
• [633] MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.EBioMedicine. 2019 Jun;44:439-451. doi: 10.1016/j.ebiom.2019.05.041. Epub 2019 May 23.
• [634] Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma.Oncol Lett. 2018 Jul;16(1):866-874. doi: 10.3892/ol.2018.8782. Epub 2018 May 22.
• [635] Knockdown of LETM1 inhibits proliferation and metastasis of human renal cell carcinoma cells.Oncol Lett. 2018 Nov;16(5):6377-6382. doi: 10.3892/ol.2018.9449. Epub 2018 Sep 18.
• [636] -1,2-Mannosidase MAN1C1 Inhibits Proliferation and Invasion of Clear Cell Renal Cell Carcinoma.J Cancer. 2018 Nov 24;9(24):4618-4626. doi: 10.7150/jca.27673. eCollection 2018.
• [637] Identification of a 5-Gene Signature Predicting Progression and Prognosis of Clear Cell Renal Cell Carcinoma.Med Sci Monit. 2019 Jun 13;25:4401-4413. doi: 10.12659/MSM.917399.
• [638] Expression of minichromosome maintenance genes in renal cell carcinoma.Cancer Manag Res. 2017 Nov 15;9:637-647. doi: 10.2147/CMAR.S146528. eCollection 2017.
• [639] MCM5 promotes tumour proliferation and correlates with the progression and prognosis of renal cell carcinoma.Int Urol Nephrol. 2019 Sep;51(9):1517-1526. doi: 10.1007/s11255-019-02169-3. Epub 2019 Jun 12.
• [640] MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9.Cancers (Basel). 2019 Nov 23;11(12):1851. doi: 10.3390/cancers11121851.
• [641] Methylenetetrahydrofolate Dehydrogenase 1 (MTHFD1) is Underexpressed in Clear Cell Renal Cell Carcinoma Tissue and Transfection and Overexpression in Caki-1 Cells Inhibits Cell Proliferation and Increases Apoptosis.Med Sci Monit. 2018 Nov 21;24:8391-8400. doi: 10.12659/MSM.911124.
• [642] Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas.Sci Rep. 2018 Aug 6;8(1):11739. doi: 10.1038/s41598-018-30168-4.
• [643] Major Differences in Hypoxia Tolerance and P38 Regulation Among Different Renal Cells.Cell Physiol Biochem. 2018;46(4):1483-1492. doi: 10.1159/000489188. Epub 2018 Apr 19.
• [644] Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.Int J Med Sci. 2019 Sep 20;16(10):1404-1411. doi: 10.7150/ijms.36128. eCollection 2019.
• [645] Renal cell carcinoma suspected at time of organ donation 2008-2016: A report of the OPTN ad hoc Disease Transmission Advisory Committee Registry.Clin Transplant. 2019 Jul;33(7):e13597. doi: 10.1111/ctr.13597. Epub 2019 Jun 25.
• [646] NudCD1 affects renal cell carcinoma through regulating LIS1/Dynein signaling pathway.Am J Transl Res. 2018 Feb 15;10(2):519-524. eCollection 2018.
• [647] The Expression Patterns of FAM83H and PANX2 Are Associated With Shorter Survival of Clear Cell Renal Cell Carcinoma Patients.Front Oncol. 2019 Jan 22;9:14. doi: 10.3389/fonc.2019.00014. eCollection 2019.
• [648] Key miRNAs and target genes played roles in the development of clear cell renal cell carcinoma.Cancer Biomark. 2018;23(2):279-290. doi: 10.3233/CBM-181558.
• [649] Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial.Urol Oncol. 2018 Jul;36(7):340.e1-340.e6. doi: 10.1016/j.urolonc.2018.04.011. Epub 2018 May 17.
• [650] The prognostic significance of nuclear expression of PHF2 and C/EBP in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution.Oncotarget. 2017 Aug 4;9(1):142-151. doi: 10.18632/oncotarget.19949. eCollection 2018 Jan 2.
• [651] Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.Int Urol Nephrol. 2017 Jul;49(7):1165-1176. doi: 10.1007/s11255-017-1578-y. Epub 2017 Mar 27.
• [652] PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.Anticancer Res. 2016 Feb;36(2):617-24.
• [653] PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma.Urol Oncol. 2018 Jul;36(7):343.e9-343.e19. doi: 10.1016/j.urolonc.2018.04.006.
• [654] Role of MR texture analysis in histological subtyping and grading of renal cell carcinoma: a preliminary study.Abdom Radiol (NY). 2019 Oct;44(10):3336-3349. doi: 10.1007/s00261-019-02122-z.
• [655] Exploring the Natural Piericidins as Anti-Renal Cell Carcinoma Agents Targeting Peroxiredoxin 1.J Med Chem. 2019 Aug 8;62(15):7058-7069. doi: 10.1021/acs.jmedchem.9b00598. Epub 2019 Jul 25.
• [656] In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma.Pathol Res Pract. 2019 Jun;215(6):152373. doi: 10.1016/j.prp.2019.03.002. Epub 2019 Mar 4.
• [657] The clinical significance of PYCR1 expression in renal cell carcinoma.Medicine (Baltimore). 2019 Jul;98(28):e16384. doi: 10.1097/MD.0000000000016384.
• [658] miR-384 suppressed renal cell carcinoma cell proliferation and migration through targeting RAB23.J Cell Biochem. 2019 Feb;120(2):1420-1426. doi: 10.1002/jcb.27180. Epub 2018 Nov 2.
• [659] RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.Int J Oncol. 2019 Sep;55(3):645-656. doi: 10.3892/ijo.2019.4849. Epub 2019 Jul 26.
• [660] The expression and function of RASAL2 in renal cell carcinoma angiogenesis.Cell Death Dis. 2018 Aug 29;9(9):881. doi: 10.1038/s41419-018-0898-x.
• [661] Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling.J Cell Physiol. 2018 Dec;233(12):9503-9515. doi: 10.1002/jcp.26849. Epub 2018 Jul 3.
• [662] RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.Exp Cell Res. 2018 Nov 15;372(2):118-128. doi: 10.1016/j.yexcr.2018.09.017. Epub 2018 Sep 27.
• [663] Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro.Int J Oncol. 2019 Jan;54(1):188-198. doi: 10.3892/ijo.2018.4611. Epub 2018 Oct 30.
• [664] Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.Med Sci Monit. 2018 Feb 19;24:1034-1043. doi: 10.12659/msm.906020.
• [665] von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.Cell Death Dis. 2019 Mar 19;10(4):266. doi: 10.1038/s41419-019-1507-3.
• [666] Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.Clin Genitourin Cancer. 2018 Oct;16(5):413-419.e1. doi: 10.1016/j.clgc.2018.07.018. Epub 2018 Aug 17.
• [667] Cyanidin Curtails Renal Cell Carcinoma Tumorigenesis.Cell Physiol Biochem. 2018;46(6):2517-2531. doi: 10.1159/000489658. Epub 2018 May 5.
• [668] MiR-376a functions as tumor suppressor by targeting SGK3 in renal cell carcinoma.Eur Rev Med Pharmacol Sci. 2019 May;23(9):3726-3732. doi: 10.26355/eurrev_201905_17798.
• [669] Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.Clin Genitourin Cancer. 2017 Oct;15(5):526-533. doi: 10.1016/j.clgc.2017.02.006. Epub 2017 Feb 27.
• [670] Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway.Biomed Pharmacother. 2019 Mar;111:917-925. doi: 10.1016/j.biopha.2018.12.143. Epub 2019 Jan 7.
• [671] Ubiquitin ligase SMURF1 functions as a prognostic marker and promotes growth and metastasis of clear cell renal cell carcinoma.FEBS Open Bio. 2017 Feb 23;7(4):577-586. doi: 10.1002/2211-5463.12204. eCollection 2017 Apr.
• [672] SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma.Oncol Lett. 2018 Apr;15(4):4564-4570. doi: 10.3892/ol.2018.7828. Epub 2018 Jan 19.
• [673] The association of speckle-type POZ protein with lymph node metastasis and prognosis in cancer patients: A meta-analysis.Medicine (Baltimore). 2019 Oct;98(40):e17439. doi: 10.1097/MD.0000000000017439.
• [674] Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma.Oncotarget. 2017 Mar 7;8(10):17012-17026. doi: 10.18632/oncotarget.15222.
• [675] Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.Oncol Rep. 2017 Jul;38(1):427-439. doi: 10.3892/or.2017.5642. Epub 2017 May 15.
• [676] Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma.APMIS. 2017 Mar;125(3):213-222. doi: 10.1111/apm.12654.
• [677] Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis.Eur Radiol. 2018 May;28(5):1854-1861. doi: 10.1007/s00330-017-5141-0. Epub 2017 Nov 24.
• [678] Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.Oncotarget. 2016 Feb 9;7(6):6824-34. doi: 10.18632/oncotarget.6829.
• [679] TRIM2 downregulation in clear cell renal cell carcinoma affects cell proliferation, migration, and invasion and predicts poor patients' survival.Cancer Manag Res. 2018 Nov 20;10:5951-5964. doi: 10.2147/CMAR.S185270. eCollection 2018.
• [680] Vitamin D receptor suppresses proliferation and metastasis in renal cell carcinoma cell lines via regulating the expression of the epithelial Ca2+ channel TRPV5.PLoS One. 2018 Apr 16;13(4):e0195844. doi: 10.1371/journal.pone.0195844. eCollection 2018.
• [681] DNA methyltransferase inhibitor-mediated apoptosis in the Wnt/-catenin signal pathway in a renal cell carcinoma cell line.Exp Biol Med (Maywood). 2013 Sep;238(9):1009-16. doi: 10.1177/1535370213498984. Epub 2013 Aug 23.
• [682] The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes.Oncotarget. 2017 May 9;8(40):66975-66986. doi: 10.18632/oncotarget.17756. eCollection 2017 Sep 15.
• [683] Predicted versus observed 30-day perioperative outcomes using the ACS NSQIP surgical risk calculator in patients undergoing partial nephrectomy for renal cell carcinoma.Int Urol Nephrol. 2018 Jul;50(7):1249-1256. doi: 10.1007/s11255-018-1898-6. Epub 2018 Jun 4.
• [684] Dual-Tracer PET/CT Differentiates 2 Types of Primary Cancers and Metastases in a Patient With Crossed Fused Renal Ectopia.Clin Nucl Med. 2019 Feb;44(2):157-158. doi: 10.1097/RLU.0000000000002390.
• [685] Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.J Natl Cancer Inst. 2012 Jun 20;104(12):906-22. doi: 10.1093/jnci/djs232. Epub 2012 May 25.
• [686] Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma.Int J Mol Sci. 2015 Jan 5;16(1):1051-65. doi: 10.3390/ijms16011051.
• [687] AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma.Theranostics. 2017 Feb 27;7(5):1100-1113. doi: 10.7150/thno.18198. eCollection 2017.
• [688] H1/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma.J Cell Mol Med. 2018 Nov;22(11):5670-5681. doi: 10.1111/jcmm.13842. Epub 2018 Aug 30.
• [689] Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1.Sci Rep. 2016 Feb 15;6:21524. doi: 10.1038/srep21524.
• [690] Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.Cancer Res. 2005 Jun 1;65(11):4598-606. doi: 10.1158/0008-5472.CAN-04-3371.
• [691] Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.Medicine (Baltimore). 2015 Nov;94(46):e2117. doi: 10.1097/MD.0000000000002117.
• [692] Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs.J Biol Chem. 2018 Jun 22;293(25):9570-9579. doi: 10.1074/jbc.RA117.000975. Epub 2018 Apr 25.
• [693] High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma.Urol Oncol. 2015 Aug;33(8):340.e1-8. doi: 10.1016/j.urolonc.2015.05.009. Epub 2015 Jun 4.
• [694] The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.Cell Commun Signal. 2017 May 2;15(1):16. doi: 10.1186/s12964-017-0170-5.
• [695] ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma.Oncotarget. 2016 Aug 9;7(32):51829-51839. doi: 10.18632/oncotarget.10386.
• [696] Rho GDP dissociation inhibitor- in renal cell carcinoma.Oncol Lett. 2017 Dec;14(6):8190-8196. doi: 10.3892/ol.2017.7233. Epub 2017 Oct 20.
• [697] Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.Mol Cancer Ther. 2016 Dec;15(12):2946-2954. doi: 10.1158/1535-7163.MCT-16-0393. Epub 2016 Sep 26.
• [698] ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma.J Exp Clin Cancer Res. 2016 Jul 4;35(1):108. doi: 10.1186/s13046-016-0383-2.
• [699] The role of CRP and ATG9B expression in clear cell renal cell carcinoma.Biosci Rep. 2017 Nov 15;37(6):BSR20171082. doi: 10.1042/BSR20171082. Print 2017 Dec 22.
• [700] Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data.Gene. 2018 Mar 20;647:205-212. doi: 10.1016/j.gene.2017.12.031. Epub 2017 Dec 15.
• [701] Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma.Transl Oncol. 2017 Aug;10(4):661-668. doi: 10.1016/j.tranon.2017.06.002. Epub 2017 Jun 30.
• [702] Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.Oncogene. 2011 Mar 24;30(12):1390-401. doi: 10.1038/onc.2010.525. Epub 2010 Dec 6.
• [703] Genetic association of polymorphisms in AXIN1 gene with clear cell renal cell carcinoma in a Chinese population.Biomark Med. 2017 Nov;11(11):947-955. doi: 10.2217/bmm-2016-0377. Epub 2017 Oct 20.
• [704] Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.J Biol Chem. 2013 Sep 6;288(36):26301-26310. doi: 10.1074/jbc.M113.466086. Epub 2013 Jul 26.
• [705] Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.Cancer Res. 2006 Dec 1;66(23):11447-54. doi: 10.1158/0008-5472.CAN-06-0998.
• [706] New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey.J Med Genet. 1999 Jun;36(6):437-46.
• [707] Suppression of PGC-1 Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma.Cell Rep. 2015 Jul 7;12(1):116-127. doi: 10.1016/j.celrep.2015.06.006. Epub 2015 Jun 25.
• [708] Overexpression of BHLHE41, correlated with DNA hypomethylation in 3'UTR region, promotes the growth of human clear cell renal cell carcinoma.Oncol Rep. 2019 Apr;41(4):2137-2147. doi: 10.3892/or.2019.7004. Epub 2019 Feb 7.
• [709] Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.Cell Death Differ. 2006 Apr;13(4):619-27. doi: 10.1038/sj.cdd.4401782.
• [710] Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.Oncogene. 2010 Apr 8;29(14):2104-17. doi: 10.1038/onc.2009.493. Epub 2010 Feb 15.
• [711] Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma.Int J Oncol. 2019 Jan;54(1):348-360. doi: 10.3892/ijo.2018.4603. Epub 2018 Oct 24.
• [712] A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.J Cancer. 2017 Aug 21;8(13):2643-2652. doi: 10.7150/jca.20234. eCollection 2017.
• [713] BSND is a Novel Immunohistochemical Marker for Oncocytic Salivary Gland Tumors.Pathol Oncol Res. 2018 Apr;24(2):439-444. doi: 10.1007/s12253-017-0248-9. Epub 2017 May 3.
• [714] Overexpression of BTG2 suppresses growth, migration, and invasion of human renal carcinoma cells in vitro.Neoplasma. 2016;63(3):385-93. doi: 10.4149/307_150822N455.
• [715] BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009 Apr;30(4):662-70. doi: 10.1093/carcin/bgp042. Epub 2009 Feb 12.
• [716] Expression and clinical significance of RCDG1 in renal cell carcinoma: a novel renal cancerassociated gene.Mol Med Rep. 2014 Sep;10(3):1583-9. doi: 10.3892/mmr.2014.2388. Epub 2014 Jul 16.
• [717] Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Sci Rep. 2017 Jul 19;7(1):5900. doi: 10.1038/s41598-017-05455-1.
• [718] Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.Int J Oncol. 2010 Nov;37(5):1261-9. doi: 10.3892/ijo_00000777.
• [719] Hypoxia-Regulated miR-146a Targets Cell Adhesion Molecule 2 to Promote Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma.Cell Physiol Biochem. 2018;49(3):920-931. doi: 10.1159/000493224. Epub 2018 Sep 5.
• [720] Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma.Int J Cancer. 2012 Mar 15;130(6):1329-37. doi: 10.1002/ijc.26160. Epub 2011 Jul 21.
• [721] Capn4 contributes to tumor invasion and metastasis in clear cell renal cell carcinoma cells via modulating talin-focal adhesion kinase signaling pathway.Acta Biochim Biophys Sin (Shanghai). 2018 May 1;50(5):465-472. doi: 10.1093/abbs/gmy031.
• [722] MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis.Oncotarget. 2015 May 30;6(15):13201-15. doi: 10.18632/oncotarget.3915.
• [723] Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma.Tumour Biol. 2013 Dec;34(6):3431-5. doi: 10.1007/s13277-013-0917-6. Epub 2013 Jun 15.
• [724] Downregulation of lncRNA SDPR-AS is associated with poor prognosis in renal cell carcinoma.Onco Targets Ther. 2017 Jun 19;10:3039-3047. doi: 10.2147/OTT.S137641. eCollection 2017.
• [725] The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway.Cell Biosci. 2018 Mar 2;8:17. doi: 10.1186/s13578-018-0212-8. eCollection 2018.
• [726] Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7.Mol Cancer. 2014 Sep 6;13:206. doi: 10.1186/1476-4598-13-206.
• [727] Nephroblastoma overexpressed gene expression and its prognostic implications of clinical outcomes in renal cell carcinoma patients.Cancer Biomark. 2017 Sep 7;20(3):241-246. doi: 10.3233/CBM-170017.
• [728] CD151 promotes cell metastasis via activating TGF-1/Smad signaling in renal cell carcinoma.Oncotarget. 2018 Jan 8;9(17):13313-13323. doi: 10.18632/oncotarget.24028. eCollection 2018 Mar 2.
• [729] CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.J Clin Pathol. 2015 Mar;68(3):200-5. doi: 10.1136/jclinpath-2014-202735. Epub 2014 Dec 4.
• [730] Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment.Urol Oncol. 2019 Jun;37(6):355.e11-355.e19. doi: 10.1016/j.urolonc.2019.01.025. Epub 2019 Feb 6.
• [731] The metastasis suppressor CD82/KAI1 regulates cell migration and invasion via inhibiting TGF- 1/Smad signaling in renal cell carcinoma.Oncotarget. 2017 May 23;8(31):51559-51568. doi: 10.18632/oncotarget.18086. eCollection 2017 Aug 1.
• [732] Loss of CDC14B expression in clear cell renal cell carcinoma: meta-analysis of microarray data sets.Am J Clin Pathol. 2014 Apr;141(4):551-8. doi: 10.1309/AJCP4PE4JPSRGBQS.
• [733] Expression of parafibromin in major renal cell tumors.Eur J Histochem. 2012 Oct 23;56(4):e39. doi: 10.4081/ejh.2012.e39.
• [734] Identification of CDCP1 as a hypoxia-inducible factor 2 (HIF-2) target gene that is associated with survival in clear cell renal cell carcinoma patients.Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3483-8. doi: 10.1073/pnas.1222435110. Epub 2013 Feb 1.
• [735] Expression of cadherin-8 in renal cell carcinoma and fetal kidney.Int J Cancer. 2002 Oct 1;101(4):327-34. doi: 10.1002/ijc.10623.
• [736] Cadherin-9 is a novel cell surface marker for the heterogeneous pool of renal fibroblasts.PLoS One. 2007 Aug 1;2(7):e657. doi: 10.1371/journal.pone.0000657.
• [737] Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression.Oncotarget. 2017 Aug 24;8(43):75076-75086. doi: 10.18632/oncotarget.20507. eCollection 2017 Sep 26.
• [738] Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.Clin Cancer Res. 2015 Aug 1;21(15):3492-500. doi: 10.1158/1078-0432.CCR-14-2049. Epub 2015 Apr 22.
• [739] Upregulation of the KIAA1199 gene is associated with cellular mortality.Cancer Lett. 2006 Jul 28;239(1):71-7. doi: 10.1016/j.canlet.2005.07.028. Epub 2005 Sep 12.
• [740] Upregulation of centromere protein H is associated with progression of renal cell carcinoma.J Mol Histol. 2015 Oct;46(4-5):377-85. doi: 10.1007/s10735-015-9635-2. Epub 2015 Aug 7.
• [741] Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.J Biol Chem. 2001 May 4;276(18):15306-15. doi: 10.1074/jbc.M010516200. Epub 2001 Feb 6.
• [742] Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.Mol Med Rep. 2019 May;19(5):3485-3496. doi: 10.3892/mmr.2019.10042. Epub 2019 Mar 15.
• [743] Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma.Cancer Lett. 2002 Jan 10;175(1):71-7. doi: 10.1016/s0304-3835(01)00724-8.
• [744] The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.Oncotarget. 2016 Apr 19;7(16):21618-30. doi: 10.18632/oncotarget.7822.
• [745] Chmp1A acts as a tumor suppressor gene that inhibits proliferation of renal cell carcinoma.Cancer Lett. 2012 Jun 28;319(2):190-196. doi: 10.1016/j.canlet.2012.01.010. Epub 2012 Jan 17.
• [746] DNA sequences proximal to human mitochondrial DNA deletion breakpoints prevalent in human disease form G-quadruplexes, a class of DNA structures inefficiently unwound by the mitochondrial replicative Twinkle helicase.J Biol Chem. 2014 Oct 24;289(43):29975-93. doi: 10.1074/jbc.M114.567073. Epub 2014 Sep 5.
• [747] Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.J Urol. 2017 Nov;198(5):1027-1032. doi: 10.1016/j.juro.2017.05.070. Epub 2017 May 25.
• [748] CIAPIN1 inhibits the growth and proliferation of clear cell renal cell carcinoma.Cancer Lett. 2009 Apr 8;276(1):88-94. doi: 10.1016/j.canlet.2008.10.044. Epub 2008 Dec 9.
• [749] High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.BJU Int. 2012 May;109(10):1565-70. doi: 10.1111/j.1464-410X.2011.10649.x. Epub 2011 Oct 7.
• [750] Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes.J Urol. 2011 Nov;186(5):2071-7. doi: 10.1016/j.juro.2011.06.049. Epub 2011 Sep 23.
• [751] Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.Neuro Oncol. 2014 Jan;16(2):256-64. doi: 10.1093/neuonc/not195. Epub 2013 Dec 4.
• [752] High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.Oncotarget. 2016 Sep 27;7(39):63661-63668. doi: 10.18632/oncotarget.11606.
• [753] Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma.J Cancer Res Clin Oncol. 2016 Sep;142(9):1947-53. doi: 10.1007/s00432-016-2207-3. Epub 2016 Jul 14.
• [754] Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.Eur Urol. 2019 May;75(5):752-763. doi: 10.1016/j.eururo.2018.09.030. Epub 2018 Oct 4.
• [755] Author Correction: The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma.Sci Rep. 2018 Apr 12;8(1):6001. doi: 10.1038/s41598-018-23756-x.
• [756] Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15040-5. doi: 10.1073/pnas.0807055105. Epub 2008 Sep 25.
• [757] COP1 is downregulated in renal cell carcinoma (RCC) and inhibits the migration of RCC ACHN cells invitro.Mol Med Rep. 2016 Aug;14(2):1371-8. doi: 10.3892/mmr.2016.5373. Epub 2016 Jun 7.
• [758] Overexpression of COPS3 promotes clear cell renal cell carcinoma progression via regulation of Phospho-AKT(Thr308), Cyclin D1 and Caspase-3.Exp Cell Res. 2018 Apr 15;365(2):163-170. doi: 10.1016/j.yexcr.2018.02.025. Epub 2018 Feb 23.
• [759] Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma. Tumour Biol. 2005 Nov-Dec;26(6):313-23. doi: 10.1159/000089262. Epub 2005 Oct 25.
• [760] Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.Urol Int. 2005;75(3):269-76. doi: 10.1159/000087807.
• [761] DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.Mol Biol Rep. 2019 Aug;46(4):4377-4383. doi: 10.1007/s11033-019-04892-7. Epub 2019 May 30.
• [762] Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery.Am J Med Genet A. 2010 Jun;152A(6):1531-5. doi: 10.1002/ajmg.a.33384.
• [763] Knockdown of Collagen Triple Helix Repeat Containing-1 Inhibits the Proliferation and Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma Cells.Oncol Res. 2016 Oct 27;24(6):477-485. doi: 10.3727/096504016X14685034103716.
• [764] The expression of Cullin1 is increased in renal cell carcinoma and promotes cancer cell proliferation, migration, and invasion.Tumour Biol. 2016 Sep;37(9):12823-12831. doi: 10.1007/s13277-016-5151-6. Epub 2016 Jul 23.
• [765] Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKTNF-BCXCL5 signaling.Sci Rep. 2016 Nov 16;6:37085. doi: 10.1038/srep37085.
• [766] Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.PLoS One. 2017 Jun 5;12(6):e0178168. doi: 10.1371/journal.pone.0178168. eCollection 2017.
• [767] Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation.Clin Cancer Res. 2019 Jul 15;25(14):4542-4551. doi: 10.1158/1078-0432.CCR-18-3004. Epub 2019 Apr 18.
• [768] Identification of novel epigenetic markers for clear cell renal cell carcinoma.J Urol. 2008 Sep;180(3):1126-30. doi: 10.1016/j.juro.2008.04.137. Epub 2008 Jul 18.
• [769] Inhibition of miR-34a-5p can rescue disruption of the p53-DAPK axis to suppress progression of clear cell renal cell carcinoma.Mol Oncol. 2019 Oct;13(10):2079-2097. doi: 10.1002/1878-0261.12545. Epub 2019 Aug 24.
• [770] DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.Cancer Res. 2012 Nov 15;72(22):5867-77. doi: 10.1158/0008-5472.CAN-12-1645. Epub 2012 Sep 27.
• [771] Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells.Cancer Sci. 2014 May;105(5):560-7. doi: 10.1111/cas.12394. Epub 2014 Apr 19.
• [772] Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion.Invest New Drugs. 2019 Dec;37(6):1177-1186. doi: 10.1007/s10637-019-00748-w. Epub 2019 Mar 7.
• [773] High expression of the secreted protein dickkopf homolog 4: roles in invasion and metastasis of renal cell carcinoma and its association with Von Hippel-Lindau gene.Int J Mol Med. 2014 May;33(5):1319-26. doi: 10.3892/ijmm.2014.1673. Epub 2014 Feb 25.
• [774] Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.Cancer Lett. 2009 Sep 28;283(1):59-67. doi: 10.1016/j.canlet.2009.03.025. Epub 2009 Apr 19.
• [775] Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage.J Urol. 2010 Aug;184(2):731-7. doi: 10.1016/j.juro.2010.03.108. Epub 2010 Jun 19.
• [776] DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma.Int J Cancer. 2007 Sep 1;121(5):992-8. doi: 10.1002/ijc.22776.
• [777] Metastatic renal clear cell carcinoma in the parotid gland: a study of immunohistochemical profile and cell adhesion molecules (CAMs) expression in two cases.Pathol Oncol Res. 2007;13(2):161-5. doi: 10.1007/BF02893494. Epub 2007 Jul 3.
• [778] TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.Am J Surg Pathol. 2016 Jun;40(6):723-37. doi: 10.1097/PAS.0000000000000631.
• [779] Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.Cancer Res. 2012 Sep 1;72(17):4361-71. doi: 10.1158/0008-5472.CAN-11-2330. Epub 2012 Jul 17.
• [780] Effect of EH domain containing protein 2 on the biological behavior of clear cell renal cell carcinoma.Hum Exp Toxicol. 2019 Aug;38(8):927-937. doi: 10.1177/0960327119842241. Epub 2019 Apr 17.
• [781] Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma.J Cancer. 2017 Sep 2;8(15):3049-3061. doi: 10.7150/jca.19594. eCollection 2017.
• [782] Upregulated expression of eIF3C is associated with malignant behavior in renal cell carcinoma.Int J Oncol. 2019 Dec;55(6):1385-1395. doi: 10.3892/ijo.2019.4903. Epub 2019 Oct 21.
• [783] EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.EBioMedicine. 2019 Nov;49:189-201. doi: 10.1016/j.ebiom.2019.10.030. Epub 2019 Oct 26.
• [784] Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.Cell Biosci. 2017 Dec 16;7:71. doi: 10.1186/s13578-017-0197-8. eCollection 2017.
• [785] The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.Twin Res Hum Genet. 2011 Aug;14(4):316-22. doi: 10.1375/twin.14.4.316.
• [786] Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.Mol Cancer. 2017 Jun 28;16(1):111. doi: 10.1186/s12943-017-0681-0.
• [787] Expression of the von Hippel-Lindau-binding protein-1 (Vbp1) in fetal and adult mouse tissues.Hum Mol Genet. 1999 Feb;8(2):229-36. doi: 10.1093/hmg/8.2.229.
• [788] An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.Hum Mol Genet. 2014 Nov 15;23(22):5976-88. doi: 10.1093/hmg/ddu321. Epub 2014 Jun 26.
• [789] Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma.Am J Surg Pathol. 2019 Aug;43(8):1135-1144. doi: 10.1097/PAS.0000000000001255.
• [790] Bioinformatic identification of key genes and analysis of prognostic values in clear cell renal cell carcinoma.Oncol Lett. 2018 Aug;16(2):1747-1757. doi: 10.3892/ol.2018.8842. Epub 2018 May 30.
• [791] Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.Oncogene. 2003 Sep 11;22(39):8053-62. doi: 10.1038/sj.onc.1206835.
• [792] Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma.Oncol Rep. 2013 Nov;30(5):2245-53. doi: 10.3892/or.2013.2698. Epub 2013 Aug 26.
• [793] Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma.Int J Cancer. 2016 Dec 15;139(12):2827-2837. doi: 10.1002/ijc.30396. Epub 2016 Sep 16.
• [794] ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.Cancer Gene Ther. 2019 Sep;26(9-10):323-333. doi: 10.1038/s41417-018-0064-8. Epub 2018 Nov 21.
• [795] Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma.Oncotarget. 2017 Dec 10;9(1):662-667. doi: 10.18632/oncotarget.23087. eCollection 2018 Jan 2.
• [796] Methylation-associated silencing of TU3A in human cancers.Int J Oncol. 2008 Oct;33(4):893-9.
• [797] Ectopic expression of the TERE1 (UBIAD1) protein inhibits growth of renal clear cell carcinoma cells: altered metabolic phenotype associated with reactive oxygen species, nitric oxide and SXR target genes involved in cholesterol and lipid metabolism.Int J Oncol. 2013 Aug;43(2):638-52. doi: 10.3892/ijo.2013.1985. Epub 2013 Jun 12.
• [798] Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression.J Urol. 2013 Jul;190(1):291-301. doi: 10.1016/j.juro.2013.01.098. Epub 2013 Feb 4.
• [799] Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project.PLoS One. 2014 Jan 15;9(1):e85621. doi: 10.1371/journal.pone.0085621. eCollection 2014.
• [800] FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.Int J Biol Sci. 2019 Jan 24;15(3):647-656. doi: 10.7150/ijbs.31293. eCollection 2019.
• [801] Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):718-25. doi: 10.1158/1078-0432.CCR-05-0857.
• [802] Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis.Cancer Cell Int. 2018 Oct 22;18:166. doi: 10.1186/s12935-018-0651-7. eCollection 2018.
• [803] miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1.Oncotarget. 2015 May 20;6(14):12543-57. doi: 10.18632/oncotarget.3815.
• [804] Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation.PLoS One. 2018 Jun 13;13(6):e0197973. doi: 10.1371/journal.pone.0197973. eCollection 2018.
• [805] Identification and characterization of a novel folliculin-interacting protein FNIP2.Gene. 2008 May 31;415(1-2):60-7. doi: 10.1016/j.gene.2008.02.022. Epub 2008 Mar 4.
• [806] Smad4 suppresses the progression of renal cell carcinoma via the activation of forkhead box protein H1.Mol Med Rep. 2015 Apr;11(4):2717-22. doi: 10.3892/mmr.2014.3061. Epub 2014 Dec 8.
• [807] Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes.Cell Rep. 2017 Aug 8;20(6):1476-1489. doi: 10.1016/j.celrep.2017.07.043.
• [808] Interleukin4R (IL4R) and IL13R1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.Cancers (Basel). 2019 Sep 18;11(9):1394. doi: 10.3390/cancers11091394.
• [809] Overexpression of FOXO4 induces apoptosis of clear-cell renal carcinoma cells through downregulation of Bim.Mol Med Rep. 2016 Mar;13(3):2229-34. doi: 10.3892/mmr.2016.4789. Epub 2016 Jan 15.
• [810] Role of secreted frizzled-related protein 3 in human renal cell carcinoma.Cancer Res. 2010 Mar 1;70(5):1896-905. doi: 10.1158/0008-5472.CAN-09-3549. Epub 2010 Feb 16.
• [811] Role of miR-1 expression in clear cell renal cell carcinoma (ccRCC): A bioinformatics study based on GEO, ArrayExpress microarrays and TCGA database.Pathol Res Pract. 2018 Feb;214(2):195-206. doi: 10.1016/j.prp.2017.11.025. Epub 2017 Dec 2.
• [812] Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.Chin J Cancer. 2018 Jan 22;37(1):2. doi: 10.1186/s40880-018-0267-2.
• [813] Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma.PLoS One. 2017 Jan 11;12(1):e0169852. doi: 10.1371/journal.pone.0169852. eCollection 2017.
• [814] Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.J Cancer. 2019 Jan 29;10(5):1237-1251. doi: 10.7150/jca.28662. eCollection 2019.
• [815] miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma.Tumour Biol. 2015 Sep;36(9):7017-26. doi: 10.1007/s13277-015-3369-3. Epub 2015 Apr 12.
• [816] Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma.Oncotarget. 2017 Sep 8;8(45):78989-79002. doi: 10.18632/oncotarget.20742. eCollection 2017 Oct 3.
• [817] A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding.Mol Cancer Res. 2019 Nov;17(11):2306-2317. doi: 10.1158/1541-7786.MCR-19-0461. Epub 2019 Aug 19.
• [818] Downregulation of OCLN and GAS1 in clear cell renal cell carcinoma.Oncol Rep. 2017 Mar;37(3):1487-1496. doi: 10.3892/or.2017.5414. Epub 2017 Jan 31.
• [819] Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma.Target Oncol. 2015 Jun;10(2):267-75. doi: 10.1007/s11523-014-0335-8. Epub 2014 Sep 19.
• [820] GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.Oncol Rep. 2014 Apr;31(4):1523-30. doi: 10.3892/or.2014.3030. Epub 2014 Feb 18.
• [821] Vitamin D binding protein and risk of renal cell carcinoma in the prostate, lung, colorectal and ovarian cancer screening trial.Int J Cancer. 2020 Aug 1;147(3):669-674. doi: 10.1002/ijc.32758. Epub 2019 Nov 19.
• [822] New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies.Biomed Pharmacother. 2019 Mar;111:821-834. doi: 10.1016/j.biopha.2018.12.099. Epub 2019 Jan 4.
• [823] Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.Anticancer Res. 2014 Nov;34(11):6515-20.
• [824] Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma.Clin Cancer Res. 2008 Dec 1;14(23):7956-62. doi: 10.1158/1078-0432.CCR-08-1199.
• [825] GFOD1 and peejar are promising markers for clear-cell renal cell carcinoma disease progression.Oncotarget. 2016 Jun 21;7(25):38004-38009. doi: 10.18632/oncotarget.9379.
• [826] Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.Histopathology. 2009 Dec;55(6):687-95. doi: 10.1111/j.1365-2559.2009.03449.x.
• [827] MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit -13 in renal cell carcinoma.Gene. 2017 Aug 30;626:275-281. doi: 10.1016/j.gene.2017.05.040. Epub 2017 May 20.
• [828] Identification of novel VHL target genes and relationship to hypoxic response pathways.Oncogene. 2005 Jun 30;24(28):4549-58. doi: 10.1038/sj.onc.1208649.
• [829] Golgi Phosphoprotein 3 Promotes Malignant Phenotypes via FAK/Raf/MEK and Wnt/-Catenin Signaling Pathways in Human Renal Cell Carcinoma.J Biomed Nanotechnol. 2019 Aug 1;15(8):1812-1823. doi: 10.1166/jbn.2019.2804.
• [830] Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion.J Urol. 2005 Jun;173(6):2154-9. doi: 10.1097/01.ju.0000158135.26893.bc.
• [831] Association of glutathione S-transferase M1, T1, and P1 polymorphisms with renal cell carcinoma: evidence from 11 studies.Tumour Biol. 2014 Apr;35(4):3867-73. doi: 10.1007/s13277-013-1513-5. Epub 2013 Dec 15.
• [832] Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.Cancer Sci. 2010 Dec;101(12):2664-9. doi: 10.1111/j.1349-7006.2010.01717.x. Epub 2010 Sep 1.
• [833] HAO2 inhibits malignancy of clear cell renal cell carcinoma by promoting lipid catabolic process.J Cell Physiol. 2019 Dec;234(12):23005-23016. doi: 10.1002/jcp.28861. Epub 2019 May 24.
• [834] Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.BMC Cancer. 2019 Jan 10;19(1):49. doi: 10.1186/s12885-019-5273-5.
• [835] HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1/NF-B Signaling Pathway.Urology. 2019 May;127:61-67. doi: 10.1016/j.urology.2018.11.033. Epub 2018 Dec 4.
• [836] Predictive values of Notch signalling in renal carcinoma.Arch Med Sci. 2017 Oct;13(6):1249-1254. doi: 10.5114/aoms.2017.65649. Epub 2017 Jan 31.
• [837] HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma.Oncogene. 2005 Sep 22;24(42):6418-31. doi: 10.1038/sj.onc.1208794.
• [838] Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.Cancer Cell Int. 2019 Apr 16;19:101. doi: 10.1186/s12935-019-0813-2. eCollection 2019.
• [839] Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.Int J Oncol. 2012 May;40(5):1650-8. doi: 10.3892/ijo.2012.1367. Epub 2012 Feb 10.
• [840] Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.Cell Cycle. 2007 Nov 15;6(22):2810-6. doi: 10.4161/cc.6.22.4947. Epub 2007 Aug 29.
• [841] Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene.Oncogene. 2004 Aug 5;23(35):5941-9. doi: 10.1038/sj.onc.1207789.
• [842] HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma.Diagn Pathol. 2012 May 29;7:58. doi: 10.1186/1746-1596-7-58.
• [843] miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5.Onco Targets Ther. 2018 Apr 18;11:2205-2216. doi: 10.2147/OTT.S156361. eCollection 2018.
• [844] Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.Exp Hematol. 2002 Sep;30(9):1029-35. doi: 10.1016/s0301-472x(02)00874-3.
• [845] Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells.PLoS One. 2015 Dec 29;10(12):e0145769. doi: 10.1371/journal.pone.0145769. eCollection 2015.
• [846] Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis.Cancer Biomark. 2013 Jan 1;13(6):411-5. doi: 10.3233/CBM-140390.
• [847] MiR-1294 acts as a tumor suppressor in clear cell renal cell carcinoma through targeting HOXA6.Eur Rev Med Pharmacol Sci. 2019 May;23(9):3719-3725. doi: 10.26355/eurrev_201905_17797.
• [848] Overexpression of HOXC11 homeobox gene in clear cell renal cell carcinoma induces cellular proliferation and is associated with poor prognosis.Tumour Biol. 2015 Apr;36(4):2821-9. doi: 10.1007/s13277-014-2909-6. Epub 2014 Dec 5.
• [849] Targeting the testis-specific heat-shock protein 70-2 (HSP70-2) reduces cellular growth, migration, and invasion in renal cell carcinoma cells.Tumour Biol. 2014 Dec;35(12):12695-706. doi: 10.1007/s13277-014-2594-5. Epub 2014 Sep 12.
• [850] Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation.Int J Oncol. 2014 May;44(5):1490-8. doi: 10.3892/ijo.2014.2314. Epub 2014 Feb 27.
• [851] Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.Cancer Immunol Immunother. 2007 Jul;56(7):1097-105. doi: 10.1007/s00262-006-0258-z. Epub 2006 Dec 5.
• [852] HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas.Biochem Biophys Res Commun. 2010 Apr 9;394(3):453-8. doi: 10.1016/j.bbrc.2009.11.163. Epub 2009 Nov 29.
• [853] Nivolumab in the treatment of advanced renal cell carcinoma.Future Oncol. 2018 Jul;14(17):1679-1689. doi: 10.2217/fon-2017-0533. Epub 2018 Feb 20.
• [854] miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma.Cell Prolif. 2015 Oct;48(5):593-9. doi: 10.1111/cpr.12207.
• [855] Insulin like growth factor binding protein 4 promotes GBM progression and regulates key factors involved in EMT and invasion.J Neurooncol. 2014 Feb;116(3):455-64. doi: 10.1007/s11060-013-1324-y. Epub 2014 Jan 7.
• [856] Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
• [857] SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.PLoS One. 2018 Feb 7;13(2):e0191510. doi: 10.1371/journal.pone.0191510. eCollection 2018.
• [858] Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.Expert Opin Biol Ther. 2011 Dec;11(12):1555-67. doi: 10.1517/14712598.2011.627852. Epub 2011 Oct 14.
• [859] Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.Elife. 2018 Oct 25;7:e37925. doi: 10.7554/eLife.37925.
• [860] Genetic variation in platelet integrin alphabeta (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma.BJU Int. 2006 Jul;98(1):201-4. doi: 10.1111/j.1464-410X.2006.06196.x.
• [861] Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor.Tumour Biol. 2014 Nov;35(11):10993-1003. doi: 10.1007/s13277-014-2393-z. Epub 2014 Aug 5.
• [862] Kank1 reexpression induced by 5-Aza-2'-deoxycytidine suppresses nasopharyngeal carcinoma cell proliferation and promotes apoptosis.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1658-65. eCollection 2015.
• [863] Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma.Biochem Biophys Res Commun. 2007 May 18;356(4):864-71. doi: 10.1016/j.bbrc.2007.03.080. Epub 2007 Mar 26.
• [864] Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma.Int J Oncol. 2014 Apr;44(4):1207-14. doi: 10.3892/ijo.2014.2266. Epub 2014 Jan 21.
• [865] Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.Sci Rep. 2017 Mar 23;7:44876. doi: 10.1038/srep44876.
• [866] Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.Clin Cancer Res. 2018 Dec 15;24(24):6433-6446. doi: 10.1158/1078-0432.CCR-18-1727. Epub 2018 Aug 14.
• [867] Expression and functional role of miR-29b in renal cell carcinoma.Int J Clin Exp Pathol. 2015 Nov 1;8(11):14161-70. eCollection 2015.
• [868] A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.Int J Oncol. 2013 Oct;43(4):1080-6. doi: 10.3892/ijo.2013.2042. Epub 2013 Jul 30.
• [869] Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.J Pathol. 2016 Jul;239(3):365-73. doi: 10.1002/path.4736. Epub 2016 May 30.
• [870] Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.Biochem Biophys Res Commun. 2008 Jun 13;370(4):536-40. doi: 10.1016/j.bbrc.2008.03.066. Epub 2008 Mar 24.
• [871] Krppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells.Cancer Sci. 2014 Sep;105(9):1109-15. doi: 10.1111/cas.12483. Epub 2014 Sep 8.
• [872] Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin.Anticancer Res. 2005 Jul-Aug;25(4):2729-35.
• [873] Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.Tumour Biol. 2006;27(1):1-7. doi: 10.1159/000090150. Epub 2005 Dec 8.
• [874] The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.
• [875] KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.Int J Clin Exp Pathol. 2015 Aug 1;8(8):9182-8. eCollection 2015.
• [876] Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma.J Clin Invest. 2019 Mar 4;129(4):1612-1625. doi: 10.1172/JCI98747. eCollection 2019 Mar 4.
• [877] The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients' Survival.Biomed Res Int. 2018 Apr 3;2018:2653623. doi: 10.1155/2018/2653623. eCollection 2018.
• [878] Roles of layilin in TNF--induced epithelial-mesenchymal transformation of renal tubular epithelial cells.Biochem Biophys Res Commun. 2015 Nov 6;467(1):63-9. doi: 10.1016/j.bbrc.2015.09.121. Epub 2015 Sep 26.
• [879] Four new human renal cell carcinoma cell lines expressing globo-series gangliosides.Tohoku J Exp Med. 1999 Oct;189(2):95-105. doi: 10.1620/tjem.189.95.
• [880] Profilin 1 overexpression in renal cell carcinoma.Int J Urol. 2011 Jan;18(1):63-71. doi: 10.1111/j.1442-2042.2010.02670.x. Epub 2010 Nov 22.
• [881] Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.Tumour Biol. 2015 Aug;36(8):5791-9. doi: 10.1007/s13277-015-3248-y. Epub 2015 Feb 26.
• [882] The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma.Oncogene. 2019 Jan;38(1):60-72. doi: 10.1038/s41388-018-0413-y. Epub 2018 Aug 3.
• [883] Over expression of HIF1 is associated with inactivation of both LimD1 and VHL in renal cell carcinoma: Clinical importance.Pathol Res Pract. 2017 Dec;213(12):1477-1481. doi: 10.1016/j.prp.2017.10.009. Epub 2017 Oct 10.
• [884] Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.
• [885] Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.J Exp Clin Cancer Res. 2017 May 12;36(1):66. doi: 10.1186/s13046-017-0525-1.
• [886] LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.Br J Cancer. 2003 Oct 6;89(7):1285-9. doi: 10.1038/sj.bjc.6601208.
• [887] Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma.Kidney Int. 2004 May;65(5):1761-73. doi: 10.1111/j.1523-1755.2004.00601.x.
• [888] Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas.Mol Med Rep. 2012 Feb;5(2):509-12. doi: 10.3892/mmr.2011.681. Epub 2011 Nov 16.
• [889] The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas.Cancer Cell. 2003 Nov;4(5):405-13. doi: 10.1016/s1535-6108(03)00269-1.
• [890] MiR-367 regulates cell proliferation and metastasis by targeting metastasis-associated protein 3 (MTA3) in clear-cell renal cell carcinoma.Oncotarget. 2017 Jun 27;8(38):63084-63095. doi: 10.18632/oncotarget.18647. eCollection 2017 Sep 8.
• [891] miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation.Cancer Res. 2014 May 1;74(9):2432-43. doi: 10.1158/0008-5472.CAN-13-2041. Epub 2014 Feb 3.
• [892] Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma.Int J Cancer. 2005 Nov 1;117(2):256-64. doi: 10.1002/ijc.21200.
• [893] MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.Cancer Biol Ther. 2005 Sep;4(9):943-8. doi: 10.4161/cbt.4.9.1907. Epub 2005 Sep 8.
• [894] MAGI1 mediates tumor metastasis through c-Myb/miR-520h/MAGI1 signaling pathway in renal cell carcinoma.Apoptosis. 2019 Dec;24(11-12):837-848. doi: 10.1007/s10495-019-01562-8.
• [895] Role of the RNA-binding protein HuR in human renal cell carcinoma.Carcinogenesis. 2010 Jun;31(6):1018-26. doi: 10.1093/carcin/bgq052. Epub 2010 Mar 10.
• [896] Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.Clin Cancer Res. 2006 Dec 1;12(23):6937-45. doi: 10.1158/1078-0432.CCR-06-1268.
• [897] TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma.Cancer Cell. 2014 Nov 10;26(5):738-53. doi: 10.1016/j.ccell.2014.09.015. Epub 2014 Nov 10.
• [898] Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?.J Proteome Res. 2011 Jan 7;10(1):191-9. doi: 10.1021/pr1011137.
• [899] Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.Oncol Res. 1998;10(3):123-32.
• [900] Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.J Clin Endocrinol Metab. 2017 Nov 1;102(11):4013-4022. doi: 10.1210/jc.2017-00562.
• [901] Myoglobin expression in renal cell carcinoma is regulated by hypoxia.Exp Mol Pathol. 2013 Dec;95(3):307-12. doi: 10.1016/j.yexmp.2013.09.003. Epub 2013 Sep 25.
• [902] Duplication of two distinct regions on chromosome 5q in non-papillary renal-cell carcinomas.Int J Cancer. 1998 May 4;76(3):337-40. doi: 10.1002/(sici)1097-0215(19980504)76:3<337::aid-ijc9>3.0.co;2-w.
• [903] Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway.Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2366-73. doi: 10.1158/1055-9965.EPI-08-0259.
• [904] Knockdown of MSP58 inhibits the proliferation and metastasis in human renal cell carcinoma cells.Biomed Pharmacother. 2017 Jul;91:54-59. doi: 10.1016/j.biopha.2017.04.036. Epub 2017 May 23.
• [905] Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.Oncotarget. 2016 Apr 26;7(17):23043-23055. doi: 10.18632/oncotarget.8469.
• [906] A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.Biomed Res Int. 2019 Nov 11;2019:5974089. doi: 10.1155/2019/5974089. eCollection 2019.
• [907] The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.Ann Diagn Pathol. 2018 Jun;34:18-26. doi: 10.1016/j.anndiagpath.2017.12.008. Epub 2017 Dec 20.
• [908] The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.Oncotarget. 2017 Oct 10;8(56):96103-96116. doi: 10.18632/oncotarget.21726. eCollection 2017 Nov 10.
• [909] Expression of the matrix Gla protein in urogenital malignancies.Int J Cancer. 1992 Oct 21;52(4):534-7. doi: 10.1002/ijc.2910520406.
• [910] Progress of small ubiquitin-related modifiers in kidney diseases.Chin Med J (Engl). 2019 Feb;132(4):466-473. doi: 10.1097/CM9.0000000000000094.
• [911] HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma.Onco Targets Ther. 2018 Aug 1;11:4501-4510. doi: 10.2147/OTT.S167197. eCollection 2018.
• [912] Copy number variations and expression of MPDZ are prognostic biomarkers for clear cell renal cell carcinoma.Oncotarget. 2017 Aug 12;8(45):78713-78725. doi: 10.18632/oncotarget.20220. eCollection 2017 Oct 3.
• [913] Loss of PIG3 increases HIF-1 level by promoting protein synthesis via mTOR pathway in renal cell carcinoma cells.Oncotarget. 2016 May 10;7(19):27176-84. doi: 10.18632/oncotarget.8401.
• [914] Induction of cell cycle arrest by increasing GTPRhoA levels via Taxolinduced microtubule polymerization in renal cell carcinoma.Mol Med Rep. 2017 Jun;15(6):4273-4279. doi: 10.3892/mmr.2017.6543. Epub 2017 May 3.
• [915] MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.Oncogene. 2019 Aug;38(34):6211-6225. doi: 10.1038/s41388-019-0869-4. Epub 2019 Jul 9.
• [916] MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.Int J Cancer. 2017 May 15;140(10):2351-2363. doi: 10.1002/ijc.30651. Epub 2017 Feb 28.
• [917] NMMHC-IIA-dependent nuclear location of CXCR4 promotes migration and invasion in renal cell carcinoma.Oncol Rep. 2016 Nov;36(5):2681-2688. doi: 10.3892/or.2016.5082. Epub 2016 Sep 12.
• [918] The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.Cancer Res. 1999 May 1;59(9):2182-9.
• [919] Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma.Lab Invest. 1996 Mar;74(3):592-9.
• [920] Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.Aging (Albany NY). 2018 Dec 11;10(12):3957-3985. doi: 10.18632/aging.101685.
• [921] Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma.Cancer Med. 2015 Jan;4(1):112-24. doi: 10.1002/cam4.351. Epub 2014 Oct 15.
• [922] Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.Cancer Med. 2014 Apr;3(2):300-9. doi: 10.1002/cam4.181. Epub 2014 Jan 27.
• [923] Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.Cancer Res. 1990 Aug 1;50(15):4504-9.
• [924] Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines.BMC Mol Biol. 2011 Jul 19;12:31. doi: 10.1186/1471-2199-12-31.
• [925] DNA repair system and renal cell carcinoma prognosis: under the influence of NBS1.Med Oncol. 2015 Nov;32(11):255. doi: 10.1007/s12032-015-0701-0. Epub 2015 Oct 22.
• [926] MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.Carcinogenesis. 2011 Aug;32(8):1133-42. doi: 10.1093/carcin/bgr070. Epub 2011 Apr 18.
• [927] Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma.Nephrology (Carlton). 2009 Apr;14(2):205-12. doi: 10.1111/j.1440-1797.2008.01027.x.
• [928] Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.Pathol Res Pract. 2019 Sep;215(9):152521. doi: 10.1016/j.prp.2019.152521. Epub 2019 Jun 27.
• [929] Characterization of Niemann-Pick Type C2 protein expression in multiple cancers using a novel NPC2 monoclonal antibody.PLoS One. 2013 Oct 17;8(10):e77586. doi: 10.1371/journal.pone.0077586. eCollection 2013.
• [930] Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.Pathol Oncol Res. 2014 Oct;20(4):829-37. doi: 10.1007/s12253-014-9761-2. Epub 2014 May 1.
• [931] Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.Int J Cancer. 2018 Jul 1;143(1):100-112. doi: 10.1002/ijc.31289. Epub 2018 Apr 2.
• [932] Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma.Int J Cancer. 2009 Jul 15;125(2):446-52. doi: 10.1002/ijc.24370.
• [933] NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.Br J Cancer. 2010 Mar 2;102(5):873-82. doi: 10.1038/sj.bjc.6605574. Epub 2010 Feb 16.
• [934] A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma.Oncol Lett. 2018 Feb;15(2):2425-2430. doi: 10.3892/ol.2017.7563. Epub 2017 Dec 8.
• [935] NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma.Oncol Lett. 2017 Nov;14(5):6121-6128. doi: 10.3892/ol.2017.6997. Epub 2017 Sep 18.
• [936] Downregulation of nucleolar and spindle-associated protein1 expression suppresses cell migration, proliferation and invasion in renal cell carcinoma.Oncol Rep. 2016 Sep;36(3):1506-16. doi: 10.3892/or.2016.4955. Epub 2016 Jul 20.
• [937] Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma.Acta Histochem. 2013 Oct;115(8):810-5. doi: 10.1016/j.acthis.2013.03.008. Epub 2013 May 10.
• [938] Odd-skipped related transcription factor 1 (OSR1) suppresses tongue squamous cell carcinoma migration and invasion through inhibiting NF-B pathway.Eur J Pharmacol. 2018 Nov 15;839:33-39. doi: 10.1016/j.ejphar.2018.09.020. Epub 2018 Sep 19.
• [939] The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.Oncogene. 2001 Aug 16;20(36):5067-74. doi: 10.1038/sj.onc.1204602.
• [940] PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome.Genes Chromosomes Cancer. 2013 Mar;52(3):265-73. doi: 10.1002/gcc.22026. Epub 2012 Nov 2.
• [941] Overexpression of Csk-binding protein contributes to renal cell carcinogenesis.Oncogene. 2009 Sep 17;28(37):3320-31. doi: 10.1038/onc.2009.185. Epub 2009 Jul 6.
• [942] Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.Med Sci Monit. 2017 Jul 8;23:3318-3323. doi: 10.12659/msm.902077.
• [943] Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer.Oncol Lett. 2017 Aug;14(2):1657-1664. doi: 10.3892/ol.2017.6282. Epub 2017 May 31.
• [944] KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin.Oncotarget. 2016 Mar 22;7(12):13520-37. doi: 10.18632/oncotarget.5876.
• [945] Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.Endocr Relat Cancer. 2010 Dec 21;18(1):73-83. doi: 10.1677/ERC-10-0113. Print 2011 Feb.
• [946] Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.Mod Pathol. 2006 May;19(5):684-94. doi: 10.1038/modpathol.3800577.
• [947] MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma.Carcinogenesis. 2012 Feb;33(2):294-300. doi: 10.1093/carcin/bgr286. Epub 2011 Dec 9.
• [948] Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma.Int J Oncol. 2013 Nov;43(5):1441-6. doi: 10.3892/ijo.2013.2073. Epub 2013 Aug 21.
• [949] Nuclear factor-B signaling pathway is involved in phospholipase C-regulated proliferation in human renal cell carcinoma cells.Mol Cell Biochem. 2014 Apr;389(1-2):265-75. doi: 10.1007/s11010-013-1948-4. Epub 2014 Feb 8.
• [950] Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer.Kidney Int. 2019 Dec;96(6):1417-1421. doi: 10.1016/j.kint.2019.08.020. Epub 2019 Sep 3.
• [951] Genetic mutations associated with metastatic clear cell renal cell carcinoma.Oncotarget. 2016 Mar 29;7(13):16172-9. doi: 10.18632/oncotarget.7473.
• [952] Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.Biochem Biophys Res Commun. 2017 Sep 2;490(4):1183-1188. doi: 10.1016/j.bbrc.2017.06.179. Epub 2017 Jun 29.
• [953] High selectivity of PI3K inhibitors in SETD2-mutated renal clear cell carcinoma.J BUON. 2015 Sep-Oct;20(5):1267-75.
• [954] Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma.PLoS One. 2010 Dec 30;5(12):e15224. doi: 10.1371/journal.pone.0015224.
• [955] Expression level of CXCL7 in peripheral blood cells is a potential biomarker for the diagnosis of renal cell carcinoma.Cancer Sci. 2017 Dec;108(12):2495-2502. doi: 10.1111/cas.13414. Epub 2017 Oct 25.
• [956] Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.Asian Pac J Cancer Prev. 2015;16(9):4071-5. doi: 10.7314/apjcp.2015.16.9.4071.
• [957] EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4.
• [958] Hypoxia inducible factor-1 suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells.FEBS Lett. 2014 Sep 17;588(18):3390-4. doi: 10.1016/j.febslet.2014.07.030. Epub 2014 Aug 2.
• [959] CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.Cancer Med. 2016 Oct;5(10):2920-2933. doi: 10.1002/cam4.886. Epub 2016 Sep 26.
• [960] Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas.Cancer Med. 2014 Aug;3(4):845-54. doi: 10.1002/cam4.270. Epub 2014 May 26.
• [961] Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.Gene. 2013 Jan 1;512(1):64-9. doi: 10.1016/j.gene.2012.09.094. Epub 2012 Oct 13.
• [962] A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.Cancer Res. 1993 Apr 1;53(7):1498-502.
• [963] YueF overexpression inhibits cell proliferation partly through p21 upregulation in renal cell carcinoma.Int J Mol Sci. 2011;12(4):2477-87. doi: 10.3390/ijms12042477. Epub 2011 Apr 11.
• [964] RNA-binding protein QKI regulates contact inhibition via Yes-associate protein in ccRCC.Acta Biochim Biophys Sin (Shanghai). 2019 Jan 1;51(1):9-19. doi: 10.1093/abbs/gmy142.
• [965] Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells.Oncol Rep. 2009 Feb;21(2):305-12.
• [966] Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma.Elife. 2015 Nov 17;4:e09214. doi: 10.7554/eLife.09214.
• [967] Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.Urol Oncol. 2014 Jan;32(1):43.e23-30. doi: 10.1016/j.urolonc.2013.05.008. Epub 2013 Aug 2.
• [968] RALY RNA binding protein-like reduced expression is associated with poor prognosis in clear cell renal cell carcinoma.Asian Pac J Cancer Prev. 2012;13(7):3403-8. doi: 10.7314/apjcp.2012.13.7.3403.
• [969] miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B.Oncotarget. 2016 Nov 8;7(45):73888-73902. doi: 10.18632/oncotarget.12516.
• [970] Rap1GAP regulates renal cell carcinoma invasion.Cancer Lett. 2012 Jul 1;320(1):65-71. doi: 10.1016/j.canlet.2012.01.022. Epub 2012 Jan 20.
• [971] Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.Tumour Biol. 2017 Jul;39(7):1010428317701653. doi: 10.1177/1010428317701653.
• [972] Preoperative serum cystatin-C as a potential biomarker for prognosis of renal cell carcinoma.PLoS One. 2017 Jun 6;12(6):e0178823. doi: 10.1371/journal.pone.0178823. eCollection 2017.
• [973] Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas.Biomark Med. 2016 Jul;10(7):721-32. doi: 10.2217/bmm.16.12. Epub 2016 Jun 24.
• [974] RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma.Cancer Lett. 2018 Sep 28;432:75-83. doi: 10.1016/j.canlet.2018.05.048. Epub 2018 Jun 1.
• [975] RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.Histopathology. 2019 Aug;75(2):254-265. doi: 10.1111/his.13866. Epub 2019 Jun 25.
• [976] Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis.Cancer Res. 2008 Oct 1;68(19):7887-96. doi: 10.1158/0008-5472.CAN-08-1734.
• [977] The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion.Tumour Biol. 2017 May;39(5):1010428317701635. doi: 10.1177/1010428317701635.
• [978] Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor- activation.PLoS One. 2013;8(2):e56667. doi: 10.1371/journal.pone.0056667. Epub 2013 Feb 27.
• [979] Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma.J Pathol. 2004 May;203(1):551-8. doi: 10.1002/path.1543.
• [980] Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Oncotarget. 2015 Jul 20;6(20):17895-910. doi: 10.18632/oncotarget.4963.
• [981] Activation of the mTOR signaling pathway in renal clear cell carcinoma.J Urol. 2007 Jan;177(1):346-52. doi: 10.1016/j.juro.2006.08.076.
• [982] SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.Epigenetics. 2017;12(12):1057-1064. doi: 10.1080/15592294.2017.1385685. Epub 2018 Jan 22.
• [983] Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis.J Natl Cancer Inst. 1989 Apr 5;81(7):527-30. doi: 10.1093/jnci/81.7.527.
• [984] Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers.Int J Mol Sci. 2018 May 28;19(6):1586. doi: 10.3390/ijms19061586.
• [985] The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma.Oncogene. 2016 Jul 7;35(27):3514-23. doi: 10.1038/onc.2015.412. Epub 2015 Nov 2.
• [986] Really interesting new gene finger protein 121 is a tumor suppressor of renal cell carcinoma.Gene. 2018 Nov 15;676:322-328. doi: 10.1016/j.gene.2018.08.067. Epub 2018 Aug 25.
• [987] Network spatio-temporal analysis predicts disease stage-related genes and pathways in renal cell carcinoma.Genet Mol Res. 2016 May 6;15(2). doi: 10.4238/gmr.15028061.
• [988] Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.Ann Diagn Pathol. 2017 Aug;29:17-22. doi: 10.1016/j.anndiagpath.2017.04.007. Epub 2017 Apr 24.
• [989] Knockdown of ribosomal protein S15A inhibits human kidney cancer cell growth invitro and invivo.Mol Med Rep. 2019 Feb;19(2):1117-1127. doi: 10.3892/mmr.2018.9751. Epub 2018 Dec 12.
• [990] The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.Oncotarget. 2016 Jan 5;7(1):418-32. doi: 10.18632/oncotarget.6225.
• [991] RNA sequencing reveals upregulation of RUNX1-RUNX1T1 gene signatures in clear cell renal cell carcinoma.Biomed Res Int. 2014;2014:450621. doi: 10.1155/2014/450621. Epub 2014 Mar 25.
• [992] Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6031-6. eCollection 2015.
• [993] LINC00997, a novel long noncoding RNA, contributes to metastasis via regulation of S100A11 in kidney renal clear cell carcinoma.Int J Biochem Cell Biol. 2019 Nov;116:105590. doi: 10.1016/j.biocel.2019.105590. Epub 2019 Aug 20.
• [994] Restricted expression of calcium-binding protein S100A5 in human kidney.Biochem Biophys Res Commun. 2002 Mar 1;291(3):623-7. doi: 10.1006/bbrc.2002.6494.
• [995] Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro.Stem Cell Res. 2015 Mar;14(2):198-210. doi: 10.1016/j.scr.2015.01.006. Epub 2015 Jan 28.
• [996] Decreased Expression of SATB2 Associates with Tumor Growth and Predicts Worse Outcome in Patients with Clear Cell Renal Cell Carcinoma.Anticancer Res. 2018 Feb;38(2):839-846. doi: 10.21873/anticanres.12292.
• [997] The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma.Oncotarget. 2017 Apr 25;8(35):58654-58667. doi: 10.18632/oncotarget.17414. eCollection 2017 Aug 29.
• [998] Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma.Cancer. 1996 Aug 15;78(4):819-26. doi: 10.1002/(SICI)1097-0142(19960815)78:4<819::AID-CNCR19>3.0.CO;2-Y.
• [999] Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance.Cancer Sci. 2018 Sep;109(9):2919-2936. doi: 10.1111/cas.13722. Epub 2018 Jul 28.
• [1000] Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway.Cancer Med. 2019 Aug;8(10):4836-4844. doi: 10.1002/cam4.2403. Epub 2019 Jul 5.
• [1001] Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis.Tumour Biol. 2014 Sep;35(9):9095-100. doi: 10.1007/s13277-014-2184-6. Epub 2014 Jun 11.
• [1002] Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.Int J Cancer. 2004 Feb 10;108(4):516-23. doi: 10.1002/ijc.11594.
• [1003] Increased expression of SET domain-containing proteins and decreased expression of Rad51in different classes of renal cell carcinoma.Biosci Rep. 2016 Jun 30;36(3):e00349. doi: 10.1042/BSR20160122. Print 2016 Jul.
• [1004] Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.Clin Cancer Res. 2017 Jul 1;23(13):3428-3441. doi: 10.1158/1078-0432.CCR-16-2020. Epub 2016 Nov 22.
• [1005] Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.Clin Cancer Res. 2006 Dec 1;12(23):6989-97. doi: 10.1158/1078-0432.CCR-06-1194.
• [1006] Enhancement of Siglec-8 expression predicts adverse prognosis in patients with clear cell renal cell carcinoma.Urol Oncol. 2017 Oct;35(10):607.e1-607.e8. doi: 10.1016/j.urolonc.2017.05.016. Epub 2017 Jun 12.
• [1007] Transcription factor Six2 induces a stem cell-like phenotype in renal cell carcinoma cells.FEBS Open Bio. 2019 Oct;9(10):1808-1816. doi: 10.1002/2211-5463.12721. Epub 2019 Sep 19.
• [1008] SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3/-catenin pathway.Cell Signal. 2019 Jul;59:1-12. doi: 10.1016/j.cellsig.2019.03.004. Epub 2019 Mar 4.
• [1009] Calcitriol inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2/3-, STAT3- and -catenin-mediated epithelial-mesenchymal transition.Cancer Sci. 2020 Jan;111(1):59-71. doi: 10.1111/cas.14237.
• [1010] SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.Hum Pathol. 2018 Jul;77:139-146. doi: 10.1016/j.humpath.2018.04.004. Epub 2018 Apr 22.
• [1011] Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.Clin Nucl Med. 2019 May;44(5):420-423. doi: 10.1097/RLU.0000000000002495.
• [1012] Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.Int J Cancer. 2010 Oct 1;127(7):1517-25. doi: 10.1002/ijc.25164.
• [1013] A human bone morphogenetic protein antagonist is down-regulated in renal cancer.Mol Biol Cell. 2008 Feb;19(2):457-64. doi: 10.1091/mbc.e07-05-0433. Epub 2007 Nov 21.
• [1014] UCA1 promotes cell proliferation and invasion and inhibits apoptosis through regulation of the miR129-SOX4 pathway in renal cell carcinoma.Onco Targets Ther. 2018 May 1;11:2475-2487. doi: 10.2147/OTT.S160192. eCollection 2018.
• [1015] Classic SRY-box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma.FASEB J. 2019 Jan;33(1):254-263. doi: 10.1096/fj.201701453RR. Epub 2018 Jun 29.
• [1016] MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma.Biochem Biophys Res Commun. 2016 Feb 12;470(3):620-626. doi: 10.1016/j.bbrc.2016.01.095. Epub 2016 Jan 23.
• [1017] SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.Mol Med Rep. 2017 Nov;16(5):7784-7790. doi: 10.3892/mmr.2017.7535. Epub 2017 Sep 20.
• [1018] Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.Int J Cancer. 1999 Nov 12;83(4):486-90. doi: 10.1002/(sici)1097-0215(19991112)83:4<486::aid-ijc9>3.0.co;2-o.
• [1019] Sprouty2 is associated with prognosis and suppresses cell proliferation and invasion in renal cell carcinoma.Urology. 2013 Jul;82(1):253.e1-7. doi: 10.1016/j.urology.2013.02.051. Epub 2013 May 17.
• [1020] lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression.Oncotarget. 2017 Jul 31;8(49):85353-85367. doi: 10.18632/oncotarget.19743. eCollection 2017 Oct 17.
• [1021] Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.Proteomics. 2011 Jun;11(12):2528-41. doi: 10.1002/pmic.201000486. Epub 2011 May 18.
• [1022] Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dub tumour suppressor gene (FLCN).Oncogene. 2014 Feb 20;33(8):956-65. doi: 10.1038/onc.2013.27. Epub 2013 Feb 18.
• [1023] Human alpha2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase.J Biol Chem. 2003 Jul 18;278(29):26474-9. doi: 10.1074/jbc.M213223200. Epub 2003 Apr 25.
• [1024] MiR-193a-3p and miR-224 mediate renal cell carcinoma progression by targeting alpha-2,3-sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway.Mol Carcinog. 2018 Aug;57(8):1067-1077. doi: 10.1002/mc.22826. Epub 2018 May 2.
• [1025] Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors.Mol Carcinog. 2001 Sep;32(1):44-53. doi: 10.1002/mc.1063.
• [1026] SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis.Oncotarget. 2016 Dec 6;7(49):80435-80449. doi: 10.18632/oncotarget.12606.
• [1027] Quantification of C13orf19/P38IP mRNA expression by quantitative real-time PCR in patients with urological malignancies.Cancer Lett. 2005 Jul 28;225(2):253-60. doi: 10.1016/j.canlet.2004.10.037. Epub 2004 Dec 9.
• [1028] SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer.Tumour Biol. 2016 Jul;37(7):9919-30. doi: 10.1007/s13277-015-4734-y. Epub 2016 Jan 27.
• [1029] Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma.Int J Oncol. 2003 Oct;23(4):991-9.
• [1030] Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.Cancer Res. 2002 Aug 1;62(15):4273-81.
• [1031] Correlation of (99m)Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression.EJNMMI Res. 2017 Oct 2;7(1):80. doi: 10.1186/s13550-017-0329-5.
• [1032] In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.BMC Mol Biol. 2007 Jun 8;8:47. doi: 10.1186/1471-2199-8-47.
• [1033] TCF21 hypermethylation regulates renal tumor cell clonogenic proliferation and migration.Mol Oncol. 2018 Feb;12(2):166-179. doi: 10.1002/1878-0261.12149. Epub 2017 Dec 14.
• [1034] TFCP2/TFCP2L1/UBP1 transcription factors in cancer.Cancer Lett. 2018 Apr 28;420:72-79. doi: 10.1016/j.canlet.2018.01.078. Epub 2018 Feb 7.
• [1035] VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.Mod Pathol. 2019 Feb;32(2):258-268. doi: 10.1038/s41379-018-0128-1. Epub 2018 Sep 11.
• [1036] Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF--dependent and -independent mechanisms.Oncogene. 2018 Apr;37(16):2197-2212. doi: 10.1038/s41388-017-0084-0. Epub 2018 Feb 2.
• [1037] Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma.Mol Med Rep. 2017 Mar;15(3):1373-1378. doi: 10.3892/mmr.2017.6139. Epub 2017 Jan 24.
• [1038] The significance of TIMD4 expression in clear cell renal cell carcinoma.Med Mol Morphol. 2017 Dec;50(4):220-226. doi: 10.1007/s00795-017-0164-9. Epub 2017 Jun 19.
• [1039] The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.Cancer Biomark. 2017;19(2):207-212. doi: 10.3233/CBM-161656.
• [1040] Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin.Cell Death Dis. 2019 Dec 4;10(12):919. doi: 10.1038/s41419-019-2088-x.
• [1041] Amplification-independent overexpression of thymosin beta-10 mRNA in human renal cell carcinoma.Ren Fail. 1994;16(2):243-54. doi: 10.3109/08860229409044864.
• [1042] Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing.Scand J Urol. 2016 Dec;50(6):452-462. doi: 10.1080/21681805.2016.1238007. Epub 2016 Oct 14.
• [1043] The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.Mol Cancer. 2013 Oct 10;12(1):120. doi: 10.1186/1476-4598-12-120.
• [1044] CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.Epigenetics. 2013 Jul;8(7):739-47. doi: 10.4161/epi.25075. Epub 2013 May 24.
• [1045] Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia.Leukemia. 2004 Nov;18(11):1804-9. doi: 10.1038/sj.leu.2403483.
• [1046] Tumor Protein D52 (TPD52) Inhibits Growth and Metastasis in Renal Cell Carcinoma Cells Through the PI3K/Akt Signaling Pathway.Oncol Res. 2017 May 24;25(5):773-779. doi: 10.3727/096504016X14774889687280. Epub 2016 Nov 8.
• [1047] Tropomyosin-1 Functions as a Tumor Suppressor with Respect to Cell Proliferation, Angiogenesis and Metastasis in Renal Cell Carcinoma.J Cancer. 2019 May 21;10(10):2220-2228. doi: 10.7150/jca.28261. eCollection 2019.
• [1048] ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.Diagn Pathol. 2019 Oct 18;14(1):112. doi: 10.1186/s13000-019-0879-0.
• [1049] Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy.Pathology. 2012 Aug;44(5):453-9. doi: 10.1097/PAT.0b013e3283557748.
• [1050] Identification and validation of novel prognostic markers in Renal Cell Carcinoma.Dan Med J. 2017 Oct;64(10):B5339.
• [1051] Valproic acid inhibits epithelialmesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression.Mol Med Rep. 2017 Nov;16(5):6190-6199. doi: 10.3892/mmr.2017.7394. Epub 2017 Aug 29.
• [1052] TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.Mol Cancer. 2017 Mar 21;16(1):67. doi: 10.1186/s12943-017-0634-7.
• [1053] ARID1A knockdown triggers epithelial-mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma.FASEB J. 2019 Nov;33(11):12226-12239. doi: 10.1096/fj.201802720RR. Epub 2019 Aug 21.
• [1054] NDUFA4L2 is associated with clear cell renal cell carcinoma malignancy and is regulated by ELK1.PeerJ. 2017 Nov 17;5:e4065. doi: 10.7717/peerj.4065. eCollection 2017.
• [1055] Diagnostic role of kidney injury molecule-1 in renal cell carcinoma.Int Urol Nephrol. 2019 Nov;51(11):1893-1902. doi: 10.1007/s11255-019-02231-0. Epub 2019 Aug 5.
• [1056] Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells.Histopathology. 2019 Mar;74(4):608-617. doi: 10.1111/his.13791. Epub 2019 Jan 31.
• [1057] Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.Medicine (Baltimore). 2016 Apr;95(17):e3225. doi: 10.1097/MD.0000000000003225.
• [1058] Mitochondrial E3 ubiquitin ligase 1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas.Cancer Sci. 2019 Nov;110(11):3533-3542. doi: 10.1111/cas.14192. Epub 2019 Sep 28.
• [1059] Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.Clin Genitourin Cancer. 2017 Aug;15(4):e551-e562. doi: 10.1016/j.clgc.2016.11.010. Epub 2016 Dec 1.
• [1060] Quantitative Global Proteome and Lysine Succinylome Analyses Reveal the Effects of Energy Metabolism in Renal Cell Carcinoma.Proteomics. 2018 Oct;18(19):e1800001. doi: 10.1002/pmic.201800001. Epub 2018 Sep 5.
• [1061] Mutant versions of von Hippel-Lindau (VHL) can protect HIF1 from SART1-mediated degradation in clear-cell renal cell carcinoma.Oncogene. 2016 Feb 4;35(5):587-94. doi: 10.1038/onc.2015.113. Epub 2015 Apr 27.
• [1062] Prognostic Role of TMED3 in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis.Front Genet. 2019 Apr 17;10:355. doi: 10.3389/fgene.2019.00355. eCollection 2019.